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EXECUTIVE SUMMARY 
The REACH Implementation Projects on Nanomaterials (RIP-oNs) seek to provide 
scientific and technical advice on key aspects of the implementation of REACH with 
regard to nanomaterials.  The objectives of the RIP-oN 3 project were to: 1) develop 
advice on how to do exposure assessment for nanomaterials within the REACH 
context to cover i) development of Exposure Scenarios, ii) evaluation of operational 
conditions and risk management/mitigation measures and iii) exposure estimation, and; 
2) to develop ideas for how to conduct hazard and risk characterisation for 
nanomaterials.  The latter will involve threshold/non-threshold considerations. 
The approach taken was largely driven by the contract specifications and comprised a 
step wise, evidence based approach, on which guidance changes were developed. 
The project was implemented through a series of specified and linked tasks (A, B1-B4, 
C1 – C3, and D).  
The project identified and reviewed relevant information sources (Task A) for carrying 
out an evaluation of the evidence base to identify the key scientific issues arising that 
had possible implications for the REACH guidance.  In relation to exposure issues, 
Task B1 comprised case studies to capture practical learning on the development of 
exposures scenarios (ES), Task B2 evaluated the evidence base on Operational 
Conditions and Risk Management Measures, and Task B3 considered exposure 
estimation.  In relation to hazard and to risk characterisation, Task C1 developed case 
studies on how no effect levels could be established and Task C2 evaluated on-going 
activities in relation to hazard and risk characterisation.  Task D comprised an analysis 
of the needs and options for metrics/parameters in the hazard assessment compatible 
with the exposure assessment parameters/metrics in order to prepare a meaningful risk 
characterisation. 
The next stage was the identification, from the perspective of the scientific evidence, of 
where recommendations for guidance changes should be made.  This comprised 
Tasks B4 (in relation to exposure issues) and C3 (in relation to hazard and risk 
characterisation issues).   
The final stage of the project was a section by section analysis of the existing REACH 
guidance. The assessment considered in detail the optimum set of changes which 
could be made to the guidance.  Based on this analysis, detailed recommendations for 
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guidance changes were developed along with recommendations for research where 
this was indicated by the evidence.  
Comprehensive discussion of the findings from the project is provided in the individual 
Task Reports.  This Final Project Report summarises the key specific issues related to 
nanomaterials in a REACH context and a form compatible with the possible future 
integration into the existing REACH Guidance on Information Requirements and 
Chemical Safety Assessment, with clear reference to the existing REACH Guidance 
Part or Chapter and Sub-chapter.  For issues that are not currently 
technically/scientifically mature for developing detailed guidance, the need for further 
research and development is indicated.  
The ES Case-Studies (Task B1) were provided by companies of various sizes and at 
different stages of the business life, in different industry sectors and at different stages 
of the nanomaterials supply chain.  They delivered detailed exposure information for 
occupational, consumer and environmental release/exposure scenarios for specific 
nanomaterials: nano-TiO2; nano-TiO2 (Mn-doped); nano-Ag; Multi-walled Carbon 
Nanotubes (MWCNTs).  Some Case-Study providers conducted state-of-the-art 
detection and measurement approaches using multi-instrument, multi-metric 
measurement studies.  While this resulted in an extensive data set, the complexity of 
the data collected made this data difficult to interpret for the purposes of exposure 
scenario development.  Some of the Case-Studies used models (e.g. Consexpo, 
ECETOC TRA) to estimate exposure.  These were used without specific modification 
for nanomaterials.  No data was available to test the validity of the model estimates.  
The reporting template (based on the ES format) was criticised due to lack of clarity, 
and guidance.  A number of specific observations were made, primarily general 
difficulties with the current REACH guidance, and might benefit any further guidance 
update.  It was considered that down-stream users may lack qualified staff to complete 
the reporting template.  The Case-Studies developed should be considered as 
nanomaterial product-specific examples only and that no generalisation with regard to 
practices within an entire nanomaterial type-specific branch could be based on these 
individual ES Case-Studies.   
Task B2 considered Operational Conditions (OC) and Risk Management Measures 
(RMM).  The ‘hierarchy of control’ concept which underpins much of the REACH 
guidance in this area was considered to be equally valid for nanomaterials as for other 
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substances.  There is evidence that control and risk management methodologies which 
are already known can provide levels of protection for workers from exposure to 
engineered nanomaterials.  It is not indicated that new nano-specific RMMs need to be 
developed.  However, the specific protection provided against specific nanomaterials 
needs to be evaluated.  Evidence indicates that emissions to the workplace are 
substantially reduced if a process involving engineered nanomaterials is performed in a 
properly designed enclosure/containment, although this was not universal.  The 
situation is further amplified when considering what happens when containment is 
opened.  Similarly, evidence indicates that worker exposure can be significantly 
reduced or prevented through the use of correctly designed and implemented 
extraction ventilation and filtration.  Filtration theory indicates that filtration will be 
effective for particles in the nanometer size range.  This also applies to personal 
protective equipment where several studies clearly demonstrate the potential of 
respirator filters to capture nanoparticles.  As for chemicals in general, further work is 
required to investigate human factors such as leakage around (rather than through) a 
face-piece filter.  The situation is not as clear with protective suits and gloves, where 
much less work has been carried out.   
Control Banding (CB) may have use in relation to the selection of control approaches.  
Attempts are being made to develop this approach for nanomaterials, but they are at 
an early stage.  However, given the current level of development, CB cannot be used 
to demonstrate that the risks are adequately controlled.  As an interim measure, users 
might consider CB approaches to provide initial selection of control measures as a 
starting point while collecting further information about exposure, toxicity and risk.  
Although preliminary medical surveillance activities, such as documentation of the 
presence of engineered nanoparticles and identification of potentially exposed workers, 
are likely to be beneficial in the long term, no clear guidance can be given at this time 
as to which specific medical endpoints should be examined.  For safety data sheets 
(SDS), it is important that information provided for a nanomaterial is representative, 
valid and provides the protection needed for the forms addressed by the SDS.  
Other than in the case of filtration, no recommendations for risk management 
measures in REACH guidance relating to the environment can be made at this time, 
due to lack of evidence.  Almost no work has been done on the effectiveness of 
consumer risk management measures. 
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For operational conditions, only limited information was found to be available in the 
public literature.  Information is available on the risk management measures adopted 
and in some cases the quantity of material produced and used on a daily or batch 
basis.  Information concerning room sizes, ventilation rates, and temperature is almost 
entirely absent.   
Task B3 considered exposure estimation.  Key issues identified included discrimination 
from background nanoparticles, measurement of size distribution, maximum relevant 
particle size, effect of high spatial and temporal variability, assessment of high aspect 
ratio nanomaterials, application of exposure models & choice of metric, and instrument 
& measurement strategy.  Alternative approaches in dealing with background particle 
measurements included a time series approach, near and far field paralleled 
measurements and off-line analysis to confirm whether peak concentrations observed 
correspond to an identified nanoparticle, either by composition, morphology or both.  
Consideration for using size distribution data concluded that recommended methods 
should be able to account for complex distributions (e.g. bimodal distributions) and that 
the full size distribution curve should be reported.  Particle size issues were concerned 
with aggregates and agglomerates and the need to identify and characterise these.  
Nanoparticles of interest may be present as primary particles, larger 
aggregates/agglomerates, and potentially background particles from which primary 
particles may subsequently be released.  It was suggested that the respirable 
convention is the appropriate upper size limit.  Given the effect of high spatial and 
temporal variability, measurements of workplace air concentrations are unlikely to 
represent personal exposure.  Therefore strategies which encourage comparison (even 
limited) between workplace air concentrations and personal exposure are 
recommended.  At this time, it is not possible to make a definitive statement concerning 
which of the metrics are the most appropriate for nanoparticles.  In relation to 
measuring exposure, the recommended practice at this time is that measurements 
should encompass assessment of at least mass, but where possible also number 
and/or surface area concentration.  This issue was considered further in Task D. 
For high aspect ratio nanomaterials, the application of the WHO approach has not yet 
been validated.  Given an absence of measurement methods or terminology to 
describe ‘bundles’ or ‘clumps’ of high aspect ratio nanomaterials, no specific guidance 
can be given at this time for quantitative assessment of these entities.  However, their 
presence should be noted in any assessment.  The limited evidence of validation for 
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occupational exposure indicates that model estimates should not be relied on alone 
without further confirmation of their validity in individual cases.  In any case, model 
estimates should be used with caution and with further scientific justification. 
Detailed implications for these issues in relation to the REACH guidance has been 
developed in Task B4 and refined through discussions with the Stakeholder 
Consultation Group (SCG) into proposals for guidance amendments, which have been 
fully elaborated in this Final Project Report.  
Task C1 involved the consideration and evaluation of the REACH approach for deriving 
no effect levels through the use of case studies for multi-walled carbon nanotubes 
(MWCNT), nano-TiO2 and silver nanoparticles.  In relation to the case studies, in all 
cases it was observed that there were some data gaps that could hinder a full 
evaluation under REACH.  Normally, the approach for dealing with deficiencies in data 
would be to look for other studies using similar materials, which may provide some 
knowledge of the likely effects of the materials (e.g. long-term effects, systemic effects 
etc.).  However, in relation to many nanomaterials, there is insufficient evidence to 
apply such an approach.   
Where data was available, a Case Study was performed.  It emerged that a major 
question relating to the applicability of the REACH guidance was the applicability of the 
current assessment factors (AF) in relation to nanomaterials, as these AF have been 
derived from classical (soluble substance) toxicity in relation to both human and 
environmental health.  Considerations have been made regarding their applicability to 
(nano)particles and the impact that alternative metrics and other issues such as 
agglomeration/aggregation state could have on the different AF.  However, it was 
considered that, for the most part, the current guidance in relation to deriving exposure 
limits provides sufficient flexibility to address areas of uncertainty, data gaps and, if 
justified, deviations from the default approach/AFs.  In relation to 
agglomeration/aggregation, it was considered that it is unclear whether aggregation/ 
agglomeration of nanoparticles will result in higher or lower toxicities found in standard 
tests.  However, the aggregation/agglomeration state could affect various parameters 
such as deposition zone in the lung, or uptake by organisms and thus characterisation 
of particles both within test systems and the exposure environment is important.   
Within Task C2, considerations were made of on-going hazard and risk 
characterisation approaches, using the case study nanomaterials (MWCNT, TiO2, 
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nanosilver).  Evaluation of the identified alternative approaches for hazard and risk 
characterisation under REACH revealed both merits and deficiencies in the derivation 
of exposure limits.  This was very much the case in relation to extrapolating from 
experimental animals to humans for inhalation exposure (pertaining to both initial 
starting point modification and interspecies adjustments).  Based on the information 
gathered and considered within the Task C2 report, and the wider particle toxicology 
literature, an alternative approach for extrapolating from experimental animals to 
humans for inhalation exposure was suggested for consideration and development in 
relation to its suitability for possible future incorporation into guidance.   
The aim of Task C3 was to evaluate the outcome of Tasks C1 and C2 in relation to the 
relevant parts of the REACH “Guidance on Information Requirements and Chemical 
Safety Assessment” for human health and the environment (specifically sections R.8. 
and R.10 of REACH Guidance).  Issues identified within these reports are discussed in 
relation to the guidance and proposals are made regarding how the current guidance 
could be adapted or complemented in order to facilitate the hazard and risk 
characterisation of nanomaterials in the REACH context.   
Task D identified the critical items on exposure/dose descriptors and outlined needs for 
adequate metrics/parameters as appropriate for exposure assessment compatible with 
those used for hazard assessment.  The metrics currently used in risk assessment 
(both regulatory and otherwise) across the three elements of exposure, toxicology and 
risk, are based on mass or number.  The most prominent emerging alternative or 
additional metric identified for use in relation to the risk assessment of nanomaterials is 
surface area.  This is based primarily on toxicological evidence relating particle surface 
area to inflammation, an indicator of toxicity.  There are currently no definitive 
conclusions on the best metric.  However, there is consensus that there should be 
sufficient characterisation of the forms of a substance tested to allow the dose-
response to be expressed in the different metrics discussed - number, surface area 
and mass.  It is important to note that there are other parameters which can act as 
modifiers of the toxicity, including particle size, size distribution, density, surface 
modification, aggregation/agglomeration state and shape, but these parameters would 
not generally be considered as scalable quantities and do not appear to conform to the 
current use of the term “metric” under REACH, and were therefore not considered 
further in relation to the metric issue.   
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On the basis of the activities undertaken in each of the Tasks, recommendations have 
been proposed for guidance updates in relation to: Part D (Exposure Scenario 
building), Part E (Risk Characterisation), Part F (Chemical Safety Report, including 
CSR format), Part G (Extending the SDS), Chapter R.12 (Use descriptor system), 
Chapter R.13 (Risk management measures and operational conditions), Chapters 
R.14, R.15, R.16, R.17 and R18 (on exposure estimation in different situations) and 
also considering the RMM library.  In each case, for each issue, all of these documents 
have been reviewed to evaluate the need for guidance changes.  
The content of a recommendation for a specific update to guidance is consistent with 
the focus of current REACH Guidance document, its level, and language, such that: 
 where the need is for ‘strategic-level’ guidance applicable to nanomaterials (i.e. 
high-level or overarching principles), succinct contextual information and 
reference(s) to primary sources of information are provided; 
 where the need is for updated detailed pragmatic information on, for example 
methods, a synopsis of specific guidance with appropriate reference(s) are 
provided; 
 where there is simply a need identified to acknowledge an important relevance 
or limitation in existing guidance to nanomaterials, a simple wording clarification 
may be proposed. 
 wide-scale acknowledgement confirming the general applicability of Guidance 
to nanomaterials has not been made.   
As necessary some of the recommendations for guidance updates make specific 
reference to nanomaterials.  For the avoidance of doubt however, with these changes, 
all clauses of the guidance document, unless explicitly stated otherwise, would be 
applicable to nanomaterials and should be used for that purpose. 
A summary of the proposals for guidance changes are now indicated on a section by 
section basis.  
In Part D, recommendations have been made to indicate the need to consider particle 
size issues when justifying “generalising” exposure scenarios (4.3.3) and the need to 
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take account of background concentrations (D.5.2). In appendix D1, a caveat has been 
added to draw attention to the limitation of models.  
In Part E, the only recommendation is the addition of a footnote to remind users that in 
risk characterisation ratios, exposure estimates and PNEC/DNEL need to have the 
same relevant metric (E.1.2).   
In Part F, a recommendation has been made to add footnotes indicating that other 
metrics should also be considered with respect to inhalation. 
In Part G, a recommendation has been made to indicate the need to consider the 
properties of the specific (nanomaterial) form when preparing the eSDS.  
In R.8, the overall conclusion from the evaluation of the Guidance document was that 
whilst the REACH guidance for hazard and risk characterisation have not been written 
primarily for nanomaterials, nonetheless due to their wide applicability and inherent 
flexibility they are, for the most, considered suitable for nanomaterials.  As may also be 
the case for various more conventional materials, information for nanomaterials on 
hazard and risk characterisation is often scarce.  For 'conventional' materials, due to 
the existence of a greater wealth of data surrounding analogous materials, other 
approaches such as read across or categorisation are available for use in the 
assessment process. The scientific understanding, such as concepts of similarity or 
drivers of toxicity, is not yet sufficiently mature for a wealth of nanomaterials to allow for 
such an approach to be taken in the absence of information with any degree of 
certainty.  As such it is suggested that, if these approaches are to be used (such as the 
use of data on the bulk or other forms of the material in place of nano-specific data) 
they must be scientifically justified and may be associated with additional uncertainty.  
It is also suggested that this point be made in relation to the use of a route-to-route 
extrapolation in determining health hazards for nanomaterials, as the use of this 
approach has yet to be established for nanomaterials.  Therefore, the use of route-to-
route extrapolation for nanomaterials must be scientifically justified on a case-by-case 
basis. 
As well as uncertainty surrounding the chronic effects of nanomaterial exposure, the 
consideration of potential systemic availability, accumulation and effects should be 
borne in mind and proposed guidance updates to this effect have been made.  It is 
suggested that the availability of chronic data (in particular addressing carcinogenic 
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endpoints), and data addressing absorption, systemic availability and accumulation 
would be seen as reducing uncertainty.  However this may require further R&D to 
develop methods of detection and analysis both of the nanomaterial and any 
associated effects. 
Within the extrapolation process from animal data to a human equivalent dose, there is 
the potential for deviation away from the REACH approach using other approaches 
such as those suggested within several publications discussed within the Task C1 and 
C2 reports.  Specifically, in deviating from the default assessment factor during the 
derivation of a Derived No (Minimal) Effect Level (DN(M)EL) for (nano)particles, a 
calculation of the actual lung dose could be performed.  However it has been noted that 
there are considerable differences in ventilation rates, deposition patterns, and 
clearance rates between humans and animals, and all of these factors should be taken 
into account within this calculation.  In addition, if performing an extrapolative 
calculation based upon physiological parameters such as ventilation rates, this should 
be assessed against other calculations performed in the derivation of a DN(M)EL (i.e. 
starting point modification for exposure duration, ventilation rates etc.).  This is to 
address potential for duplication of calculations.  As part of the proposed Guidance 
update, text has been suggested covering such issues as lung deposition and 
clearance rates as well as the suggestion that consideration be given to the use of 
alternative physiological parameters to body weight, e.g. lung weight, lung surface 
area.  In relation to both deviation from the REACH default approach and the use of 
alternative parameters etc., these should be scientifically justified.  The use of 
additional exposure metrics such as particle surface area or number concentration 
(especially for fibres) should be considered when performing analysis. Sufficient 
characterisation of a material being tested, to allow obtained results to be expressed 
using several different metrics in addition to the conventional mass metric, should be 
encouraged and would be seen as a benefit to study design   
In R.10, a caveat is recommended indicating a limitation of the use of the equilibrium 
partitioning method for nanomaterials (R.10.5.2.1, R.10.5.3.1, and R.10.6.1). In 
addition a recommendation is made to highlight the increased uncertainty when no 
nanomaterial-specific data are available.   
In R.13, a paragraph has been added to indicate that the effectiveness of risk 
management measures (RMM) for nanomaterials should not be assumed to be the 
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same as for other substances.  Additional changes are proposed to the RMM library in 
the form of notes concerning the effectiveness of enclosure, Respiratory Protective 
Equipment (RPE), hand protection and suits, and health surveillance.   
In R.14, changes are recommended to provide more information on the technical 
issues relating to the measurement on nanomaterials, the need to consider other 
metrics, the applicability of simulation studies, and the limitations of models.  An 
extensive appendix dealing with discrimination from background particles, 
measurement of size distribution, maximum relevant size, spatial and temporal 
variability, choice of metric, high aspect ratio nanomaterials, measurement instruments 
and sampling strategy has been developed. The recommendation is made that this 
appendix should also be linked to R.7.  In R.14.2, a paragraph has been added to 
recommend consideration of other units, in addition to mass based ones for inhalation.  
Several recommendations to consider the use of simulation studies have been made 
(R.14.4.1, R .14.4.4).  In R.14.4.7, a caveat has been added to indicate that exposure 
models have not been validated for nanomaterials and should be used with caution.  
Caveats in relation to modelling have also been added in several places in several 
other exposure related chapters (R15.2.3, R.16.5, R.17.2, R.17.4.1, R.17-1 and 
18.5.2).   
In R.15.2, a paragraph has been added to recommend consideration of other units, 
rather than only mass based ones for inhalation.  In R.15.3.1, reference is made to the 
relevance of the respirable fraction for nanomaterials. 
In addition to these guidance recommendations, a series of recommendations for 
further research have been made. Specifically, 
In R.8: 
• Establishing the most appropriate metric(s) upon which to base a derived 
exposure limit. 
• An improved understanding of the drivers of toxicity and the influencing 
physico-chemical attributes which affect absorption kinetics. 
• Generation of quantitative or at least qualitative approaches for addressing 
respiratory sensitisation. 
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In R.13: 
• Assessment of the effectiveness of a whole range of RMM needs to be 
established for use with different types of nanomaterials. 
• Collection of fundamental information about how RMM and OC are actually 
implemented through industrial practice. 
• More information on the efficacy of any of the consumer RMMs for substances 
containing nanomaterials. 
• More information is required on the effectiveness of prevention of release to air, 
and to water, and in relation to release to soil.  
In R.14: 
• There is a need for development of improved measurement tools for 
assessment of exposure to nanomaterials.  These would include tools which 
give the possibility of multi-metric approaches.  Linked to this issue is the need 
for development of a personal sampler.   
• Improved methods and approaches for discrimination of background 
nanoparticle aerosols are required.  These could take the form of measurement 
or analytical solutions or improved validated strategic approaches (experimental 
design approaches) which would enable discrimination to be more clearly 
demonstrated and achieved.   
• There is a need for a much improved sampling strategy to be implemented to 
take account of the multiple needs and the issues which have been identified.  
In the context of REACH, the development of a strategy specifically for REACH 
compliance issues is necessary.  
• There is also a need to further develop the evidence base about the potential 
for release from a whole range of types of activities and processes.  This would 
include measurements made in actual industrial scenarios but also laboratory 
based simulation experiments which would provide the basis for more rapid 
gathering of data and information.   
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• Collection of available evidential data concerning release and exposure would 
enable much more extensive validation of models to be carried out if required 
and, based on these validation exercises, new model approaches could be 
developed.  
• Most of the published data concerns synthesis/manufacturing processes.  
There is a clear need for more information to be gathered from other stages of 
the life cycle of substances.  For example, uniform release of nanomaterials 
during the use of products containing nanomaterials is currently almost 
completely absent from the literature.   
In R.15: 
• Substantial additional work is required to be done in order to validate the 
models for use with nanomaterials.  This includes generation of base data for 
validation including for example through simulations and use of this data to test 
and adapt the models. 
In R.17: 
• Much more work is required to assess the potential emissions of articles which 
contain nanomaterials or are coated with nanomaterials.  This would include the 
use of simulation type studies (in practice simulation studies are probably the 
only way by which useful data can be obtained).  Based on the collection and 
assembly of such data, the efficacy of the release models could be validated.  
This should be considered a high priority for research.  This applies both to 
release and exposure for humans and for the environment.  
In conclusion, the RIP-oN 3 project has been performed an objective scientific review 
based on an informed, objective and systematic gathering and consideration of 
evidence by experts who have used their knowledge and professional judgement when 
considering the impact and contribution of the scientific evidence towards delivering the 
project’s objectives.  A comprehensive synthesis of findings, implications, issues and 
advice has been developed and integrated through the Task Reports and the Final 
Project Report.  Where considered relevant, feasible and justified, specific advice for 
updating guidance has been provided.  For issues which are not currently 
technically/scientifically mature for developing detailed guidance, the need for further 
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research and development has been indicated.  The assessment of the scientific 
evidence and subsequent recommendations are the considered opinion of the authors 
and are submitted for consideration by the European Commission. 
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1 INTRODUCTION 
This document constitutes the Final Report provided by the contractor to the 
Joint Research Centre (JRC) on the project "Specific Advice on Exposure 
Assessment and Hazard/Risk Characterisation for Nanomaterials under 
REACH (RIP-oN 3)”. 
1.1 PREFACE 
1.1.1 The implementation of the European Union's Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) Regulation (EC) No 
1907/2006, represents a fundamental shift in the regulation of manufactured 
and imported chemicals in the European Union.  Having entered 'into force' 
on 1 June 2007 and 'into operation' on 1 June 2008, the new regime's 
overriding objective is 'to ensure a high level of protection of human health 
and the environment, including the promotion of alternative methods for 
assessment of hazards of substances, as well as the free circulation of 
substances on the internal market while enhancing competitiveness and 
innovation '. Its provisions are underpinned by the precautionary principle. 
1.1.2 As REACH effectively shifts responsibility from authorities to industry to gather 
information on chemical substances and assess their safety. It has been 
clarified that the provisions of REACH refer to substances (in whatever size or 
forms) and also apply to nanomaterials that are considered either as distinct 
substances or forms of a substance (CA/59/2008rev1).  However, a degree of 
uncertainty exists concerning the adequacy of the regulation and the 
accompanying guidance for the emerging and rapidly developing 
nanomaterials industry.  
1.1.3 Therefore the Commission launched the REACH Implementation Projects on 
Nanomaterials (RIP-oNs) with the objective to provide scientific and technical 
advice on key aspects of the implementation of REACH with regard to 
nanomaterials, namely:  
i) Substance Identification (SI) (RIP-oN 1) 
ii) Information Requirements (IR) (RIP-oN 2) 
iii) Chemical Safety Assessment (CSA) (RIP-oN 3) 
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1.1.4 The Institute for Health and Consumer Protection (IHCP) of the JRC was 
asked to perform and coordinate the activities aimed at developing advice for 
possible future REACH guidance improvement. The advice should be based 
on the scientific and technical state of the art information, experience and 
methodology regarding nanomaterials (NM). It should provide concrete 
proposals that could be implemented directly, and indicate the possible way 
forward for any issues and methods that need further work and could be 
implemented in the short and medium term. The main focus should be on 
issues and methods that could be included in the REACH guidance and 
possibly implemented in the short term, after the pertinent further development 
and consultation process. These recommendations would contain practical 
proposals for how and based on which information this update could take 
place. The outputs are to be developed in such a way that the advice on 
specific issues related to nanomaterials can be integrated into the existing 
REACH guidance documents and/or propose research and development 
(R&D) needed for developing such guidance. The actual inclusion of any of 
the advice into the guidance documents is the responsibility of the European 
Chemicals Agency (ECHA) and is not part of commissioned projects. The 
work is performed in close collaboration with Directorate-General (DG) 
Environment, DG Enterprise and ECHA who constitute the steering group for 
these activities. 
1.1.5 JRC let competitive tenders and commissioned two REACH Implementation 
Projects on Nanomaterials (RIP-oN 2 and RIP-oN 3), with the purpose of 
advising how the Information Requirements (IR) and Chemical Safety 
Assessment (CSA) guidance could be updated to better reflect the REACH 
requirements for nanomaterials.   
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1.2 CONSIDERATION OF THE PURPOSE, SCOPE AND FINDINGS OF THE 
RIP-ON3 PROJECT IN THE CONTEXT OF SUBSTANCE IDENTIFICATION 
AND REGISTRATIONS ADDRESSING SEVERAL FORMS, INCLUDING 
NANOFORMS 
1.2.1 Assisted by the 'Guidance for identification and naming of substances in 
REACH'1, the registrant shall decide whether different forms of a 
(nano)material shall be registered in their own right or together with other 
forms, e.g. the micron or bulk (non-nanoscale) form.  It should be noted that 
the ongoing RIP-oN 1 project is addressing how the guidance on identification 
and naming could be updated to reflect in more detail how to address 
nanoforms.  The results of RIP-oN 1 will eventually be handed over to ECHA 
and ECHA might in turn decide to update the guidance for identification and 
naming of substances.   
1.2.2 Until a possible update of the identification and naming guidance, the 
registrant is referred to the document 'Nanomaterials in REACH' (CA/59/2008 
rev. 1)2, specifying, between others:  
"REACH is based on the principle that it is for manufacturers, importers 
and downstream users to ensure that they manufacture, place on the 
market or use such substances that do not adversely affect human 
health or the environment (Article 1(3) of REACH). This principle is 
applicable to substances in whatever size or form and for all their 
identified uses. Thus, a registration of a nanomaterial has to include all 
relevant information on the nanomaterial as manufactured or imported, 
covering the properties, uses, effects and exposure related information 
as well as the relevant classification and labelling, safety assessment 
and any relevant exposure scenarios " (p. 6), and;  
"For substances at nanoscale that are phase-in substances, the 
registration can be more complex, especially when the same substance 
exists in the nanoform as well as in the bulk form. In such a case not 
only the information of the substance in the bulk form should be included 
                                                
1http://guidance.echa.europa.eu/docs/guidance_document/substance_id_en.htm?time=130164
2719 
2 http://ec.europa.eu/environment/chemicals/reach/pdf/nanomaterials.pdf 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 4 - 
in the registration dossier, but also any information regarding intrinsic 
properties where the properties of a substance in the nanoform differs 
from the bulk form, any different classification and labelling, any different 
chemicals safety assessment as well as all identified uses (see also 
Annex VI.3 of REACH) and relevant exposure scenarios for the 
nanoform of the substance." (p.8). 
1.2.3 Until more concrete guidance is provided by ECHA, it is suggested that the 
registrant follows this line.  This has a direct influence on the generation of 
hazard data, e.g. any read-across from one form to the other (being from a 
bulk form to a nanoform or between nanoforms) should be scientifically 
justified.  It also has influence on the information in the supply chain, which 
has to be appropriate to the form(s) passing down the supply chain and the 
Chemical Safety Assessment should support this.  The suggested guidance 
updates from the RIP-oN 3 project need to be seen in this light. 
1.3 PROJECT OBJECTIVES 
1.3.1 The objectives of the RIP-oN 3 project were to: 
 Develop advice on how to do exposure assessment for 
nanomaterials within the REACH context. This shall be the main 
focus of project and shall cover: 1) development of Exposure 
Scenarios, 2) evaluation of operational conditions and risk 
management/mitigation measures and 3) exposure estimation; 
 Develop ideas for how to conduct hazard and risk characterisation 
for nanomaterials. The latter will involve threshold/non-threshold 
considerations. 
1.3.2 The results of this project are to be developed in such a way that the advice 
on specific issues related to nanomaterials can be integrated into the existing 
REACH guidance documents and/or propose research and development 
(R&D) needed for developing such guidance. 
1.4 THE PROJECT CONSORTIUM 
1.4.1 The consortium awarded the tender for RIP-oN 3 comprises the Institute of 
Occupational Medicine (IOM) through its SAFENANO initiative, the 
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Nanotechnology Industries association (NIA), the European Chemicals 
Industry Association (CEFIC) and Solluzioni Informatiche (S-IN). 
1.4.2 IOM/SAFENANO, with an established reputation for independent scientific 
work, led the consortium and carried out the bulk of the technical activities.  
NIA facilitated and provided a transparent interface between the project and 
the stakeholder group, as well direct access to industry and industrial 
knowledge. CEFIC contributed a breadth of experience and expertise on 
REACH activity as well direct access to industry and industrial knowledge.  S-
IN contributed primarily to the C1 task. 
2 DESCRIPTION OF THE PROJECT 
2.1 OVERVIEW 
2.1.1 The main overall aim of this project is to develop recommendations for 
changes to the REACH guidance which take account of specific issues in 
relation to nanomaterials. This assessment is based on current generation 
NMs and consequently future generation NMs have not been addressed. The 
approach taken was largely driven by the contract specifications and 
comprised a step wise, evidence based approach, on which guidance 
changes were developed. The approach therefore is based on a number of 
interlinked tasks which are identified below.   
A. Identification & Review of Information Sources 
B1. Exposure scenario cases/examples 
B2. Operational conditions & Risk Management Measure (RMMs) - 
harvesting results from on-going  activities 
B3. Exposure estimation -  harvesting results from on-going activities 
B4 Advisory report on Operational Condition (OC), RMM, Exposure Scenario
(ES) and Exposure estimation with the  purpose of conducting Exposure 
assessment of NM for REACH 
C1. Case studies on how no effect levels could be established 
C2. Hazard / risk characterisation – harvesting results from on-going activities
C3. Advisory report on hazard and risk characterisation for NM 
D. Metrics to compare in risk characterisation 
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2.1.2 The initial activity was the collection and review of information from a wide 
range of sources. This comprised the main activity in Task A.   
2.1.3 This was followed by an evaluation of the evidence base to identify the key 
scientific issues arising that had possible implications for the REACH 
guidance. This included, in relation to exposure and exposure scenarios 
Tasks B1, B2 and B3, in relation to hazard and to risk characterisation the 
Tasks C1 and C2, and in relation to metrics the Task D.   
2.1.4 The next stage was the identification, from the perspective of the scientific 
evidence, where changes should be made within the guidance. This 
comprised Tasks B4 (in relation to exposure issues) and C3 (in relation to 
hazard and risk issues).   
2.1.5 The final stage of the project was a section by section analysis of the existing 
REACH guidance.  Specifically, for the B tasks: Part D (Exposure Scenario 
building), Part F (Chemical Safety Report (CSR), incl. CSR format), Part G 
(Extending the Safety Data Sheet (SDS)), Chapter R.12 (Use descriptor 
system), Chapter R.13 (Risk management measures and operational 
conditions), including the RMM library and Chapters R.14, R.15, R.16 and 
R.17 (on exposure estimation in relation to different types of scenario).  It also 
considers the RMM library. For the C tasks: the focus was on Chapters R.8 
and R.10.  
2.1.6 The assessment considered in detail the optimum set of changes which could 
be made to the guidance.  Based on this analysis, detailed guidance changes 
were developed along with recommendations for research where this was 
indicated. This activity forms the main aspect of the final project report (this 
document).  
2.2 DELIVERABLES 
2.2.1 A series of reports were developed for the specified tasks, as summarised in 
the table below. 
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Task Deliverable 
A A short report containing: 
1. A brief description of the approach/methodology used to identify relevant 
information sources; 
2. A list of identified information sources with clear indications of which 
ones are relevant for the subsequent tasks; 
3. For relevant information sources, a brief summary of relevant content 
and timelines for final outputs (in the case of on-going projects). 
B1 Exposure Scenario Examples for the selected 3-4 cases, including the 
process of identifying uses, the process of obtaining the right information from 
the downstream users, ESs in the iterative CSA and how the ESs can be 
incorporated into SDSs, as well as a list of types and efficiency of Risk 
Management Measures (RMM) and operational conditions typically applied 
within the branch and, where necessary, additional RMMs or refinement of 
operational conditions needed to adequately control risks.  When 
measurements are applied, advice on available instrumentation and 
equipments should be specified, as well as how to deal with background 
exposure. 
B2 A working document summarising what can be harvested in relation to 
applicability and efficiency of operational conditions and risk management 
measures for controlling nanomaterial exposure to workers, consumer, the 
environment and man via the environment. 
B3 A working document summarising what can be harvested in relation to 
exposure estimation (sampling, modelling and measurements) of workers, 
consumer, the environment and man via the environment to nanomaterials. 
When measurements are considered, this should address potential 
background exposure to nanoparticles and choice of instrumentation and 
equipment for detection of nanoparticles  
B4 An advisory report with detailed proposals with a view to be considered, if 
appropriate, for possible future guidance in relation to information 
requirements and chemical safety assessment, i.e. in relation to operational 
conditions, Risk Management Measures, Exposure Scenarios and Exposure 
Estimation (sampling, modelling, measuring and how to deal with background 
exposure to nanoparticles) and for measurements issues related to 
monitoring devices and equipments; and where detailed technical proposals 
are not yet possible, indications of further research and development needs 
and likely time frame  
C1 3-4 case examples demonstrating how no-effect levels can be established. 
C2 A working document summarising what can be harvested from ongoing 
activities in relation to qualitative and quantitative hazard/risk characterisation 
for nanomaterials. 
C3 An advisory report with detailed proposals with a view to be considered, if 
appropriate, for possible future guidance in relation to information 
requirements and chemical safety assessment, i.e. in relation to hazard and 
risk characterisation; and where detailed technical proposals are not yet 
possible, indications of development needs and possible time frame . 
D A working document on identification of critical items on exposure/dose 
descriptors and related parameters, outlining needs for adequate 
metrics/parameters as appropriate for exposure assessment compatible with 
the ones used for hazard assessment as well as for the read-across from 
bulk substances and from other nanomaterials.  This document will be 
developed in close collaboration with RIP-oN 2. 
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2.2.2 The present report, as already indicated in the introduction, constitutes the 
Final Project Report and provides advice for updating the guidance and on 
R&D needs.  This takes the form of specific recommendations or options for 
consideration by the Commission. For issues which are not currently 
technically/scientifically mature for developing detailed guidance, the need for 
further R&D is indicated.   
2.2.3 The focus of the RIP-oN 3 project has been on nanomaterial relevant issues. 
Nevertheless, due to the nature of some NMs, some proposals may have 
implications for other substances that are not nanomaterials. These would 
need to be considered if reshaping of the REACH guidance takes place. 
2.3 LIST OF TASK REPORTS 
2.3.1 The following task reports have been developed during the project and are 
referred to further in the current document using the names indicated: 
 Final Report on Task A: Identification and Review of Information 
Sources (RNC/RIP-oN3/A/1/FINAL) 
 Final Report on Task B1: Exposure Scenario Case Studies 
(RNC/RIP-oN3/B1/2/FINAL) 
 Final Report on Task B2: Operational conditions and risk 
management measures - harvesting results from on-going activities 
(RNC/RIP-oN3/B2/2/FINAL) 
 Final Report on Task B3: Exposure estimation (modelling and 
measurements) - harvesting results from on-going activities 
(RNC/RIP-oN3/B3/2/FINAL) 
 Final report on Task B4: Advisory Report on Operational Conditions, 
Risk Management Measures, Exposure Scenarios and Exposure 
Estimation (modelling and measurement) with the Purpose of 
Conducting Exposure Assessment of Nanomaterials for REACH 
purposes (RNC/RIP-oN3/B4/2/FINAL) 
 Final Report on Task C1: Case-studies on how no-effect-levels for 
health and the environment could be established (RNC/RIP-
oN3/C1/2/FINAL) 
 Final Report on Task C2: Hazard / risk characterisation harvested 
from on-going activities (RNC/RIP-oN3/C2/2/FINAL) 
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 Final Report on Task C3: Advisory Report on Hazard and Risk 
Characterisation of Nanomaterials (RNC/RIP-oN3/C3/2/FINAL) 
 Joint Final Report on RIP-oN2 Task C & RIP-oN3 Task D: Metric(s) 
to compare in the risk characterisation (RNC/RIP-oN3/D/2/FINAL) 
2.4 REVIEW AND CONSULTATION WITH THE EC-APPOINTED 
STAKEHOLDER CONSULTATION GROUP (SCG) 
2.4.1 All Task Reports were subject to review by the project’s Steering Group 
(constituting representatives of JRC, DG Environment, DG Enterprise and 
ECHA) and a Stakeholder Consultation Group (SCG) consisting of the 
members of the REACH Competent Authorities Sub-Group on Nanomaterials 
(CASG-Nano) and other relevant experts from Member States, industry and 
Non-Governmental Organisation (NGOs) nominated by the REACH and 
Classification, Labelling & Packaging (CLP) Competent Authorities 
(CARACAL).  The draft Task Reports were opened for consultation with the 
above mentioned groups, discussed at meetings of the SCG, revised by the 
Project Consortium and re-opened for comment before being finalised.   
2.5 TECHNICAL APPROACH 
2.5.1 The project has been performed as an objective review of the existing 
guidance and available scientific evidence pertinent to the specified tasks.   
2.5.2 The conduct of this scientific review is based on an informed, objective and 
systematic gathering and consideration of evidence by experts who have 
used their knowledge and professional judgement when considering the 
impact and contribution of a source document to the task objective. It is 
important to note the inherent limitations of a review activity. Reviews are 
conducted at a fixed point in time which precludes the inclusion of information 
that becomes available after a set cut-off date.  Information sourced may be 
incomplete or, on closer inspection, the content of a source document bears 
no relevance to the issues being considered. Information may also change in 
revisions of the sources considered.   
2.5.3 Based on the objective and informed assessment of published reports 
constituting the evidence-base available to call upon, a synthesis of findings, 
implications and/or issues distilled from the sources has been developed and 
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integrated into the task reports.  The review of source reports has identified 
and used the methods and materials used (as appropriate), key findings, and 
remaining gaps in establishing the technical basis facilitating the development 
of advice pertinent to the project.   
2.5.4 Identification and review of information sources (Task A) 
2.5.5 Relevant information was collected, assessed, categorised and made 
available for the project team.  There is a range of relevant information and 
information types. The information includes background information from 
organisations such as CASG Nano, Organisation for Economic Co-operation 
and Development Working Party on Manufactured Nanomaterials (OECD 
WPMN), Scientific Committee on Emerging and Newly Identified Health Risks 
(SCENIHR), Standards organisation such as International Organization for 
Standardization (ISO) and European Committee for Standardization (CEN), 
FP6/7 projects, other ongoing national projects, other international regulatory 
organisations such as National Institute for Occupational Safety and Health 
NIOSH and Environmental Protection Agency (EPA) and from the peer 
reviewed literature.  Reports and papers were assessed for specific relevance 
to the project.   
2.5.6 The report from Task A comprised a brief description of the 
approach/methodology used to identify relevant information sources, the list 
of identified information sources with clear indications of their relevance to the 
respective tasks and comment of the relevant content.   
2.5.7 Exposure Scenario (ES) case studies (Task B1) 
2.5.8 In this task, Exposure Scenario (ES) case studies for nanomaterials were 
developed working with industry “Case Study Providers”. They were intended 
to investigate the process of collating, reporting and processing information 
required for the building of ES on specific nanomaterials, providing 
information to downstream users and obtaining the right information from the 
downstream users in return, as well as providing a list of types and efficiency 
of Risk Management Measures (RMM) and Operational Conditions (OCs). 
The Case-Studies furthermore aimed to evaluate the use of ESs in the 
iterative CSA, including estimating exposure to nanomaterials, the possibility 
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of incorporating ESs into Safety Data Sheets (SDSs) for the purpose of 
communication down the supply chain. Specific emphasis was given to 
reviewing the methodology applied by a Case-Study providing company to 
estimate the generic exposure, providing details on any assumptions made, 
models applied or instrumentation and equipment used to conduct static or 
personal (monitoring) exposure measurements. The review of this 
methodology allowed for a case-specific evaluation of: a) the clarity of 
guidance given on generic exposure estimation, and; b) the applicability of 
modelling tools and measurement equipment to the case-specific 
nanomaterials, with view to expressing recommendations on potentially 
necessary additions to the REACH guidance. 
2.5.9 The ES Case-Studies were based on the reporting template provided in the 
ECHA Guidance on information requirements and chemical safety 
assessment – Part D: Exposure Scenario Building; Part F: CSR Format 
(Version available January 2010). This was close to, but not identical to, the 
version subsequently published by ECHA in May 2010.  
2.5.10 The tables outlined in this ECHA Guidance were reproduced in an Excel 
Spreadsheet (with extra columns added for the provision of details on any 
assumptions made, models applied or instrumentation and equipment used to 
conduct static or personal (monitoring) exposure measurements).  
2.5.11 For each ES Case-Study, the ES reporting templates were completed and 
discussed in an iterative process involving the case study providers and 
experts from the RIP-oN 3 team through a series on meetings and telephone 
discussions.  During the iterative discussion process between Case-Study 
providers and RIP-oN 3 team experts, specific attention was given to obtain 
feedback from both the Case-Study providers and the RIP-oN 3 team experts.   
2.5.12 Case-Study providers were asked to provide feedback with regard to: the 
technical process of working with the reporting template provided by ECHA 
Guidance Document Part D & F as a reporting template for ES on 
nanomaterials; the information required in completing the reporting template 
for nanomaterials, and the overall experience in building exposure scenarios 
for nanomaterials. Experts were asked to comment on their opinion on 
interpreting the data delivered by the Case-Study providers in the reporting 
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template, with a specific view to: compare the data delivered by the individual 
Case-Study providers; consider the appropriateness of exposure estimation 
approaches, with a specific view to highlighting the gaps arise from the non-
nano-specific nature of the methods, and; consider the appropriateness of the 
reporting template for building ES for nanomaterials, highlighting the 
shortcoming and gaps in the reporting template. 
2.5.13 Operational Conditions and Risk Management Measures - harvesting 
results from on-going activities (Task B2) 
2.5.14 Task B2 was a review task.  The inputs to the task included literature 
(guidance, reports, standards, peer reviewed) identified in Task A of RIP-oN 3 
as well as the information collected from industrial sources in the exposure 
scenario case studies that make up Task B1.  Sources of information include 
standards from ISO (ISO, 2007; 2008) and the British Standards Institution 
(BSI, 2007), reports from the Organisation for Economic Co-operation and 
Development (OECD, 2010) and outputs from European projects such as 
NanoSafe2 (http://www.nanosafe.org; accessed 4th September 2010), as well 
as the general scientific literature.   
2.5.15 The literature identified in Task A was reviewed to harvest the relevant 
material relating to operational conditions and risk management measures.  
The review had a primary focus of identifying and capturing such information 
as was likely to make a material contribution to the development and 
guidance of the REACH guidance.   
2.5.16 The deliverable foreseen in this task was a working document summarising 
what can be harvested in relation to applicability and efficiency of operational 
conditions and risk management measures for controlling nanomaterials 
exposure to workers, consumer, the environment and man via the 
environment. 
2.5.17 Exposure estimation (modelling and measurements) - harvesting results 
from on-going activities (Task B3) 
2.5.18 The technical approach taken in this task mirrored that taken in Task B2 but 
considered the evidence relating to exposure estimation.  In this task all 
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relevant information pertaining to availability, adequacy and applicability of 
methods for sampling, modelling and/or measuring exposure of workers, 
consumers, the environment and man via the environment to nanomaterials 
was estimated.   
2.5.19 The deliverable foreseen in this task was a working document summarising 
what can be harvested in relation to estimation of exposure to workers, 
consumer, the environment and man via the environment. 
2.5.20 Advisory report on Operational Conditions, Risk management 
Measures, Exposure Scenarios and exposure estimation (modelling and 
measuring) with the purpose of conducting exposure assessment of 
nanomaterials for REACH purposes (Task B4) 
2.5.21 In this task, Tasks A to B3 were drawn together to prepare an advisory report, 
in order to cover the exposure assessment of nanomaterials in the REACH 
context.  
2.5.22 It was the intention that the contents of the report would be presented in such 
a form that the advice on specific issues related to nanomaterials is 
scientifically justified and written in a form that will facilitate easily the future 
integration into the existing REACH Guidance on Information Requirements 
and Chemical Safety Assessment (i.e. guidance text/language) with clear 
reference to the existing REACH Guidance Part and Chapter and Sub-
chapter.   
2.5.23 Case examples on how no-effect-levels for health and the environment 
could be established (Task C1) 
2.5.24 The aim of sub-task C1 was to examine how no-effect-levels for health and 
the environment could be established using case examples of four 
nanomaterials, namely carbon nanotubes, nano-titanium dioxide (nano-TiO2), 
nano-particulate silver, and nano-zinc oxide (nano-ZnO) (the latter for 
ecotoxicology aspects). Our selection of these nanomaterials is based on the 
relative widespread use of these materials and evidence of differing 
toxicological profiles. (Note that these cases do not necessarily address the 
same nanomaterials as those in Task B1).  
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2.5.25 The task began with a consideration of the publically available literature 
surrounding these four materials and, from the identified sources, data of 
particular relevance to the derivation of no-effect-levels for health and the 
environment was selected. As the concepts of similarity between 
nanomaterials is ill defined and methods such as grouping or classification is 
not yet apparent (suggested as a high R&D  priority within RNC/RIP-
oN2/B5/2/FINAL and RNC/RIP-oN2/FPR/1/FINAL), a case-by-case approach 
was taken. 
2.5.26 Using the identified data sources, an assessment of the REACH approach for 
the generation of no-effect-levels for health and the environment was made in 
the context of the current data, scientific understanding and the approach 
taken by others.   
2.5.27 When considering human health effects of a substance, a level needs to be 
specified at which no adverse effects will occur or where this is not possible, a 
level at which only minimal adverse effects may occur. In order to achieve 
this, REACH introduces a methodology for deriving a derived no effect level 
(DNEL) or when a threshold can not be determined, a derived minimal effect 
level (DMEL). Studies identified under Task A were reviewed in regard to 
deriving a human exposure limit for case-study nanomaterials. 
2.5.28 Whilst an increasing volume of data exists surrounding the potential (adverse) 
health effects of nanomaterials, only a few studies have been performed 
using acceptable methodologies and study design suitable for DN(M)EL 
derivation. These studies were identified and used as a starting point in the 
consideration of whether effects were threshold or not and the reported 
no/low observed adverse effect level (N(L)OAEL) used in the derivation of an 
exposure limit.  
2.5.29 Within the studies considered, two further approaches to deriving exposure 
limits were identified within the literature for nanomaterials, specifically that of 
Pauluhn (2010a) and that of the Japanese New Energy and Industrial 
Technology Development Organisation (NEDO) project (Hanai et al. 2009; 
Kobayashi et al. 2009). These approaches were also evaluated for scientific 
merit and compared to the REACH default approach.    
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2.5.30 In the case of effects to environmental species, the REACH regulation uses 
the Predicted No Effect Concentration (PNEC) in order to specify the 
concentration of the substance below which no adverse effects are expected 
to occur.  Studies identified under Task A were reviewed in regard to deriving 
a PNEC.  
2.5.31 Water and soil were considered as the environmental compartments for the 
case example nanomaterials - MWCNT, nano-titanium oxides, nano-silver, 
and nano-zinc oxide. For each environmental compartment, the available 
concentration-response data (Half Maximal Lethal Concentration (LC50), 
Lowest Observed Effect Concentration (LOEC) and No Observed Effect 
Concentration (NOEC)) was obtained from the peer reviewed literature and 
reports accessible via the information resource constructed under Task A in 
RIP-oN 3.  Notably, the recent Engineered Nanoparticles – Review of Health 
& Environmental Safety (ENRHES) report (Stone et al., 2009) has been used 
as a starting point and subsequently updated with further scientific data and 
information considered to be of specific relevance in the context of the RIP-oN 
3 project.  The same approach to examining the data as used by Stone et al. 
(2009) in the FP7 ENRHES project was followed. 
2.5.32 A limited number of ecotoxicological studies have explored nanomaterial 
toxicity towards the base-set organisms used in the REACH risk assessment 
procedures for chemicals (fish, crustacean and algae).  Few studies report the 
results of these studies in the format required by the REACH risk assessment 
procedures for chemicals (LC50, EC50, NOEC, and LOEC).   
2.5.33 The identified data on MWCNT, nano-titanium oxides, nano-silver, and nano-
zinc oxide was evaluated with regard to its adequacy and completeness.   
2.5.34 The kind of data available (e.g. one long-term test (NOEC or Effective 
Concentration at 10% mortality rate (EC10)), one acute freshwater or marine 
test), according to R.10.3-10.10 on the derivation of PNEC, was determined 
for: 
2.5.35 a) aquatic compartments (freshwater and marine) (table R.10-4 
Assessment factors to derive a PNECaquatic and table R.10-5 
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Assessment factors proposed for deriving PNECwater for saltwater for 
different data sets); 
2.5.36 b) micro organisms in sewage treatment plants (STP) (table R.10-6 
Test systems for derivation of PNECmicroorganisms); 
2.5.37 c) Freshwater and marine sediment (table R.10-7 Assessment 
factors for derivation of PNECsed, table R.10-8 Assessment factors 
for derivation of PNECmarine sediment from short-term sediment 
toxicity tests, table R.10-9 Assessment factors for derivation of 
PNECmarine sediment from long-term sediment toxicity tests); 
2.5.38 d) Terrestrial (soil) compartment (table R.10-10 Assessment factors 
for derivation of PNECsoil). 
2.5.39 Based on the available data, the appropriate assessment factor was identified 
and a PNEC was derived and commented on.   
2.5.40 Hazard/risk characterisation - harvesting results from on-going activities 
(Task C2) 
2.5.41 In this review activity, we harvested relevant information concerning how 
human and environmental hazards and risks of nanomaterials could be, or 
have been characterised – quantitatively and/or qualitatively by others. The 
report investigated aspects of quantitative hazard characterisation relevant to 
nanomaterials covering particle size and surface area with particular focus on 
their relevance to toxicology/ ecotoxicology. 
2.5.42 In the discussion of the hazard/risk characterisation from on going activities, 
the approach again focused upon three case examples of nanomaterials 
(MWCNT, nano-titanium dioxide and nano-particulate silver). Specifically key 
relevant work already identified was summarised and discussed in its 
relevance to REACH  from sources including NIOSH (on TiO2), BSI (BSI PD 
6699-2: 2007), RIVM (on silver) and outputs by the NEDO covering both TiO2 
and MWCNT.  
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2.5.43 Advisory report on hazard and risk characterisation of nanomaterials 
(Task C3) 
2.5.44 Based on the findings from tasks C1, C2 and gleaned from other sources 
within the RIP-oN 3 project, a report was prepared advising as to how the 
“Guidance on Information Requirements and Chemical Safety Assessment” 
could be adapted or complemented in order to facilitate the hazard and risk 
characterisation of nanomaterials in the REACH context.   
2.5.45 The consideration of guidance in relation to its applicability to nanomaterials 
and the identification of any deficiencies was performed on a section-by-
section basis of the relevant guidance documents.  
2.5.46 All identified issues within each guidance sub-section were presented in such 
a form that the advice on specific issues related to nanomaterials is justified 
based on the current scientific literature available. In addition, where issues 
have been identified that are not currently technically/scientifically mature for 
developing detailed guidance, further research and development has been 
suggested and where possible these have been prioritised. 
2.5.47 Metric(s) to compare in the risk characterisation (Task D) 
2.5.48 Task D was also primarily an analysis and reporting task.  The primary inputs 
were the information developed in Task A and considerations from Task B.  In 
this task, a working document on identification of critical items on those 
descriptors and related perimeters, outlining needs of what were adequate 
metrics was deployed. 
2.5.49 Key issues considered are the feasibility of measurement for different relevant 
metrics and the links between toxicology (including how to express no-effect 
levels) and exposure assessment. Specifically the relationship between 
measured exposure parameters (alone or in combination) and existing 
metrics used for dosages (and vice versa). In addition, the possibility and 
relevance of ‘read-across’ from bulk substances and from other nanomaterials 
and to historical data were considered.  As indicated in the call text, this 
document was developed in close collaboration with the similar task in RIP-
oN 2 and with the agreement of the Commission, a single joint report covering 
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the issue from the hazard side (RIP-oN2) and the exposure side (RIP-oN3) 
was the final deliverable. This report was prepared by a small team with a 
multi-disciplinary expertise in exposure, toxicology and eco-toxicology.   
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3 SUMMARY OF FINDINGS 
3.1 PREAMBLE 
3.1.1 A comprehensive discussion of the findings is provided in the individual task 
reports. This Final Project Report compiles findings from the previous 
deliverables into a single document, summarising the key specific issues 
related to nanomaterials in a REACH context in a form compatible with 
eventual future integration into the existing REACH Guidance on Information 
Requirements and Chemical Safety Assessment. Clear references are 
provided to the existing REACH Guidance Part and Chapter and Sub-chapter.   
3.1.2 The summary of findings is presented, with cross-referencing, according to 
the key outcomes from each task undertaken.   
3.2 TASK A: IDENTIFICATION & REVIEW OF INFORMATION SOURCES  
3.2.1 The identification and review of information sources (Task A) in RIP-oN 3 has 
identified, screened (for relevance) and then categorised as comprehensive a 
range of sources of information as possible, to compile a resource for use in 
subsequent tasks of the project.   
3.2.2 Key organisations, FP6/7 projects and other national projects of relevance to 
the scope of the project were identified by the project team and through 
consultation with the European Commission, via JRC. Publically-available 
reports and outputs from these sources of relevance to the project were then 
identified and obtained directly from their associated websites and/or through 
web-based searching.  
3.2.3 In relation to the OECD WPMN, three levels of accessible documents which 
were used and referenced: 
 Published documents available on the public OECD WPMN website; 
 Documents approved for declassification but not yet published; 
 OECD documents developed by the Steering Groups and presented 
in meetings of the WPMN. 
3.2.4 Documentation at an earlier stage of development (e.g. committee draft) was 
not considered. 
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3.2.5 With regard to ISO and CEN publications, only published documents and 
those classified as being at Final Draft International Standard (FDIS) or Draft 
International Standard (DIS) stage were assessed and utilised where 
appropriate.  Documents in development but not able to be cited at the time of 
carrying out the RIP-oN 3 project have been identified and recommendations 
for them to be considered as soon as they become available have been 
made.   
3.2.6 A substantial resource of peer-reviewed literature references was 
constructed.  Literature from the recently completed FP7 Coordination & 
Support Action ENRHES (Stone et al., 2009), provided an initial 
comprehensive listing of literature published up to 31st December 2008.  The 
ENRHES literature search was updated for the period 1st January 2009 - 3rd 
March 2010 and supplemented with additional literature of specific relevance 
to the RIP-oN 3 project through a non-date-limited Boolean search strategy 
similar to that of ENRHES using PubMed and Web of Knowledge.  In cases 
where excessively large numbers of references were obtained, the searches 
were refined by incorporating material-specific terms (e.g. silver, titanium 
dioxide, zinc oxide).   
3.2.7 This search strategy provided a comprehensive bibliography of references 
across the topic areas of physico-chemical characterisation, production, use 
and exposure, toxicology, epidemiology, ecotoxicology, and environmental 
fate and behaviour.   
3.2.8 The criteria upon which judgements were made for tagging a reference as 
relevant for a task are outlined in the table below: 
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Task Task Name Criterion for Inclusion 
B1 Exposure scenario (ES) cases studies 
 
Reports and publications outlining 
exposure assessment case studies for 
nanomaterials or other relevant 
substances.   
B2  Operational conditions and risk 
management measures - harvesting 
results from on-going activities 
Reports and publications which discuss 
operational conditions and risk 
management measures for 
nanomaterials or other relevant 
substances. 
B3 Exposure estimation (modelling and 
measurements) - harvesting results from 
on-going activities 
Reports and publications which discuss 
occupational, environmental and 
consumer exposure for nanomaterials or 
other relevant substances, including 
literature relating to fate and behaviour 
in the environment. 
B4 Advisory report on operational conditions, 
risk management measures, exposure 
scenarios and exposure estimation 
(modelling and measuring) with the 
purpose of conducting exposure 
assessment of NMs for REACH purposes 
N/A.   
 
This Task is based on Tasks B1-B3 and 
the literature discussed therein. 
C1 Case-examples on how no-effect-levels 
for health and the environment could be 
established 
Reports and publications, relevant to 
nanomaterials, which discuss derivation 
of no effects levels, approaches, 
threshold considerations and relevant 
metrics.   
C2 Hazard/risk characterisation - harvesting 
results from ongoing activities 
Reports and publications relating to 
hazard or risk characterisation for 
nanomaterials or other relevant 
substances. 
D Metrics to compare in the risk 
characterisation 
Reports and publications dealing 
specifically with metrics relevant to risk 
characterisation. 
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3.2.9 The number of information sources identified and categorised for RIP-oN 3 
are as follows: 
 74  published reports and standards from key organisations; 
 30 reports and standards under development from key 
organisations; 
 92 reports and publications from EU FP6/7 and other relevant 
international projects; 
 515 reports and publications reviewed in the ENRHES report; 
 630 additional publications from the peer-reviewed literature.  
3.2.10 An appendix in the task report provides the complete listing of the sources of 
information.   
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3.3 TASK B1: CASE STUDIES 
3.3.1 The Case-Studies were intended to illustrate the development of branch-
specific general exposure scenarios that take into account normal practice 
within these branches, cover several processes and, where relevant, be 
applicable to ranges of nanomaterials and the challenges related to their 
sampling, detection, measurement and monitoring.  
3.3.2 The industrial Case-Studies presented in this report have been collected in 
the context of REACH; they deliver detailed exposure information for 
occupational, consumer and environmental release/exposure scenarios for 
specific MNMs; available information on three very relevant NMs was collated 
and reviewed: 
 nano-TiO2 
 nano-TiO2 (Mn-doped) 
 nano-Ag 
 Multi-walled Carbon Nanotubes (MWCNTs) 
3.3.3 The ES Case-Studies were provided by companies of various different sizes 
and at different stages of the business life, working with nanomaterials in 
different industry sectors and at different stages of the nanomaterials supply 
chain. The ES Case-Studies presented and discussed in this report therefore 
have to be regarded as snapshots of various individual and sometimes 
independent parts of different nanomaterials supply chains; the Case-Studies 
do not aim to deliver a complete set of ES that covers the entire life-cycle of a 
specific nanomaterial. 
3.3.4 The case studies developed are summarised in the table below. 
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Case study Exposure scenario 
nano-TiO2 (BASF) 
 
The TiO2 (BASF) Case-
Study encompasses 5 
Exposure Scenarios 
(ES), each with 
Contributing Exposure 
Scenarios (CESs), 
describing the different 
sequential steps in 
respective TiO2 
downstream use and 
consumer use processes 
ES1: ‘Transfer of pure nanomaterial for cosmetic 
formulation (industrial scale, in compliance with GMP)’ 
 
CES1.1: Contributing exposure scenario (1) controlling 
environmental exposure for ‘Transfer of nanomaterial into 
formulation vessel’ 
CES1.2a:Contributing exposure scenario (2) controlling 
worker exposure for ‘Transfer of nanomaterial into 
formulation vessel – PROC2’ 
CES1.2b:Contributing exposure scenario (3) controlling 
worker exposure for ‘Transfer of nanomaterial into 
formulation vessel – PROC8b’ 
 
ES2: ‘Cosmetic formulation and handling of processed 
nanomaterial (industrial scale, in compliance with 
GMP) 
 
CES2.1:Contributing exposure scenario (1) controlling 
environmental exposure for ‘Formulation of sunscreen 
(large scale)’ 
CES2.2:Contributing exposure scenario (2) controlling 
worker exposure for ‘Formulation of nanomaterial in oil in 
closed process’ 
CES2.3:Contributing exposure scenario (3) controlling 
worker exposure for ‘Sampling of sunscreen formulation 
and maintenance of equipment’ 
CES2.4:Contributing exposure scenario (4) controlling 
worker exposure for ‘Sampling and packaging of sunscreen 
formulation’ 
 
ES3: ‘Exploratory cosmetic formulation (on laboratory 
scale)’ 
 
CES3.1:Contributing exposure scenario (1) controlling 
environmental exposure for ‘Formulation of sunscreen 
(small scale)’ 
CES3.2:Contributing exposure scenario (2) controlling 
worker exposure for ‘Use as laboratory agent’ 
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Case study Exposure scenario 
nano-TiO2 (UMICORE; 
Manganese-doped) 
 
The TiO2 (UMICORE) 
Case-Study 
encompasses 2 
Exposure Scenarios 
(ES), each with 
Contributing Exposure 
Scenarios (CESs), 
describing the different 
sequential steps in a the 
respective Mn-doped-
TiO2 manufacturing 
process 
ES1: ‘Production of intermediate TiO2 nanomaterial’: 
 
CES1.1:Contributing exposure scenario (1) controlling 
environmental exposure for ‘Production of intermediate 
TiO2 nanomaterial (reactor room)’ 
CES1.2:Contributing exposure scenario (2) controlling 
worker exposure for ‘Control of production of intermediate 
TiO2’ 
CES1.3:Contributing exposure scenario (3) controlling 
worker exposure for ‘Cleaning, maintenance of reactor 
room and control room’ 
 
ES2: ‘Collection & Treatment of Intermediate TiO2’ 
 
CES2.1:Contributing exposure scenario (1) controlling 
environmental exposure for ‘Collection & Treatment of 
Intermediate TiO2’ 
CES2.2:Contributing exposure scenario (2) controlling 
worker exposure for ‘Collecting Intermediate TiO2 into bins’ 
CES2.3:Contributing exposure scenario (3) controlling 
worker exposure for ‘Transfer (of Intermediate TiO2) from 
bins to fluidised bed and treatment’ 
CES2.4:Contributing exposure scenario (4) controlling 
worker exposure for ‘Bagging / Packing of treated TiO2 into 
bags’ 
CES2.5:Contributing exposure scenario (5) controlling 
worker exposure for ‘Cleaning and  maintenance in 
treatment room’ 
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Case study Exposure scenario 
NANO-SILVER 
The Nano-Ag Case-
Study encompasses 4 
Exposure Scenarios 
(ES), each with 
Contributing Exposure 
Scenarios (CESs), 
describing the different 
sequential steps in the 
Nano-Ag value chain 
ES1: ‘Production of aqueous silver dispersion 
'AgPURE W10' ‘(conducted at RAS Materials): 
 
CES1.1:Contributing exposure scenario (1) controlling 
environmental exposure for ‘Production of aqueous silver 
dispersion 'AgPURE W10'’ 
CES1.2:Contributing exposure scenario (2) controlling 
worker exposure for ‘Preparation/Synthesis of ‘AgPURE 
W10 ‘nanomaterial’ 
CES1.3:Contributing exposure scenario (3) controlling 
worker exposure for ‘Transfer of product dispersion into 
shipment canisters’ 
CES1.4:Contributing exposure scenario (4) controlling 
worker exposure for ‘Quality Assurance Process’ 
 
ES2: ‘Nano-Ag - Polyethylene terephthalate (PET) 
Masterbatch Production’ (conducted at Silanotex or at 
Silanotex subcontractors) 
 
CES2.1: Contributing exposure scenario (1) controlling 
environmental exposure for ‘Nano-Ag - PET Masterbatch 
Production’ 
CES2.2: Contributing exposure scenario (2) controlling 
worker exposure for ‘Nano-Ag - PET Masterbatch 
Production’ 
 
ES3: ‘Use/Processing of Nano-Ag - PET Masterbatch’ 
(conducted at Silanotex or at Silanotex subcontractors) 
 
CES3.1: Contributing exposure scenario (1) controlling 
environmental exposure for ‘Use/Processing of Nano-Ag - 
PET Masterbatch’ 
CES3.2: Contributing exposure scenario (2) controlling 
worker exposure for ‘Fibre Production’ 
CES3.3: Contributing exposure scenario (3) controlling 
worker exposure for ‘Fibre Processing’ 
CES3.4: Contributing exposure scenario (4) controlling 
worker exposure for ‘Fabric Production’ 
CES3.5: Contributing exposure scenario (4) controlling 
worker exposure for ‘Garment Tailoring’ 
 
ES4: ‘Consumer use of treated Fabrics/Materials’ 
(conducted by consumers)   
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Case study Exposure scenario 
Multi-Walled Carbon 
Nanotubes (MWCNTs 
 
The MWCNT Case-
Study encompasses 4 
Exposure Scenarios 
(ES), each with 
Contributing Exposure 
Scenarios (CESs), 
describing the different 
sequential steps in 
selected MWCNT value 
chains, ES1 describes 
the manufacture of crude 
MWCNTs, while ES2 
and ES3 correspond to 
down-stream use 
processes of MWCNT-
preparations; these are 
conducted at NanoCyl 
and the resulting 
preparations are sold by 
NanoCyl, but these 
processes might also be 
conducted by 
downstream users, 
which purchase 
MWCNTs from NanoCyl. 
ES4 does not 
correspond to a real-life 
process, but simulates a 
worse-case heavy-duty 
occupational service life 
scenario, using a 
MWCNT-containing 
thermoplast preparation 
ES1: ‘Nanocyl: Upstream manufacture of MWCNTs’ 
(conducted at NanoCyl): 
 
CES1.1:Contributing exposure scenario (1) controlling 
environmental exposure for ‘Upstream manufacture of 
MWCNTs’ 
CES1.2:Contributing exposure scenario (2) controlling 
worker exposure for ‘Manufacturing and packaging of 
MWCNTs’ 
CES1.3:Contributing exposure scenario (3) controlling 
worker exposure for ‘Reactor Maintenance’ 
CES1.4:Contributing exposure scenario (4) controlling 
worker exposure for ‘Quality Control’ 
ES2: ‘Production of Thermoplastic Masterbatches’ 
(conducted at NanoCyl) 
 
CES2.1: Contributing exposure scenario (1) controlling 
environmental exposure for ‘Production of thermoplastic 
masterbatch’ 
CES2.2: Contributing exposure scenario (2) controlling 
worker exposure for ‘Production of thermoplastic 
masterbatches by extrusion’ 
CES2.3: Contributing exposure scenario (3) controlling 
worker exposure for ‘Cleaning of extruder’ 
CES2.4:Contributing exposure scenario (4) controlling 
worker exposure for ‘Quality Control’ 
ES3: ‘Production of Liquid for Coating’ (conducted at 
NanoCyl) 
 
CES3.1: Contributing exposure scenario (1) controlling 
environmental exposure for ‘Production of preparation for 
coating’ 
CES3.2: Contributing exposure scenario (2) controlling 
worker exposure for ‘Production of preparation for coating’ 
CES3.3: Contributing exposure scenario (3) controlling 
worker exposure for ‘Cleaning of the device’ 
 
ES4: ‘Generic Occupational Service Life Scenario of 
CNTs (heavy-duty abrasion study simulating a sanding 
process of CNT-containing Thermoplast)’  
 
CES4.1: Contributing exposure scenario (1) controlling 
environmental exposure for ‘Generic Occupational Service 
Life Scenario of CNTs (heavy-duty abrasion study 
simulating a sanding process of CNT-containing 
Thermoplast)’ 
CES4.2: Contributing exposure scenario (2) controlling 
consumer exposure for ‘Generic Occupational Service Life 
Scenario of CNTs (heavy-duty abrasion study simulating a 
sanding process of CNT-containing Thermoplast)’ 
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3.3.5 The original aim of RIP-oN 3 Task B1 Exposure scenario (ES) Case-Studies 
was to develop ‘branch-specific general exposure scenarios that take into 
account normal practice within these branches, cover several processes (i.e. 
have a good life cycle coverage), and where relevant be applicable to ranges 
of nanomaterials and the challenges related to their sampling, detection, 
measurement and monitoring’. During the discussion of the ES Case-Studies, 
however, it became clear that these Case-Studies could serve as 
nanomaterial product-specific examples only and that no generalisation with 
regard to practices within an entire nanomaterial type-specific branch could 
be based on these individual ES Case-Studies.   
3.3.6 The main findings of the case studies are outlined below. 
3.3.7 Some of the Case-Studies used models (e.g. Consexpo, ECETOC TRA) to 
estimate exposure.  These were used without specific modification for 
nanomaterials.  No data was available to test the validity of the model 
estimates. 
3.3.8 Some Case-Study providers conducted state-of-the-art detection and 
measurement approaches using multi instrument, multi-metric measurement 
studies in their facilities. 
3.3.9 While this resulted in an extensive data set, this was largely collected on the 
basis of investigative type studies, rather than a programme of work to collect 
data for REACH compliance issues.  As a result the complexity of the data 
collected, the fact that in many cases measurements were taken which 
spanned more than one identified exposure scenario, the fact that multi metric 
approaches were taken, the fact that in some cases continuous 
measurements were taken however only a single number was reported (as 
compared to guidance in REACH which requires demonstration of, e.g. 
median and 95th percentile measurements) made all of this data rather 
difficult to interpret for the purposes of exposure scenario development. 
3.3.10 The data measurement approaches taken also included the application of 
new measurement systems e.g. in the case of NanoCyl, the applied Naneum 
detector was specifically designed to detect MWCNTs with high selectivity 
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3.3.11 In the case of detection and measurement data, it would be important to have 
more than one or two measurement periods available for entering these data 
into modelling of scenarios.  
3.3.12 The reporting template, (based on the ES format) received heavy general 
criticism from the Case-Studies providers, due to: 
 lack of clarity of the information required to be entered in the 
spreadsheet, combined with a; 
 lack of guidance on how to complete the template, and; 
 the difficulty of handling the reporting template, as well as the 
adapted Excel Spreadsheet  
3.3.13 A number of specific observations were made. None of these issues are 
nano-specific, but rather general difficulties with the current REACH guidance 
and might benefit any further guidance update. 
3.3.14 Case study providers considered that it would be good to better “guide” the 
person filling in the fields in the template, clearly state what information is 
required (e.g. ‘information required to estimate the exposure of a worker: 
enter either a) size ventilation protection means etc. PLUS measurement 
results, or b) enter the description of the facilities [e.g. what size ventilation 
protection means, etc.] and provide additional information needed to model 
the exposure with a worst-case first tier model’). 
3.3.15 Throughout all Case-Studies, both RIP-oN experts and case-study providers 
had difficulty in distinguishing ‘Exposure Scenario’ (ES) from ‘Contributing 
Exposure Scenario’ (CES)., as well as distinguishing ‘Service-Life’ ES from 
non-Service-Life ES. 
3.3.16 The companies had some problems to define PROCs for the individual 
process steps (cf. cleaning, etc.), but all were resolved. 
3.3.17 The companies considered that it is not always clear what constitutes an 
‘Exposure Scenario’ (ES) and what constitutes a ‘Contributing Exposure 
Scenario’ (CES). 
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3.3.18 Down-stream users may lack qualified staff to complete the reporting 
template. 
3.3.19 The issue of Environmental Release Categories (ERCs) were mentioned by 
the case study providers, not as much in relation to naming the ESs, but 
rather in relation to using these as input to as yet unvalidated environmental 
exposure models. The main question is how to develop relevant 
environmental release factors/coefficients for nanomaterials where there is 
limited or no evidence base. The examples of processes and uses for which 
emission/release data are missing were: i) manufacture of substances 
(ERC1), ii) formulation in materials (ERC3), iii) industrial use resulting in 
inclusion into or onto a matrix (ERC5), iv) industrial use of reactive processing 
aids (ERC6b), v) industrial use resulting in inclusion into a matrix (ERC5), vi) 
wide dispersive indoor use of long-life articles and materials with high or 
intended release (including abrasive processing) (ERC11b).  
3.3.20 In the absence of good information about environmental release, providers 
questioned whether it was possible to use occupational exposure 
measurements in environmental release studies. In general it was questioned 
how or if one can extrapolate information from a single event (worker 
exposure) to model release to a work space and subsequent release to 
natural and technical compartments (such as to waste-water, incineration 
plants as part of waste flows, or directly to surface waters and air).  However, 
given that this is not normal practice for substances in general, there seems 
no basis for attempting this approach for nanomaterials.  
3.3.21 Additional analysis of the case studies not previously published in RNC/RIP-
oN3/B1/2/FINAL is included as Appendix 1 of this report.  
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3.4 TASK B2: OPERATIONAL CONDITIONS AND RISK MANAGEMENT 
MEASURES - HARVESTING RESULTS FROM ON-GOING ACTIVITIES 
3.4.1 In this task, evidence on the pertinent issues and the effectiveness of 
workplace controls to prevent or minimise exposure to engineered 
nanomaterials was collated and evaluated.  
3.4.2 Types of literature contributing to this activity included: 
 Guidance documents developed by national or international 
organisations providing information about good practice in relation to 
exposure control; 
 Review documents carried out by national or international 
organisations examining the evidence relating to the availability and 
effectiveness of control approaches; 
 Other review or guidance documents, either produced by industry 
associations, individual companies or from the peer-reviewed 
literature identifying or recommending effective control approaches; 
 Studies where management measures have been specifically 
evaluated to determine their efficacy of use along with nanoparticles; 
 Studies in which the performance of management methods may be 
inferred for measurements of exposure concentration; 
 Studies which provide information on operational conditions 
(process, use, duration, amount used etc) which may drive exposure 
and release, including simulation studies;  
 Studies which provide information on nanoparticle behaviour 
including dispersion, scavenging etc. 
3.4.3 Where available and relevant, reference was made to other authoritative 
reviews and these were quoted extensively.   
3.4.4 Information collected was assessed to identify the key technical issues to be 
considered in relation to any proposed changes to the REACH guidance, 
sources and reference documents for these changes as well as the need for 
further research. 
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3.4.5 A number of initial (provisional) conclusions were drawn concerning possible 
implications for aspects of the REACH guidance and these are included 
below. These were not intended to be a definitive analysis but rather intended 
to serve as a starting point for discussion with the SCG and the Commission 
prior to finalisation of the project. 
3.4.6 Hierarchy of control 
3.4.7 Based on the current guidance available from a wide range of organisations, 
there is a consensus view that the conventional approach to control of 
hazardous chemicals based on elimination, substitution, engineering control, 
administrative control and use of PPE, sometimes referred to as the hierarchy 
of control, can be an effective framework on which to base control 
approaches also for nanomaterials. 
3.4.8 Possible implications for REACH guidance. These approaches are highly 
consistent with the general measures necessary for safety and health 
protection of workers (Article 6 of Directive 89/391/EC), the reduce-to-a-
minimum principle (Article 6 of Chemical Agents Directive 98/24/EC) and the 
hierarchy of RMM prescribed in the Chemical Agents Directive and therefore 
do not in themselves suggest a need to change the guidance.   
3.4.9 Existing methods (general) 
3.4.10 As a general statement, there is evidence that control and risk management 
methodologies which are already known can provide levels of protection for 
workers from exposure to engineered nanomaterials in the occupational 
environment, depending on the specific hazards of the nanomaterial and 
whether these have been adequately identified. It is not indicated that new 
nano-specific RMMs need to be developed. Further testing and data are 
however often needed in each specific workplace situation to understand the 
levels of protection afforded, and ensure effectiveness.  
3.4.11 Possible implications for REACH guidance: (D.4.6.1 Effectiveness of RMMs, 
R. 13.3 Effectiveness of RMMs, R.13.4.2.5 Estimation and documentation of 
RMM effectiveness in the library). Available “typical default value” (an 
estimate of the 50th percentile) and a “maximum achievable” value (best 
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practice) may not be achievable and should not be assumed. Additional 
research concerning the effectiveness of control approaches may be 
necessary in some circumstances. These are explored in more detail below. 
3.4.12 Substitution and modification 
3.4.13 Modification of the hazard potential of certain types on nanomaterials 
appeared to have some, as yet not fully explored possibilities. There are 
approaches (surface modification, encapsulation, particle size control, 
functionalisation and crystalline phase control) which have been shown to 
have the potential to modify the toxicity of nanoparticles (Section 5.4). 
3.4.14 Any substitution or modification process adopted would have the added 
requirement to maintain the desired functionality.   
3.4.15 In the context of REACH such modifications would be done as a prior step 
before developing the specific ES as the specific ESs should control the risk 
of what is actually handled – not how it is redesigned. 
3.4.16 Possible implications for REACH guidance: No specific implications foreseen. 
3.4.17 Enclosure 
3.4.18 Evidence indicates that emissions to the workplace are substantially reduced 
if a process involving engineered nanomaterials is performed in a properly 
designed enclosure/containment. In most of the studies where an enclosed or 
sealed process was used, containment was effective as long as it was 
maintained, however this was not universal. In one study, a leak was 
identified which was not evident from other process parameters. In two others 
releases were measured but no leakage point was identified. Thus it cannot 
be said that enclosure of a process is always completely effective. A 
conclusion to be drawn would be that use of an enclosed system is not 
sufficient in itself to guarantee that there is no release of nanomaterials into 
the workplace air. This would imply that such systems should be tested 
directly to demonstrate effective containment.  
3.4.19 The situation is further amplified when considering what happens when 
containment is opened. In almost all cases, elevated level were measured 
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associated with opening of the containment for recovery of testing of the 
product. In a general sense, even for other (non-nano) substances, this is 
always considered to be a critical point.  
3.4.20 In relation to the REACH guidance, relevant areas are D.4.6.1 Effectiveness 
of RMMs, R. 13.3 Effectiveness of RMMs, R.13.4.2.5 Estimation and 
documentation of RMM effectiveness in the library. From the RMM library, in 
relation to process control, RMM W8.01 and W8.02 under the heading 
Automation and enclosure are most relevant. These have default values of H 
(High). This is probably still justified but use of appropriate caveats to reflect 
the requirement for effectiveness to be directly assessed should be 
considered.     
3.4.21 Ventilation (including LEV) 
3.4.22 Evidence indicates that worker exposure can be significantly reduced or 
prevented through the use of correctly designed and implemented extraction 
ventilation and filtration for processes involving engineered nanomaterials that 
would normally result in the release of airborne particles. The types of 
systems evaluated here cover a range of designs and operational parameters 
(e.g. ventilation rates, size, degree of enclosure, process being ventilated). In 
practice very few of the details on degree of enclosure or ventilation rate are 
available in the publications.  In addition there was almost no quantification of 
the degree of effectiveness provided i.e. what level of effectiveness was given 
by the local exhaust ventilation (LEV).  Such information requires comparison 
of a process with LEV and without LEV. These studies in the main were not 
set up to measure this. What is observed is that in some cases the LEV was 
effective, in some cases not.  Again this could be considered to be similar for 
substances in general. 
3.4.23 In relation to the REACH guidance, relevant areas are D.4.6.1 Effectiveness 
of RMMs, R.13.3 Effectiveness of RMMs, R.13.4.2.5 Estimation and 
documentation of RMM effectiveness in the library. Information concerning 
the effectiveness of RMM is provided in the RMM library. In this document the 
default efficiency given for Labhoods (W.15 EX4), Extracted booth (W.15 
Ex5). Laminar flow booths (W.16 Ex1) and LEV captor hood (W17.Ex1) is 
80%, there is no expectation of 100% in the general operation of these 
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devices. The maximum efficiency values range from 99% to 90%. Based on 
the information presented above there is no justification for a change to the 
default values for these types of RMM.  
3.4.24 Filtration 
3.4.25 Filtration is relevant both as an occupational and environmental RMM. The 
better extraction methods have involved the use of high efficiency particulate 
air (HEPA) filtration and electrostatic precipitation. HEPA filtration, as theory 
predicts, appears to be very effective at the nanoscale.  
3.4.26 Filtration theory indicates that filtration will be effective for particles in the nm 
size range. The evidence available appears to support this. Whilst theory 
would predict that some improvement in filtration efficiency at particle sizes of 
less than 100 nm there is insufficient evidence to demonstrate such improved 
performance.  In many cases, the challenge aerosol to control will be 
aggregates or agglomerates on nanoparticles and will therefore be > 100nm 
and possibly be closer to 300-500 nm normally considered to be the most 
penetrating size for filters.  However this most penetrating size is the one 
generally used to test these filters. 
3.4.27 In relation to the REACH guidance, relevant areas are D.4.6.1 Effectiveness 
of RMMs, R.13.3 Effectiveness of RMMs, R.13.4.2.5 Estimation and 
documentation of RMM effectiveness in the library. There is no evidence to 
support any change to the quantification of the Effectiveness of filtration as a 
RMM (as indicated in the RMM library). 
3.4.28 Electrostatic precipitators also appear to be effective at capturing 
nanoparticles. Again, no change to the effectiveness is appropriate based on 
the evidence available.   
3.4.29 Administrative controls 
3.4.30 There are a range of administrative controls that may be implemented for 
workers involved in handling engineered nanomaterials. These are usually 
implemented in combination with other control measures e.g. enclosure, 
extraction and Personal Protective Equipment (PPE). 
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3.4.31 Summary: There is no specific evidence to suggest that administrative 
controls which are used for substances in general will not be appropriate or 
equally effective for nanomaterials. 
3.4.32 Personal protective equipment including respirators and gloves 
3.4.33 Evidence suggests that the performance of respiratory protective equipment 
(RPE) will be effective against particles in the nanoscale size range. 
Research on this issue has been largely based on the standard test methods 
used for respirator filters in which filters are challenged with a NaCl or Dioctyl-
pthalate aerosol with a median diameter of 300 nm.  Particle theory suggests 
that the maximum penetrating particle size is of the order of 300 nm and that 
collection efficiency improves below that particle size due to capture by 
diffusion. This has been confirmed in several studies evaluating filter 
penetration although some studies have reported lower maximum penetrating 
particle sizes (as low as 100 nm) but with capture efficiencies increasing 
below this size. An implication of this, however, is that aggregates or 
agglomerates of nanoparticles, which could well be around the maximum 
penetrating size, are likely to be more penetrating than the primary 
nanoparticles. Only a limited number of material types have been tested but it 
is not expected, based on diffusion theory, that the chemical composition 
would greatly affect filter performance. However, a lack of any testing data for 
instance for CNT must be considered to be a gap. 
3.4.34 As for chemicals in general, further work is required to investigate human 
factors such as leakage around (rather than through) a face-piece filter.   
3.4.35 In relation to dermal exposure the use of gloves and airtight fabric clothing 
has been examined.  It has been suggested that some kinds of skin protective 
equipment (SPE) might have limited effectiveness.  For gloves, manufacturing 
design and material thickness are major issues in determining whether or not 
nanoparticles penetrate.  In some cases two layers are recommended.  More 
work is required.   
3.4.36 The use of PPE should be considered as the last line of defence in the 
hierarchy of workplace exposure mitigation approaches. PPE should also be 
worn on a precautionary basis whenever the failure of a single control, 
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including an engineering control, could entail a significant risk of exposure to 
workers. PPE will also be needed in situations where the use of engineering 
controls is impractical.  
3.4.37 In relation to the REACH guidance, relevant areas are (D.4.6.1 Effectiveness 
of RMMs, R.13.3 Effectiveness of RMMs, R.13.4.2.5 Estimation and 
documentation of RMM effectiveness in the library). Available evidence 
suggests that current “typical default value” and a “maximum achievable” 
value for other respiratory protective equipment are likely to be appropriate. 
Additional information may be necessary for dermal protective equipment. 
3.4.38 Control Banding (CB) 
3.4.39 The use of control banding (CB) has importance in relation to the selection of 
control approaches for conventional material.  However, even for such 
materials use of control banding still has some limitations. The Nano-tool 
(Paik et al., 2008) is a potentially important development and brings the same 
structured approach towards decision-making.  However, it is challenging to 
see how this tool could be used without very critical review of the input 
parameters and collection of much more information about them in relation to 
each case of its use or without at least a general knowledge on the risks of 
particles in the nano form and compared to the bulk (non-nano) form.  Such 
validation of the Nano-tool that has been done is primarily only based on 
expert judgement.  It could be argued that, if all the evidence necessary for 
proper use of the Nano-tool were collected, it would not be necessary to use 
the tool at all. 
3.4.40 The Nano-tool is the only well documented CB approach currently available.  
However to use this as a basis for guidance at this time would be problematic.  
It is not at the current time sufficiently well developed or validated to be 
recommended.  More development of CB approaches are on-going under ISO 
229 using the approach developed by Paik et al. (2008), however publication 
of this guidance is some years away.   
3.4.41 In relation to REACH, control banding in its current form, given its current 
level of development cannot be used to demonstrate that the risks are 
adequately controlled. However, as an interim measure, users might consider 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 38 - 
CB approaches to provide initial selection of control measures as a starting 
point while collecting further information about exposure, toxicity and risk. 
3.4.42 Occupational Exposure Limits (OELs) 
3.4.43 At present, there are in a practical sense no new OELs specific to 
nanomaterials that have been adopted or promulgated by authoritative 
standards and guidance organisations. The vast heterogeneity of existing and 
potential nanomaterials suggests that a large number of specific OELs may 
have to be developed in due course. Some OELs could be developed more 
quickly for some nanomaterials by applying increasingly available dose–
response data generated from animal studies across categories of 
nanomaterials with similar properties and modes of action. Controls must still 
be applied even before OELs are available. However, in the absence of 
DNELs/OELs it is difficult to be certain that applied control measures are 
controlling exposure to levels which are low enough. 
3.4.44 In relation to the REACH guidance, it should be made clear that an OEL is not 
a technical risk management measure.  Relevant areas are B, D, E, R.14, 
R.15, R.16, R.8. It is important that where guidance is given in SDS 
concerning published OELs, this reflects that these are not based on the 
nanoform of the material and may therefore not offer adequate protection for 
the nanoform. 
3.4.45 Medical surveillance 
3.4.46 Although preliminary medical surveillance activities such as documentation of 
the presence of engineered nanoparticles and identification of potentially 
exposed workers are likely to be beneficial in the long term, no clear guidance 
can be given at this time as to specific medical endpoints which should be 
tested for.  
3.4.47 Safety Data Sheets 
3.4.48 The information provided reflects only one study (SWA, 2010b). This study 
was carried out in relation to Australian regulation. However the requirements 
against which appropriateness of the SDSs were judged were generic rather 
than specific to local regulation. The conclusions are very clear and 
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summarised as: “Overall [only] 18% (9/50) material safety data sheet (MSDS) 
were assessed as providing reliable information to appropriately inform an 
occupational risk assessment”. The authors view that there was an urgent 
need for improvement is justified on the evidence presented. 
3.4.49 As indicated in Annex II of REACH, the Safety Data Sheet provides a 
mechanism for transmitting appropriate safety information on classified 
substances and preparations, including information from the relevant 
Chemical Safety Report(s) down the supply chain to the immediate 
downstream user(s). The information provided in the Safety Data Sheet shall 
be consistent with the information in the Chemical Safety Report, where one 
is required. The information provided by Safety Data Sheets shall also meet 
the requirements set out in Directive 98/24/EC on the protection of the health 
and safety of workers from the risks related to chemical agents at work. In 
particular, the Safety Data Sheet shall enable the employer to determine 
whether any hazardous chemical agents are present in the workplace, and to 
assess any risk to the health and safety of workers arising from their use. 
3.4.50 It is clearly of concern if SDSs are not providing this fundamental mechanism. 
It is important that information provided on SDSs for a nanomaterial is 
representative, valid and provides the protection needed for the forms 
addressed by the SDSs.  
3.4.51 RMM relating to consumers 
3.4.52 Due to lack of evidence, no recommendation relating to REACH guidance for 
RMM relating to consumers can be made at this time.  
3.4.53 RMM relating to the environment 
3.4.54 Other than in the case of filtration, due to lack of evidence no 
recommendation relating to REACH guidance for RMM relating to 
environment can be made at this time.  
3.4.55 Operational conditions 
3.4.56 Operational conditions include duration and frequency of exposure, the 
applied amount of chemical, temperature, containment of process, capacity of 
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surroundings. Only limited information on occupational conditions was found 
to be available in the public literature. Information is available on the risk 
management measures adopted and in some cases the quantity of material 
produced are used on a daily or batch basis. Information concerning room 
sizes, ventilation rates, and temperature is almost entirely absent.  
3.4.57 The possible implications for REACH include a lack of information relating to 
R.13.2.2 Operational conditions and risk management measures related to 
workers. There is also likely to be a lack of information in relation to 
estimation of exposures using Tier 1 models (R. 14. R.15. R.16) and a limited 
opportunity to validate assumptions in these models.  
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3.5 TASK B3: EXPOSURE ESTIMATION (MODELLING AND 
MEASUREMENTS) - HARVESTING RESULTS FROM ON-GOING 
ACTIVITIES 
3.5.1 This is a review task. The inputs to the task included literature identified in 
Task A of RIP-oN 3 as well as the information collected from industrial 
sources in the exposure scenario case studies that make up Task B1.  In 
relation to the scientific literature, initial examination of the information 
collected in Task A indicates that the sources of information include ISO 
(2007, 2008), BSI (2007), OECD (2010) and European projects such as 
NanoSafe2 (http://www.nanosafe.org; accessed 6th September 2010) and 
NANOSH as well as the general scientific literature (e.g. Brouwer et al., 2004, 
Maynard and Aitken 2007).   
3.5.2 Various types of relevant studies were identified. These include: i) studies 
which have attempted to characterise exposure or release in specific 
situations; ii) studies focused on the development or evaluation of new 
measurement methods; iii) guidance documents where measurement 
methods and approaches have been recommended (based either on 
evidence or not) and; iv) modelling studies.   
3.5.3 In this task, all relevant information pertaining to availability, adequacy and 
applicability of methods for sampling, modelling and/or measuring exposure of 
workers, consumers, the environment and man via the environment to 
nanomaterials will be evaluated.  
3.5.4 In developing this report the following were produced: 
 An overview and summary of the literature; 
 Identification of issues where further adjustment of the guidance 
may be relevant for nanomaterials in general or for specific 
categories of nanomaterials;  
 Evidence for each issue including examples or approaches or 
limitations or actions to improve; 
 A first look at implications for the guidance and how this could be 
modified in the light of the information collected.  
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3.5.5 Discrimination from background nanoparticles 
3.5.6 Typical urban air contains anywhere between 10,000 to 40,000 particles.cm-1 
which come from a variety of sources including, industrial pollution, traffic and 
domestic emissions.  
3.5.7 In industrial settings, evidence of measurement problems relating to 
background aerosols has been reported in several studies (e.g. Kuhlbusch et 
al., 2004, 2006; Demou et al., 2008; Park et al., 2009). Specifically identified 
sources include heating units, fork lift trucks and vacuum cleaners.  
3.5.8 These background number concentrations are dominated by particles smaller 
the 1000 nm and much of the distribution is typically in the range 10 to 300 
nm.  The presence of this ambient particulate creates problems when 
attempting to measure emissions of engineered nanoparticles from 
nanomaterials sources. 
3.5.9 Three strategies have been reported (including combinations) to address this 
issue of these with varying success. The first is to take time series, or time 
differentiated measurements with associated log of events, typically including 
activities such as pre-operation of reactor, to determine a plausible 
relationship between events and levels.  
3.5.10 A second approach is to take parallel samples with the same instrumentation 
in an area where it is expected that there is only background aerosol present, 
i.e. there is no expected contribution from the source (e.g. Kuhlbusch et al. 
2004, 2006).  This is sometimes called the “far field” and can be outside, or at 
another point in the production building/laboratory.  For this type of approach, 
care is required that there is no contribution from the sources of interest, or 
from other background sources in the far field sample.  
3.5.11 A third approach is to collect physical samples of the aerosol for off-line 
analysis to confirm that the peak concentrations observed correspond to an 
identified NM, either by composition (elemental analysis of the primary 
material or impurity) or morphology or both, for example by Scanning Electron 
Microscopy (SEM)/ Transmission Electron Microscopy (TEM) and Energy-
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dispersive X-ray Spectroscopy (EDAX) analysis (e.g. Methner et al., 2010; 
Brouwer et al., 2009). 
3.5.12 While all of these approaches have utility, all must be applied with care to 
ensure that no confounding effects, such as a change in the far field 
background with time, corrupt the data. Combination approaches have been 
described and are generally more successful. Brouwer et al. (2009) used a 
combination of these approaches as the basis of a semi-formal decision logic 
to determine whether nano-objects were present in the workplace air. This 
required an exceedance of a predetermined near-field/far field ratio (in the 
reference ratio 1.05 was used), that changes in concentration or size 
distribution corresponded to observed activities and that the chemical 
composition of the sample (in the near and far field) matched that expected. 
The obvious limitation of the method in the light of the dynamic response, 
detection limits and the measurement uncertainty of the applied 
measurements is in its ability to detect statistically significant deviations in the 
ratio. Currently available sampling and analytical methods might also have 
insufficient sensitivity to assess very low levels required when in due course 
OELs/DNELs for nanomaterials may be substantially lower than current 
OELs/DNELs,(e.g. NIOSH (2005) for TiO2)).  
3.5.13 Conclusions and possible implications for the REACH guidance: 
 Background aerosol will be an important contribution towards the 
total number , mass and surface area concentration; 
 Where possible, background should be subtracted. Viable 
approaches are available on which guidance should be based; 
 If it is not possible to remove the background contribution, then the 
total concentration could be considered to be a worst case. 
However, this may be considered to be over-precautionary. 
 Background particle may also act as carriers for nanomaterials 
which have aggregated with them. 
3.5.14 Measurement of size distribution  
3.5.15 Measurement of size distribution is clearly an important parameter. The size 
information may be obtained through a number of instrumental routes. Based 
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on the evidence available, it seems unlikely that the size distribution of 
aerosols measured in the workplace is the same as the size distribution of the 
primary material. There is evidence that distributions are complex, not log 
normal (as might be expected for laboratory generated samples).   
3.5.16 Such irregular or sometimes bimodal distributions are quite typical in the 
published literature available. Various reasons have been suggested for this. 
One is that the smaller mode represents primary particles and the larger 
mode either agglomerates or aggregates of these materials or agglomerates 
in combination with background particles, following scavenging by these 
particles. 
3.5.17 Thus an important question in relation to the ultimate risk to consider is 
whether these aggregates/agglomerates could subsequently de-agglomerate 
e.g. when depositing in the lung lining. This may have implications for the 
potential risk. Given the irregular nature of the distribution in most cases, it is 
inappropriate to summarise the distribution by a single set of parameters such 
as median and diameter and geometric standard deviation. 
3.5.18 Devices which measure size distribution such as the Scanning Mobility 
Particle Sizer (SMPS) and Fast Mobility Particle Sizer (FMPS) provide a 
particularly data rich output. These devices produce count data in several size 
bins either collected in parallel (in the case of the FMPS) or in a very close 
time sequence (in the case of the SMPS). There are several ways in which 
this data might be used. The simplest approach is to inspect the complete 
size distribution. This is particularly useful in assessing single events or single 
changes (e.g. the implementation of a control measure, or the comparison 
between an aerosol and a background).  This type of analysis, however, is 
difficult to quantify as the data are often multimodal.  As such, the distributions 
cannot be described and compared by unique parameters such as the 
geometric mean and standard deviation.  
3.5.19 An alternative is to sum the total counts to provide a single number. However 
this approach looses the size information and so it is of limited value. In the 
reviewed studies, several authors (e.g. Fujitani et al., 2008; Bello 2008, 2009) 
have grouped (integrated) the size distribution into several discrete size 
ranges e.g. < 10 nanometres, < 100 nm , < 1000 nm etc. and compared their 
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respective time series to support the development of the background 
discrimination strategies or understanding of the particle formation dynamics.  
3.5.20 Conclusions and possible implications for the REACH guidance: 
 Particle size information is clearly important and the full size 
distribution curve should be reported;  
 The size distribution of aerosols measured in the workplace is 
unlikely to be the same as the primary material; 
 Recommended methods should be able to account for complex form 
of the distributions (e.g. bimodal distributions).  
3.5.21 Maximum relevant size  
3.5.22 Use of size dependent-health related criteria is common practice in 
measurement of occupational exposure (ISO, 1995). It has been shown that 
the size distribution of aerosols that are present in workplaces where 
nanomaterials are synthesised or used can often have a broad distribution.  
An important issue to consider is whether it is appropriate to impose an upper 
size limit of the particles to be collected or measured in order to characterise 
exposure to NM. One option would be to exclude all particles with physical 
dimensions greater than 100 nm, providing methods were available.  This 
would allow estimation of people’s exposure to “nanoparticles” as formally 
defined in ISO/TS 27687:2008 (BSI, 2008).  
3.5.23 Evidence from the studies reviewed suggests that emissions are rarely in the 
form of single nanoparticles (this is not to exclude this possibility entirely). In 
most cases the measurements indicated that, where nanoparticles were 
present, they were in an aggregated or agglomerated form or were associated 
with other materials including background particles. In the main studies 
reviewed, the selected strategies were to maximise the information available 
by looking at a wide particle size range (and thus not operate with a 100nm 
cut-off). The implicit assumption in that is that agglomerates, aggregates and 
other combined particles are at least potentially relevant NM exposures. The 
relevance of these agglomerated forms, including potential for dissolution, or 
dissagregation, needs to be considered also from the toxicological 
perspective in the risk characterisation.  
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3.5.24 Many devices used do already have a maximum measurable particle size. 
This can be to protect the instruments’ detection system or because of 
decreasing detection efficiency beyond that size. For example, several of the 
Condensation Particle Counters (CPCs) have a cut-off (maximum size) of 
around 1000 nm which is achieved by including an impactor in the inlet. There 
is an argument to standardise on that size, particularly if emphasis is given to 
(total) number concentration as a parameter. Otherwise, two instruments, with 
different maximum sizes will give different results. However, this is not a 
health based selection criterion.   
3.5.25 One approach could be to use the respirable convention (CEN, 1993) as an 
upper size limit.  This would have the advantage of being biologically relevant 
and would provide coherence with current practice in occupational exposure 
assessment. Use of the respirable convention has been recommended by 
several authors (e.g. Schneider and Jensen, 2008). Respirable 
concentrations have been measured in several of the reviewed studies (e.g. 
Peters et al., 2009; Han et al., 2008). 
3.5.26 In general however, given the current state of knowledge, the practice 
adopted in the reviewed scientific studies, assessing multiple parameters with 
multiple instruments, seems correct. Though the maximum (and indeed 
minimum) size limits of an instrument and the instrument response function 
are usually known, they are unfortunately seldom reported.  
3.5.27 Conclusions and possible implications for the  for the REACH guidance: 
 Evidence suggests that nanoparticles of interest may be present as 
primary particles and larger aggregates/agglomerates potentially 
including background particles from which primary particles may 
subsequently be released.  Therefore these larger agglomerates, not 
just primary particles should be measured. Measurement of primary 
particles alone is not sufficient to fully understand exposure in these 
situations; 
 The use of the respirable fraction, representing the fraction of 
aerosol capable of entering the alveolar region of the lung is 
recommended as the default definition of maximum particle size; 
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 If instruments which have a smaller cut off point than the respirable 
convention are used, the value of the cut off point should be 
reported in any document in which this information is given. 
3.5.28 Effect of high spatial and temporal variability 
3.5.29 In occupational settings it is common that airborne concentrations are higher 
and closer to the source worker (near-field) than at some distance point (far-
field). High spatial variability has been reported in the studies reviewed. 
Demou et al. (2009) reported both high and low spatial variability in different 
settings. Plitzco (2009) reported “genuine nanoparticles” emitted from a 
reactor that agglomerated in a very short time and immediately led to a 
lowering of the number concentration.  Seipenbusch et al. (2008), as part of 
the FP6 project NANOTRANSPORT, investigated the evolution in time of a 
nanoparticle aerosol released into a particle-free atmosphere and in presence 
of a pre-existing background aerosol and demonstrated rapid agglomeration 
and scavenging by the background aerosol. 
3.5.30 High spatial and temporal variability emphasises that the need for 
measurements of exposure in workplaces are based on personal sampling, 
i.e. by using a sampling device located in the breathing zone of the worker 
being assessed.  Studies with other particles have generally shown that 
personal exposure is higher compared to exposure as measured in the 
general environment of a workplace e.g. Stevens (1969). This is partly 
because the worker is usually closer to the source than static environmental 
monitors are able to be placed but also from the activities undertaken by the 
worker himself, and the extent to which these modify the exposure levels.  
This may be particularly relevant for NM due to high transport, agglomeration 
and scavenging rates.   
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3.5.31 Conclusions and possible implications for the  for the REACH guidance: 
 Measurements of workplace air concentrations may not adequately 
represent personal exposure; 
 A preferred approach is the use of personal sampling devices; 
 Given the current lack of such a device, measurements strategies 
which encourage (even limited) comparison between workplace air 
concentrations and personal exposure are recommended.  However 
there is no current definitive guidance in this respect which could be 
implemented at this time. 
3.5.32 Choice of metrics and instruments 
3.5.33 There are three main metrics, all of which could have some utility in 
measuring exposure to nanoparticles. These are: i) mass concentration (units 
mg m-3); ii) number concentration (units m-3) and; iii) surface area 
concentration units (units m2 m-3). A case may be made for the use of any of 
these metrics under certain circumstances. 
3.5.34 The metric used to assess exposure to nanomaterials should be that which 
most closely links to any potential health effect.  The current evidence 
suggests that no single metric (or method) for monitoring nano-aerosol 
exposure will suit all nanomaterials. Rather, there will be occasions where 
particle number, surface area and mass concentration measurements will 
play an important role in evaluating potential impact.  
3.5.35 Instrumentation is available to measure each of these metrics but there are 
identified practical issues in the selection, use and analysis of metrics data. 
For mass, a key issue is a lack of sensitivity towards the particle sizes of 
interest. Measurement of number concentration is in contrast highly sensitive.  
In general, analytical methods that measure particle numbers can easily 
assess much lower levels than analytical methods that measure mass. 
However, measuring particle number concentration in isolation can be 
misleading. In all particle number concentration measurements, the 
integration limits over which a particular instrument operates are critical to the 
reported results. Real-time measurements of surface area concentration are 
technically feasible but there is very limited practical experience with these 
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instruments. The results obtained need to be carefully interpreted and the 
limitations and boundaries carefully examined. Issues to consider are to 
include the effect of initial aerosol charge, the composition of the material, 
how aggregates are dealt with (in particular where both external and internal 
surfaces are available) and the effect of extreme particle shape.  
3.5.36 An ideal approach is to choose a metric which is correlated with the health 
effect of concern, which can be relatively easily measured and be both 
measurable and sensitive enough to detect differences in the probable ranges 
encountered.  However, given current knowledge, it is probably not useful to 
ask “which is the best metric for nanoparticles.” Useful preliminary questions 
might be “what types of particles are we interested in?” and “what is the 
health effect we are trying to correlate with?”. 
3.5.37 Conclusions and possible implications for the  for the REACH guidance: 
 The issues of metrics should not be decided on exposure 
assessment issues alone, toxicological information needs to be 
carefully considered; 
 At this time it is not possible to make a definitive statement 
concerning which of the metrics are the most appropriate for 
nanoparticles.  In relation to measuring exposure, the best available 
guidance at this time is that measurements should encompass 
assessment of at least mass, but where possible also number and/or 
surface area concentration;   
 Methods which could be recommended in relation to these metrics is 
provided in this report;   
 In addition, measurements of size distribution should also be made 
as discussed in this report. 
3.5.38 Assessment of high aspect ratio nanomaterials   
3.5.39 Exposure to fibrous aerosols is assessed by measuring the number 
(concentration) of fibres in the air with a specific shape and composition 
(WHO, 1997). Critical to the method is definition of a fibre, specifically a 
respirable fibre. The World Health Organisation (WHO) defines a respirable 
fibre as an object with length greater than 5 x 10-6 m (5000 nm) a width less 
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than 3 x 10-6 m (3000 nm), and a length to width ratio (aspect ratio) greater 
than 3:1. It relies on manual counting of fibres by optical microscopy 
according to a set of counting rules governing size (as above), number of 
areas (graticules) scanned, number of fibres scanned,  number density of 
fibres on the collection substrate, and how to deal with “bundled” or 
overlapping fibres. The scope of application of the WHO method is broad, as 
indicated in the following statement: “The method [..] is applicable to the 
assessment of concentrations of airborne fibres in workplace atmospheres 
most commonly personal exposures - for all natural and synthetic fibres, 
including the asbestos varieties, other naturally occurring mineral fibres and 
man-made mineral fibres” (WHO, 1997). 
3.5.40 Several high aspect ratio nanomaterials (HARN) could fall within this scope. It 
has been suggested that fibre counting could be an appropriate method to 
assess exposure to HARN (BSI 6699-2:2007; BSI, 2007). However concerns 
have been raised regarding the applicability of the WHO criteria for HARN, 
specifically for carbon nanotubes (CNT). Optical microscopy would not detect 
individual CNT although it could detect bundles of CNT.  The higher 
magnification needed would require SEM/TEM, which would increase the 
counting time substantially.  
3.5.41 It is known that optical microscopy is less sensitive than SEM/TEM to very 
fine fibres and therefore underestimates the total number of fibres collected. 
SEM/TEM will measure these very fine fibres, which would not be observed 
by optical microscopy, leading to larger counts in what would be an equivalent 
sample.  This would lead to difficulties in making comparison with limit values 
for fibres set using optical microscopy. 
3.5.42 Only one study, Han et al. (2008), used an approach based on the WHO 
approach and reported fibre concentrations. It is not clear the extent to which 
WHO counting rules were applied. However it is noted that all the fibres 
reported were shorter than the WHO definition and so, by strict application of 
the fibre counting rules, the count would be zero.  Bello et al. also collected on 
to a filter for electron microscopy analysis, but no fibres were identified. Han 
et al. (2008) made measurements of total carbon using a portable 
aethalometer. Other investigators used Condensation Particle Counter (CPC), 
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Optical Particle Counter (OPC) and Scanning Mobilty Particle Sizer (SMPS) 
to try to detect, although these devices prove no morphological information. A 
recent review on options for carbon nanotube (CNT) detection and analysis 
(SWA, 2010a) concluded that the Electrical Low Pressure Impactor (ELPI) 
spectrometer may have some utility in this respect. Various off-line 
measurement approaches were reviewed by Tantra et al. (2007) and it was 
concluded that none were immediately appropriate for measurement of 
occupational exposure.  Currently there is no consensus on the most 
appropriate approach.   
3.5.43 Conclusions and possible implications for the  REACH guidance: 
 Assessment of fibre concentration is likely to be relevant to some 
high aspect ratio nanomaterials in terms of their exposure; 
 The presence of “fibres” is only likely to be detected by electron 
microscopy; 
 Application of the WHO approach has not yet been validated for any 
types of high aspect ratio nanomaterials; 
 Encouragement should be made in the guidance towards checking 
of whether fibres are present in exposure assessment samples for 
all materials which have some potential for the release of fibres; 
 Given an absence of measurement methods or terminology to 
describe bundles or clumps of high aspect ratio nanomaterials, no 
specific guidance can be given at this time for quantitative 
assessment of these entities. However their presence should be 
noted in any assessment. 
3.5.44 Exposure models 
3.5.45 Only limited assessment of the models used in exposure estimation has been 
carried out so far.  The most extensive validation was for occupational 
exposure by inhalation. Evaluating Stoffenmanager and ECETOC TRA, the 
conclusion drawn in the FP7 NANEX project (Development of Exposure 
Scenarios for Manufactured Nanomaterials - NANEX (Grant agreement no.: 
247794) was that there was no correlation between the model estimates and 
measurement data. Neither of the models is tuned to and calibrated for 
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nanomaterial exposure situations, and hence the actual model estimate will 
be inaccurate and possibly overestimate the (mass) concentration levels.  
3.5.46 For consumer exposure, NANEX evaluated Consexpo, (inhalation, dermal, 
oral), ECETOC TRA (inhalation, dermal,oral), RiskofDerm (dermal). The 
authors concluded that dermal modules might be suitable for use for 
manufactured nanomaterials (MNMs) as the underlying equations do not 
appear to rely on nano-specific properties. The dermal modules of the models 
may therefore be applied to nanomaterials, however, they should be used 
with care as they are not yet validated nor calibrated for MNMs and the output 
(the exposure estimate) is given in a mass-based metric. There are greater 
limitations in the currently available inhalation modules in the exposure 
estimation models. These inhalation modules do not consider the nano-
specific properties of the materials that could affect the exposure, e.g. 
agglomeration effects.  Therefore, in the authors view, inhalation modules 
should be used with even greater care. 
3.5.47 In relation to environmental exposure models such as (EUSES), these are 
often based on QSPR (Quantitative Structure-Property Relationship) 
calculations using physicochemical properties of the substance, mainly 
Octanol-Water Partition Coefficient (KOW) and Partition Coefficient (Kp) values. 
At present, it is highly unlikely that these QSPRs will be applicable for 
nanomaterials. It is therefore recommended to not use these QSPRs 
(including read-across approaches) to estimate properties of nanomaterials 
without relevant scientific justifications, as long as there is no (solid) basis to 
do so.  Instead, measured partition coefficients (i.e. Kp values) should be 
used to estimate environmental distribution. When sufficient information on 
the fate and behaviour of nanomaterials becomes available it may either be 
concluded that the current QSPR estimations are applicable for nanomaterials 
as well, or new QSPRs for nanomaterials can be developed.  
3.5.48 At present, however, there is a need for specific information on 
nanomaterials, especially on properties that are necessary for (estimating) 
fate and behaviour and (modelling) hazard characteristics. In addition, 
information that enables a proper comparison between bulk form and 
nanoforms is lacking (RNC/RIP-ON3/B3/4/FINAL, (8.4)) 
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3.5.49 While there is information available on models for nanoparticle transportation, 
aggregation and deposition available in the literature deriving primarily from 
the colloid literature, this is either theoretical and/or based on idealised 
relatively simple model systems (e.g. Weisner and Bottero 2007). The models 
have not been adapted for the large number of components present in natural 
water which may include salts, clays, micro-organisms, natural organic matter 
and other colloidal materials (Mylon et al., 2004). At present these are not 
appropriate for use in a regulatory context without further scientific 
justification. 
3.5.50 Conclusions and possible implications for the REACH guidance: 
 Exposure models are a key element of the exposure estimation 
process; 
 The limited evidence of validation for occupational exposure 
indicates that model estimates should not be relied on alone without 
further confirmation of their validity in individual cases. In any case, 
model estimates should be used with caution and with further 
scientific justification; 
 It is not possible to provide reference to models which have been 
validated for nanomaterials. Therefore, cautionary statements 
should be added to the relevant parts of the guidance. 
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3.6 TASK B4: ADVISORY REPORT ON OC, RMM, ES AND EXPOSURE 
ESTIMATION WITH THE PURPOSE OF CONDUCTING EXPOSURE 
ASSESSMENT OF NANOMATERIALS FOR REACH 
3.6.1 In this task, information collected and analysed in Tasks A to B3 was drawn 
together to provide an advisory report suggesting how the relevant parts of 
the REACH "Guidance on Information Requirements and Chemical Safety 
Assessment" could be adapted or complemented in order to facilitate the 
exposure assessment of nanomaterials in the REACH context. 
3.6.2 The report covers inter alia operational conditions, risk management 
measures, development of exposure scenarios and exposure estimation (via 
modelling and/or measurements). For measurements, issues related to 
potential background exposure to nanoparticles, choice of instrumentation 
and equipments for sampling and detection of nanoparticles have been 
addressed. 
3.6.3 The report provided considerations of where in REACH guidance (highlighting 
specific sections) there may be implications arising from the issues identified.  
For each section where a need for change had been identified, key issues 
relating to what changes are needed were identified as e.g. bullet points. It 
thus covers where and, in general terms, how the guidance would need to be 
changed. The need for research and of what type are also discussed where 
there are significant knowledge gaps.  
3.6.4 The primary reference documents for this report are the RIP-oN 3 documents 
RNC/RIP-ON/B1/2/FINAL, RNC/RIP-ON/B2/2/FINAL and RNC/RIP-
ON/B3/2/FINAL in which the available evidence has been gathered together, 
harvested and analysed, and the current REACH guidance documents.   
3.6.5 In these earlier documents a series of key issues relating to nanomaterial 
properties, which were considered to have possible implications for the 
REACH guidance, were identified. For each of theses issues, the evidence 
was drawn together, analysed and conclusions made.  
3.6.6 RNC/RIP-ON/B4/2/FINAL builds on these conclusions but does not repeat or 
reference the evidence base or the analysis in the previous documents. 
Rather, the report considers, on an issue by issue basis, possible implications 
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for the REACH guidance and identifies those issues for which a guidance 
change is recommended. In these cases, an assessment of where and how 
the guidance could be modified in order to accommodate the specific issue 
was made. References are made to the specific REACH guidance clause 
number (e.g. R.13.4). 
3.6.7 The analysis is presented in a tabular format in which there is the identified 
issue, a summary of the key points in the argument (drawn from RNC/RIP-
ON3/B1/2/FINAL, RNC/RIP-ON/B2/2/FINAL, RNC/RIP-ON/B3/2/FINAL) and 
an assessment of the guidance changes. Where specific knowledge gaps 
have been identified the need for additional research is indicated. 
3.6.8 RNC/RIP-oN3/B4/2/FINAL does not cover detailed proposals for modifications 
of the guidance text.  This report was discussed at the SCG meeting on 13th 
December 2010 and has subsequently been revised, taking into account 
these comments.  The summary tables shown below are from the revised 
report.  
3.6.9 For the avoidance of doubt, the discussion of these elements in this report at 
this time does not represent a final recommendation with regard to an 
inclusion or exclusion in the REACH guidance 
3.6.10 Assessment regarding the learning from ES case studies 
3.6.11 Table 4.1 is drawn from and based on the arguments contained in the 
RNC/RIP-oN3/B1/2/FINAL and summarises the conclusions on the key issues 
identified and an assessment of possible implications for the REACH 
guidance. 
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3.6.12 Table 4.1 Issues arising from the ES Case studies 
Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Applicability of Sector of 
Use Categories (SUs) 
 
 
Relevant SUs found for all scenarios The information available suggests that, for this issue, 
the current guidance works (reasonably) well for 
nanomaterials. No change to the guidance 
recommended. 
Applicability of Process 
Categories (PROCs) 
 
Relevant PROC found for all scenarios The information available suggests that, for this issue, 
the current guidance works (reasonably) well for 
nanomaterials. No change to the guidance 
recommended. 
Applicability of ERCs 
 
Relevant ERC found for all scenarios The information available suggests that, for this issue, 
the current guidance works (reasonably) well for 
nanomaterials. No change to the guidance 
recommended. 
 
It should be stressed that this conclusion holds for using 
the ERC for naming ESs. It does not imply using the 
ERC in Tier 1 exposure estimation tools. 
Complexity of 
measurement 
programmes and data 
Case study providers used a range of instrument types with 
differing measurement ranges and metrics as identified in 
RNC/RIP-oN3/B1/2/FINAL. Measurement programme designs 
were experimental in nature rather that being specifically 
designed for REACH compliance. Partly as a result of this, use 
of the data for ES building was challenging.  More information on 
the issues experienced, along with implications for the guidance 
are detailed below.  
See below. 
Discrimination from 
background particles 
In the case study, attempts were made to compare process 
counts with background based on expert advice. This was not 
informed by REACH guidance as far as we were aware.  
See guidance recommendations in Table 4.3 
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Maximum particle size In the case studies instruments with differing maximum particle 
size were used. Providers had different approaches towards 
what was the relevant maximum particle size of interest. The 
importance of the maximum particle size was not really 
recognised, and was not informed by REACH guidance. 
See guidance recommendations in Table 4.3 
Metrics Attempts were made to use different metrics (mass, number, SA 
concentrations. No definitive guidance within REACH was 
available 
See guidance recommendations in Table 4.3  
Use of instruments Measurements of emissions were made using a range of 
instruments relevant to the metrics described above. Different 
instruments with different applicability were used. No definitive 
guidance within REACH was available 
See guidance recommendations in Table 4.3 
Data handling -
Uncertainty of 
measurement 
Guidance for exposure data recommends the use of the 90th 
percentile. In the case studies there was difficulty in interpreting 
data from real time instruments, for the measurement of particle 
number or size distribution in this way. Typically only single 
values were recorded which were averaged over unspecified 
time periods. In other cases time series measurements were 
made which would provide data from which 90th percentiles (and 
other summary statistics) could be derived. 
More information on the handling of data from real-time 
instruments should be added to R.14.4.5 (or to Appendix 
to R.14.4.5) Specifically to include how single value 
estimates would be derived and used. This could for 
example include advice on time periods over which data 
should be added.  
 
Use of exposure models Exposure models were used to estimate environmental and 
consumer exposure. Models were used in an unmodified way. 
See guidance recommendations in Table 4.3 
Applicability of ES The ES format was assessed through the ES case studies. 
(Details are provided in Appendix 1 of this report). In the main 
the assessment showed that the format was generic and equally 
applicable to nanomaterials as for substances in general. 
Specific aspects to the relating to the measurement of 
nanomaterials were identified. In general, these were the same 
issues which were picked up in the literature review in Task B3.  
See guidance recommendations in Table 4.3 
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3.6.13 Assessment regarding operational conditions and risk management 
measures 
3.6.14 Table 4.2 is drawn from and based on the arguments contained in the RIP-oN 
3 Task B2 report (RNC/RIP-ON/B2/2/FINAL) and summarises the conclusions 
on the key issues identified and an assessment of possible implications for 
the REACH guidance. 
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3.6.15 Table 4.2 Issues arising from the RNC/RIP-ON/B2/2/FINAL report on OC and RMM 
Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Hierarchy of control 
 
 
Based on the current guidance available from a wide range of 
organisations, there is a consensus view that the conventional 
approach to control of hazardous chemicals based on elimination, 
substitution, engineering control, administrative control and use of 
PPE, sometimes referred to as the hierarchy of control, is likely to be 
an effective framework on which to base control approaches 
[RNC/RIP-ON/B2/2/FINAL (5.8.2, 8.2)]. 
 
These approaches are highly consistent with the general measures 
necessary for safety and health protection of workers (Article 6 of 
Directive 89/391/EC), the reduce-to-a-minimum principle (Article 6 of 
Chemical Agents Directive 98/24/EC) and the hierarchy of RMM 
prescribed in the Chemical Agents Directive.   
Guidance: 
The information available suggests that, for this issue, 
the current guidance works (reasonably) well for 
nanomaterials. No change to the guidance 
recommended. 
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Existing methods (in 
general) 
 
 
As a general statement there is evidence that control and risk 
management methodologies which are already known can provide 
levels of protection for workers from exposure to engineered 
nanomaterials in the occupational environment. 
  
It is not indicated that new “nano-specific RMMs” need to be 
developed. Further testing and data is needed on specific workplace 
situations to understand the levels of protection afforded, and ensure 
effectiveness. [RNC/RIP-ON/B2/2/FINAL (8.3)], 
 
In relation to the REACH guidance, relevant areas are D.4.6.1 
Effectiveness of RMMs, R. 13.3 Effectiveness of RMMs, R.13.4.2.5 
Estimation and documentation of RMM effectiveness in the library. The 
information in the library on RMM efficiency is determined by two  
descriptors: a “typical default value” (an estimate of the 50th percentile) 
and a “maximum achievable” value (best practice). 
 
It is considered that for some RMM, the assumption that the available 
“typical default value” (an estimate of the 50th percentile) and a 
“maximum achievable” value (best practice) may not be achievable 
and should not automatically be assumed. Additional research may be 
necessary in order to establish the actual effectiveness of any specific 
RMM. This will be further specified below for specific RMMs like 
enclosure, filtration PPE, etc. 
 
Note that current guidance requires that If M/I assumes a certain 
effectiveness of a measure, the source of this assumption needs to be 
documented in the CSR. (D.4.6.1) 
Guidance: 
R.13.4.2.5 Insert caveat to indicate that particle size can 
affect RMM performance 
 
Any other changes would be in relation to the default 
values in the RMM library. This is not a general indicator 
of the need for changes of existing methods, rather that 
the evidence for each should be considered. This is 
elaborated for each RMM (below). 
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Modification and 
substitution 
Modification of the hazard potential of certain types on nanomaterials 
appeared to have some, as yet not fully explored possibilities. There 
are approaches (surface modification, encapsulation, particle size 
control, functionalisation and crystalline phase control) which have 
been shown to have the potential to modify the toxicity of nanoparticles 
[RNC/RIP-ON/B2/2/FINAL (6.4, 8.4)]. 
 
In the context of REACH such modifications would be done as a prior 
step before developing the specific ES. Therefore the ES would be 
developed for the modified substance and the modification step would 
not be a RMM for that modified substance. 
  
Possible implications for REACH guidance. No specific implications 
foreseen.  
Guidance: 
The information available suggests that, for this issue, 
the current guidance works (reasonably) well for 
nanomaterials. 
No change to the guidance recommended. 
Enclosure In relation to NM, enclosure has been mostly observed as an RMM for 
synthesis processes. Evidence reported in RNC/RIP-ON/B2/2/FINAL 
indicates that emissions to the workplace are substantially reduced if a 
process involving engineered nanomaterials is performed in a properly 
designed enclosure/containment. However this is not always the case. 
Emissions to the workplace have been reported which were 
subsequently attributed to a leak in the system. Emissions were also 
reported during activities such as product recovery and cleaning. 
Quantification of the effectiveness (e.g. the percentage reduction in 
emissions associated with use of enclosure) has not been reported. It 
is acknowledged that these aspects are also relevant to non-
nanomaterial process. It is not possible to make an evidence based 
judgement on whether this reduced performance is more or less likely 
to occur during nanomaterial processes than non-nanomaterial 
processes. However it has been suggested that because of their high 
mobility, nanoparticles are more likely to find leakage paths than larger 
particles. [RNC/RIP-ON/B2/2/FINAL (6.5, 8.5)]. It is concluded that use 
of an enclosed system is not sufficient in itself to guarantee that there 
is no release of nanomaterials into the workplace air. (This is also true 
for substances in general.) 
Guidance: 
Guidance to be modified to reflect the need to assess 
the level of containment provided by enclosed systems. 
Recommended change is the addition of notes or 
caveats added to the RMM library, in the remarks 
column. 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 62 - 
Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
 
In relation to the REACH guidance, relevant areas are D.4.6.1 
Effectiveness of RMMs, R. 13.3 Effectiveness of RMMs, R.13.4.2.5 
Estimation and documentation of RMM effectiveness in the library 
which already contain several caveats requiring justification of 
effectiveness values used. From the RMM library, in relation to process 
control, RMM W8.01 and W8.02 under the heading Automation and 
enclosure are most relevant. These have default values of H (High), 
which, based on R.13.4.2.4 is because “it would be inappropriate to 
give any figure due to the fact that no quantitative information is 
available or because these are strongly dependent on the local 
operational conditions and the skills of the user”  Based on the 
evidence, this assessment (H) is still justified.   
 
However, given additional concerns regarding the possibility of leakage 
it should be recommended that enclosed systems should be tested to 
demonstrate effective containment. 
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Ventilation, LEV, 
including fume hood, 
cabinets and other 
extraction 
Evidence reported in RNC/RIP-ON3/B2/2/FINAL indicates that worker 
exposure can be significantly reduced or prevented through the use of 
correctly designed and implemented extraction ventilation or processes 
involving engineered nanomaterials that would normally result in the 
release of airborne nanoparticles. Some evidence of inadequate 
control was reported but with no clear pattern.  Quantification of the 
effectiveness (e.g. the percentage reduction in emissions associated 
with use of LEV) has not been reported [RNC/RIP-ON/B2/2/FINAL 
(6.6, 8.6)]. It is acknowledged that these aspects are also relevant to 
non-nanomaterial processes It is not possible to make an evidence 
based judgement on whether this reduced performance is more or less 
likely to occur during nanomaterial processes than non-nanomaterial 
processes. 
 
There is no expectation of 100% effectiveness in the general operation 
of LEV devices in the current guidance. Relevant areas are D.4.6.1 
Effectiveness of RMMs, R.13.3 Effectiveness of RMMs, R.13.4.2.5 
Estimation and documentation of RMM effectiveness in the library 
which already contain several caveats requiring justification of 
effectiveness values used. Information concerning the effectiveness of 
RMM is provided in the RMM library. In this document the default 
efficiency given for Lab-hoods (W.15 EX4), Extracted booth (W.15 
Ex5). Laminar flow booths (W.16 Ex1) and LEV captor hood 
(W17.Ex1).Default values appear to be typically 80%.  
 
Based on the evidence collected, there is at present no justification for 
a change to the default values for these types of RMM.  
 
Guidance: 
The information available suggests that, for this issue, 
the current guidance works (reasonably) well for 
nanomaterials. No change to the guidance 
recommended. 
 
Research: 
More research on the quantification of the performance 
of LEV systems is recommended. 
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Filtration Filtration theory indicates that filtration will be effective for particles in 
the nm size range. The evidence presented in RNC/RIP-
ON3/B2/2/FINAL appears to support this. There is no requirement to 
develop new types of filters [RNC/RIP-ON/B2/2/FINAL (6.7, 8.7)]. 
  
In relation to the REACH guidance, relevant areas are D.4.6.1 
Effectiveness of RMMs, R. 13.3 Effectiveness of RMMs, R.13.4.2.5 
Estimation and documentation of RMM effectiveness in the library. 
There is no evidence to support any change to the quantification of the 
Effectiveness of filtration as a RMM (as indicated in the RMM library). 
Electrostatic precipitators also appear to be effective at capturing 
nanoparticles. Again no change to the effectiveness is appropriate 
based on the evidence available.   
 
Guidance: 
The information available suggests that, for this issue, 
the current guidance works (reasonably) well for 
nanomaterials. No change to the guidance 
recommended. 
Administrative controls There are a range of administrative controls that may be implemented 
for workers involved in using engineered nanomaterials. These are 
usually implemented in combination with other control measures e.g. 
enclosure, extraction and PPE [RNC/RIP-ON/B2/2/FINAL (6.8, 8.8)]. 
 
Summary: There is no evidence to suggest that administrative controls 
which are used for conventional materials will not be appropriate for 
nanomaterials.   Nor is there any expectation of this. 
 
Guidance: 
The information available suggests that, for this issue, 
the current guidance works (reasonably) well for 
nanomaterials. No change to the guidance 
recommended. 
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Respiratory protective 
equipment - RPE 
Evidence reported in RNC/RIP-ON3/B2/2/FINAL generally supports 
that the performance of respiratory protective equipment (RPE) will be 
effective against nanomaterials. There is no requirement to develop 
new types of filters. This is based both on theory and on laboratory test 
data where measured penetration data has been reported. [RNC/RIP-
ON/B2/2/FINAL (6.9, 8.9)]. 
 
Typically test evaluations been based evaluation of the highest level of 
respirator in common use ie P3 (or N95 in the US). 
 
In relation to the REACH guidance, relevant areas are (D.4.6.1 
Effectiveness of RMMs, R. 13.3 Effectiveness of RMMs, R.13.4.2.5 
Estimation and documentation of RMM effectiveness in the library. 
 
Default values provided in the RMM library are based on national and 
international standards against which these devices are tested for the 
purposes of certification. .Available evidence indicates that current 
“typical default value” and a “maximum achievable” value already 
applied in the library are likely to be appropriate and do not require 
modification.  
 
Guidance: 
The information available suggests that, for this issue, 
the current methods and guidance works (reasonably) 
well for nanomaterials. However, this should be 
augmented by providing advice that P3 filters should be 
used. An appropriate place for this advice would be in 
the RMM library.   
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Other PPE, gloves 
suits etc 
Some evidence reported by the European project NANOSAFE2 
suggests that nanoparticles can penetrate through commercially 
available gloves and recommends that two layers of gloves (double 
gloving) are worn. The use of impermeable, non-woven, materials is 
preferred. For clothing, use of cotton fabrics should be avoided. Glove 
selection is in general very dependant on several factors including 
tasks, materials and solvents handled, glove performance [RNC/RIP-
ON/B2/2/FINAL (6.9.13, 8.9.3)]. 
 
In relation to the REACH guidance, relevant areas are (D.4.6.1 
Effectiveness of RMMs, R. 13.3 Effectiveness of RMMs, R.13.4.2.5 
Estimation and documentation of RMM effectiveness in the library. 
 
No default values are provided for gloves in the RMM library. It is 
recommended to add a note in the remarks column relating to double 
gloving. 
 
Guidance: 
Recommended change is the addition of remarks 
relating to consideration of double gloving, provided that 
this in itself does not cause further problems ,e.g. 
handling issues   added to the RMM library. In addition a 
note recommending that cotton fabrics (for gloves or 
suits) should be avoided should also be added. 
 
Research: 
More research on the quantification of the performance 
of  gloves and other protective clothing is recommended, 
building on the research carried out in NANOSAFE2 
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Control banding The use of control banding has importance in relation to selection of 
control approaches for conventional materials.  However, even for 
such materials, use of control banding still has some limitations, in 
particular in relation to demonstrating control of risk as required by 
REACH. The Nano-tool is a potentially important development and 
brings the same structured approach towards decision-making. Work is 
underway in ISO and in the French agency for food, environmental and 
occupational health and safety (ANSES) based on the same tool. 
However, it is challenging to see how this tool, which has not been 
validated, could be used without very critical review of the input 
parameters and collection of much more information about them in 
relation to each case of its use. As more refined validated tools 
become available these may have more utility. [RNC/RIP-
ON/B2/2/FINAL (6.10, 8.10)]. 
 
In relation to REACH, control banding in it current form, given its 
current level of development cannot be used to demonstrate that the 
risks are adequately controlled. However, as an interim measure, 
users might consider CB approaches to provide initial selection of 
control measures as a starting point for the collection of more 
information. 
 
Guidance: 
No evidential basis for a change to the guidance. No 
change recommended 
 
Research: 
Further research towards the development and 
validation of control banding tools is required  
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Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Development of OELs OELs are not in themselves technical RMM nor are they necessarily 
equivalent to DNELs (without appropriate justification). In that sense 
discussion of them at this point is perhaps inappropriate. Well 
validated, justified OELs are however clearly helpful in understanding 
the relevance of exposure levels and support performant RMM. At 
present, there are in a practical sense no OELs specific to 
nanomaterials that have been adopted or promulgated by authoritative 
standards and guidance organisations [RNC/RIP-ON/B2/2/FINAL 
(6.11, 8.11)]. 
 
It is not appropriate to make guidance recommendations regarding the 
developments of OELs for the reasons described above. 
 
Guidance: 
It is not appropriate to make guidance recommendations 
regarding the developments of OELs for the reasons 
described and as OELs are developed in support of 
other legislation. 
 
For REACH DNELs are derived. For suggested changes 
to R.8, see RIP-oN3 Task C3. 
 
 
 
Medical surveillance Although preliminary medical surveillance activities such 
documentation of the presence of engineered nanoparticles and 
identification of potentially exposed workers are likely to be beneficial 
in the long term, no clear guidance at this time can be given at this 
time as to specific medical endpoints which should be tested for. 
[RNC/RIP-ON/B2/2/FINAL (6.12, 8.12)], In the absence of this, there is 
no basis for providing any guidance amendment recommendation.  
 
Guidance: 
No evidential basis for a change to the guidance. No 
change recommended 
 
Safety Data Sheets Limited evidence appears to suggest that “current” (the Australian 
study primarily reviewed SDS’s produced before 2009) SDS are 
inadequate as to their coverage of different nano-forms of materials. 
[RNC/RIP-ON/B2/2/FINAL (6.13, 8.13)]. 
 
In any case, it is appropriate to highlight in the guidance that in 
developing the SDS any data derived for non-nano” form of a material 
should not be assumed to be relevant to the different nano-forms, 
unless scientific  justification can be provided. 
 
Guidance: 
Insertion of a clause in G4 to the effect that any data 
derived for "non-nano” form of a material should not be 
assumed to be relevant to the different nano-forms, 
unless justification can be provided. 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 69 - 
Issue Possible implications for the REACH guidance Assessment of guidance changes & research needs 
Consumer RMM There is almost no evidence relating to the effectiveness of consumer 
RMM. Therefore no recommendation relating to REACH guidance for 
RMM relating to consumers can be made at this time. [RNC/RIP-
ON/B2/2/FINAL (6.15, 8.15)]. 
 
Note that R13 advises that it is difficult to estimate the real 
effectiveness values for consumer RMMs that depend on the action by 
consumers due to high uncertainty about consumer behaviour.  This is 
also likely to be true for products containing NM 
 
Guidance: 
Although there is no direct evidence to support it, it is 
considered that the current guidance will work 
(reasonably) well for nanomaterials. No change to the 
guidance recommended. 
 
Research: 
Additional research required to evaluate the 
effectiveness of this RMM. 
Environmental RMM Other than in the case of filtration, due to lack of evidence no 
recommendation relating to REACH guidance for RMM relating to 
environment can be made at this time. [RNC/RIP-ON/B2/2/FINAL (7.1, 
8.16)]. 
Guidance: 
No evidential basis for a change to the guidance. No 
change recommended. 
 
Research: 
Additional research required to evaluate the 
effectiveness of this RMM. 
 
Operational Conditions Only limited information on occupational conditions was found to be 
available in the public literature.  
  
Possible implications for REACH. Lack of information relating to 
R.13.2.2 Operational conditions and risk management measures 
related to workers. Lack of information in relation to estimation of 
exposures using Tier 1 models (R. 14. R.15. R.16) Limited opportunity 
to validate assumptions in these models.  
 
No evidential basis for a change to the guidance. No 
change recommended. 
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3.6.16 Assessment regarding exposure estimation 
3.6.17 Table 4.3 is drawn from and based on the arguments contained in RNC/RIP-
ON/B3/2/FINAL and summarises the conclusions on the key issues identified 
and an assessment of possible implications for the REACH guidance. 
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3.6.18 Table 4.3 Issues arising from the RNC/RIP-ON/B3/2/FINAL report on exposure assessment 
Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
Discrimination from 
background 
nanoparticles 
 
Background aerosol will be an important contribution towards the 
total number concentration (and possibly mass and surface area 
concentration also) [RNC/RIP-ON/B3/2/FINAL, (10.1)]. 
 
Where possible, this should be subtracted from the measured 
count. Viable approaches are available on which guidance should 
be based including a time series approach contrasting periods of 
activity with periods of no activity [RNC/RIP-ON/B3/2/FINAL 
(10.1.4)], parallel sampling of background [RNC/RIP-
ON/B3/2/FINAL (10.1.5)], or collection of samples for offline 
analysis [RNC/RIP-ON/B3/2/FINAL (10.1.6)]. Combinations of 
these approaches have been advocated [RNC/RIP-
ON/B3/2/FINAL (10.1.7)]. Background particles may also act as 
carriers or scavengers for nanomaterials which have aggregated 
with them [RNC/RIP-ON/B3/2/FINAL (10.1.8)]. 
 
If it is not possible to remove the background count contribution, 
then the total count concentration could be considered to be a 
worst case. 
 
In case studies, attempts were made to compare process counts 
with background based on expert advice including the 3 
approaches described above. None were entirely satisfactory. 
Approaches chosen were not informed by REACH guidance as far 
as we were aware. 
 
 
Guidance: 
D.5.2 Generalise and apply the “have background 
concentrations been taken into account” statement. 
 
R.14.4.5 Provide a paragraph in the text to indicate the 
complexity of issues in relation to NM measurement and 
a link to an annex of additional information An alternative 
anchor point is R.7.1.14. 
 
R.7.1.14 Information on options for discrimination from 
background nanoparticles to be included in this section. 
 
Research: 
Additional research required on the usefulness of 
approaches for discrimination from background 
nanoparticles is required. Research on instruments also 
appropriate. 
Measurement of size 
distribution  
 
Particle size information is clearly important and should be 
collected and reported [RNC/RIP-ON/B3/2/FINAL (10.2)]. 
  
The size distribution of aerosols measured in the workplace is 
unlikely to be the same as the primary material. Various methods 
are available which can be used to measure size distribution. 
Guidance: 
R.7.1.14 Information on options for measurement of 
particle size information to be included. Include 
instrument options as indicated in ISO 12885 (2008), 
ISO 27628 (2008) BSI 6699-3 (2010) and provide advice 
on their application, limitation and data handling. 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 72 - 
Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
These are detailed in ISO 12885 (2008), ISO 27628 (2008) and 
include instruments such as SMPS, FMPS and off-line methods. 
[RNC/RIP-ON/B3/2/FINAL (10.2.1)]. 
 
Recommended methods should be able to account for complex 
form of the distributions (e.g. bimodal distributions) and should 
provide a meaningful and useful parameter(s).  Various 
approaches have been described including direct inspection of the 
distribution, extraction of median and other statistical parameters 
and summation number counts into size intervals [RNC/RIP-
ON/B3/2/FINAL (10.2.5)], The size interval of interest should 
include consideration of the maximum relevant particle size (see 
next issue).  
 
In the case studies, there was no unified approach towards the 
measurement or reporting of size distributions. Various methods 
were used (as described in the two ISO documents.  The methods 
actually used in the case studies were based on expert advice. 
This was not informed by REACH guidance. 
 
 
R.14.4.5 Provide a paragraph in the text to indicate the 
complexity of issues in relation to NM measurement and 
a link to an annex of additional information. An 
alternative anchor point is R.7.1.14. 
 
Maximum relevant size  
 
Evidence suggests that nanoparticles of interest may be present 
as primary particles and larger aggregates/agglomerates 
potentially including background particles therefore these larger 
agglomerates, not just unbound primary particles should be 
measured.  Measurement of unbound primary particles alone is not 
sufficient to fully understand exposure in these situations 
[RNC/RIP-ON/B3/2/FINAL (10.3.1)]. 
 
For inhalation exposure, measurement of the respirable fraction, 
representing the fraction of aerosol capable of entering the alveolar 
region of the lung has been successfully used [RNC/RIP-
ON/B3/2/FINAL (10.3.4)], Measurement of the respirable fraction is 
recommended. 
 
Guidance: 
R.14.4.5 Provide a paragraph in the text to indicate the 
complexity of issues in relation to NM measurement and 
a link to an annex of additional information which 
includes discussion relating to the relevance of 
maximum particles size to be included An alternative 
anchor point is R.7.1.14. 
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Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
If instruments which have a smaller cut off point than the respirable 
convention are used, the value of the cut off point should be 
reported in any document in which this information is given. 
 
In the case studies instruments with differing maximum particle 
size were used. Providers had different approaches towards what 
was the relevant maximum particle size of interest. This was not 
informed by REACH guidance. 
Effect of high spatial and 
temporal variability 
 
Typically, airborne concentrations are higher and closer to the 
source worker (near-field) than at some distance point (far-field). 
High spatial variability has been reported in the studies reviewed. 
Therefore measurements of workplace air concentrations (i.e 
emissions) will not adequately represent personal exposure 
[RNC/RIP-ON/B3/2/FINAL (10.4)]. A preferred approach is the use 
of personal sampling devices [RNC/RIP-ON/B3/2/FINAL (10.4.2)]. 
 
There is no current suitably validated device which can be used in 
this way to collect the range of data of interest. There is activity to 
develop such devices (for example in the European FP7 project 
NANODEVICE and elsewhere [RNC/RIP-ON/B3/2/FINAL (6.3)].  
Therefore measurement strategies which encourage (even limited) 
comparison between workplace air concentrations and personal 
exposure are recommended.  Issues related to measurement 
strategies are discussed below. 
 
Only one of the case studies used personal sampling. 
 
Guidance: 
R.14.4.5 Provide a paragraph in the text to indicate the 
complexity of issues in relation to NM measurement and 
a link to an annex of additional information which 
includes discussion relating to the relevance of personal 
sampling.  An alternative anchor point is R.7.1.14 
 
 
Research: 
More research is required to develop appropriate 
methods for measurement of personal exposure. This 
includes methodological research and research into new 
instruments. 
 
Choice of metrics and 
instruments 
 
There are three main metrics, all of which could have some utility 
in measuring exposure to nanoparticles. These are: i) mass 
concentration (units mg m-3); ii) number concentration (units m-3) 
and; iii) surface area concentration units (m2 m-3). A case may be 
made for the use of any of these metrics under certain 
circumstances [RNC/RIP-ON/B3/2/FINAL (5.1)]. 
 
The issues of metrics should not be decided on exposure 
Guidance: 
D.1 Add caveat to indicate that the same relevant 
metric(s) should be used for DNEL and exposure 
estimate. 
F.10 Comment to provide the possibility on using 
surface area and/or number (especially for fibres) as 
additional metric(s). 
R.14.2 Indicate the possible use of other metrics 
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Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
assessment issues alone, toxicological information needs to be 
carefully considered. In [RNC/RIP-ON/D/2/FINAL(11)], it is 
recommended that surface area is a potentially useful metric with 
which to describe the dose (hazard) for inhalation. This implies 
there is also utility in using surface area as a metric to describe 
exposure. (It is not suggested that this is the only useful metric for 
either dose or exposure). It should be recognised that these two 
metrics are not the same. In relation to dose, SA is usually 
estimated using a mass dose and applying a specific surface area 
value for the powdered material as obtained by BET analysis. 
Surface area concentration of an aerosol in exposure terms can be 
measured “directly” using the appropriate monitoring instruments. 
Whilst these two measures should be in related, this has not been 
demonstrated. Any comparison between the two should be 
supported with evidence of their equivalence.  Further research is 
required to establish these relationships for different materials 
under an appropriate set of conditions. 
 
Number concentration has also been demonstrated to be a useful 
metric in detecting emissions.  
 
In relation to measuring exposure the best available guidance at 
this time is that measurements should encompass assessment of 
mass, number and surface area concentration where possible 
[RNC/RIP-ON/B3/2/FINAL (10.5.5)],.  Measurement methods 
which could be recommended in relation to these metrics are 
provided in RNC/RIP-ON/B3/2/FINAL (6.2). 
 
In the case studies, instruments a range of metrics and 
instruments were used. Providers had difficulty in interpreting the 
data obtained from these instruments. In particular there was 
understanding the relevance of number concentrations and size 
distributions and how these could be used in relation to DNELs 
(derived or assumed) which were based on mass concentrations. 
There were also differences between measures of the same metric 
R.15.2.3 Indicate/recommend where possible the  use of 
complementary metrics. 
 
R.14.4.5 Provide a paragraph in the text to indicate the 
complexity of issues in relation to MN measurement and 
a link to an annex of additional information 
Provide the same annex with an anchor point at R7.1.14 
 
Information on options for measurement of particle size 
information to be included. Include instrument options as 
indicated in ISO 12885 (2008), ISO 27628 (2008), and 
provide advice on their application, limitation and data 
handling. Additional comprehensive information on the 
applicability and limitations of instruments for exposure 
assessment has just be been published by BSI 6699-3 
(2010), not available and therefore not referred to in 
previous reports, which could form the basis of 
guidance. 
 
Further information to be provided on the usefulness and 
applicability of the three metrics.  
 
Based on the toxicology, recommendations will be made 
elsewhere on the applicability of additional metrics such 
as surface area or number concentration (especially for 
fibres) as a dose metric. 
 
Research: 
Research is required to understand the relationship 
between mass, surface area and number concentrations 
for materials of interest 
 
Research is also required to establish these 
relationships between different measures of surface 
area (e.g. for hazard and for exposure) for different 
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Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
from different instruments.  
 
Resolving these issues is likely to be challenging (and beyond the 
scope of the current work) in that relationships between these 
metrics will be highly dependant on the extent to which aerosols 
are aggregated/agglomerated or not which will in turn depend on 
the type of process which leads to the emission or release of 
aerosol. Simple constant relationships will not be routinely 
available.  [RNC/RIP-ON/D/2/FINAL(10)], 
 
In addition, guidance for exposure data recommends the use of the 
90th percentile. In the case studies there was difficulty in 
interpreting data from real time instruments, for the measurement 
of particle number or size distribution in this way. Typically only 
single values were recorded which were averaged over 
unspecified time periods. In other cases time series measurements 
were made which would provide data from which 90th percentiles 
(and other statistical outputs) could be derived.  
 
materials under an appropriate set of conditions. 
Emerging measurement 
strategy 
The issues described above are considerations in relation to what 
has been described as an emerging measurement strategy. 
Measurement strategy includes definition of the purpose of 
sampling, selection of instruments, how they are used, the number 
and type of samples taken, what data is collected and how this 
date is used. There is unlikely to be a universal strategy due the 
many differing purposes for which measurements may be made 
[RNC/RIP-ON/B3/2/FINAL (6.9)]. 
 
Published studies suggest a multi-instrument approach in an 
attempt to capture all relevant metrics and characteristics 
[RNC/RIP-ON/B3/2/FINAL (6.9.2)], This could include for example, 
a multi-instrument approach in which CPCs are used to identify 
potential sources of emissions (and background sources), an 
SMPS or ELPI is used to characterise size distribution and how 
this varies as a function of time or space combined with SEM or 
Guidance: 
R.14.4.5 Provide a paragraph in the text to indicate the 
complexity of issues in relation to NM measurement and 
a link to an Annex of additional information. An 
alternative anchor point is R7.1.14 
 
Research: 
Research required to investigate the effectiveness of 
different strategies in particular to measure personal 
exposure and to assess within the reach context. 
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Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
TEM analysis of samples collected on filters to characterise the 
physical or chemical form of the aerosol. 
 
Published guidance for example in the document 
ENV/JM/MONO(2009)16 Emission Assessment for the 
Identification of Sources and Release of Airborne Manufactured 
Nanomaterials in the Workplace: Compilation of Existing Guidance 
(OECD 2009) also supports this stepwise approach [RNC/RIP-
ON/B3/2/FINAL (6.9.13)] however this in particular requires routine 
use of Transmission Electron Microscopy. which is unlikely to be 
routinely available.  A similar approach is described in BSI 6699-3 
(2010), not available and therefore not referred to in previous 
reports. 
 
Both the published research and the available guidance provide 
good information of which guidance recommendations can be 
developed but do not at this stage provide a complete solution. 
Neither, for example, provides an validated methodology for 
assessment of personal exposure at this stage. 
 
Assessment of high 
aspect ratio 
nanomaterials   
 
Exposure to fibrous aerosols is assessed by measuring the 
number (concentration) of fibres in the air with a specific shape 
and composition (WHO, 1997). Assessment of fibre concentration 
is likely to be relevant to some high aspect ratio nanomaterials in 
terms of their exposure [RNC/RIP-ON/B3/2/FINAL (10.6.1)]. 
 
The presence of fibres is only likely to be detected by electron 
microscopy. Application of the WHO approach has not yet been 
validated for any types of high aspect ratio nanomaterials. Only 
one study has used an approach based on the WHO method and 
report fibre concentrations. It is not clear the extent to which WHO 
counting rules were applied [RNC/RIP-ON/B3/2/FINAL (10.6.4)]. 
 
Encouragement should be made in the guidance towards checking 
of whether fibres (according to the WHO definition) are present in 
Guidance: 
R.14.4.5 Provide a paragraph in the text to indicate the 
complexity of issues in relation to NM measurement and 
a link to an annex of additional information An alternative 
anchor point is R.7.1.14 
 
Research: 
More research is required to develop validated robust 
methods for the assessment of HARN. This includes 
image analysis methods and instrumental approaches. 
This should have a very high priority. 
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Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
exposure assessment samples for all materials which have some 
potential for the release of fibres. 
 
No specific guidance can be given at this time towards assessing 
bundles or clumps of high aspect ratio nanomaterials. 
 
One of the case studies (CASE1 Nanocyl) was concerned with 
nanomaterials which could be considered to be HARN (CNT). 
Primarily they measured mass concentrations (size differentiated) 
which they compared with a DNEL which was also expressed in 
term of mass concentration. This was used in their production 
scenarios. 
 
However they also considered the potential for fibre release in a 
simulation study (see issue of simulations below) by collection onto 
a filter for off-line analysis by TEM. They reported that no fibres 
were observed.  
 
Exposure modelling Limited assessment of the models used in exposure estimation 
has been carried out.  The most extensive validation was for 
occupational exposure. 
 
Evaluating Stoffenmanager and ECETOC TRA, the conclusion 
drawn in the FP7 NANEX project (NANEX 2011) was that there 
was no correlation between the model estimates and 
measurement data. Neither of the models is tuned to and 
calibrated for nanomaterial exposure situations, and hence the 
actual model estimate will be inaccurate and possibly overestimate 
the (mass) concentration levels. 
 
For consumer exposure NANEX evaluated Consexpo, (inhalation, 
dermal, oral), ECETOC TRA (inhalation, dermal,oral), RiskofDerm 
(dermal). The authors concluded that dermal modules might be 
suitable for use for MNMs as the underlying equations do not 
appear to rely on nano-specific properties. The dermal modules of 
Guidance: 
Additional commentary relating to the applicability of 
models to nanomaterials to be added  in Appendix D1, 
“strengths and limitations of available tier 1 exposure 
estimation tools” 
R.14.4.7 Caveat to be added indicating the limitations of 
the models. 
R.15.3.1. Caveat to be added indicating the limitations of 
the models. 
R.16. Caveat to be added indicating the limitations of the 
models 
R.17.2. Caveat to be added indicating the limitations of 
the models. 
 
Research 
Substantial addition research is required to develop and 
validate exposure models, in in relation to occupational, 
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Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
the models may therefore be applied to nanomaterials, however, 
should be used with care as they are not yet validated nor 
calibrated for MNMs and the output (the exposure estimate) is 
given in a mass-based metric.  
 
There are greater limitations in the currently available inhalation 
modules in the exposure estimation models. These inhalation 
modules do not consider the nano-specific properties of the 
materials that could affect the exposure, e.g. agglomeration 
effects. 
Therefore, in the authors view, inhalation modules should be used 
with even greater care. 
 
For environmental models, given the specific properties of 
nanomaterials it can be concluded that the existing exposure 
models need to be adapted in order to be ready for use for 
nanomaterials. Input for environmental exposure models such as 
EUSES are often based on QSPR (Quantitative Structure-Property 
Relationship) calculations using physicochemical properties of the 
substance, mainly KOW and Kp values. At the moment it is highly 
unlikely that these QSPRs will be applicable for nanomaterials. It is 
therefore recommended to not use these QSPRs (including read-
across approaches) to estimate properties of nanomaterials, as 
long as there is no (solid) basis to do so. Instead, measured 
partition coefficients (i.e. Kp values) should be used to estimate 
environmental distribution [RNC/RIP-ON/B3/2/FINAL (8.4)] 
 
While there is information available on models nanoparticle 
transportation, aggregation and deposition available in the 
literature deriving primarily from the colloid literature, this is either 
theoretical and/or based on idealized relatively simple model 
systems. (e.g. Weisner and Bottero 2007). The models have not 
been adapted for the large number of components present in 
natural waster which may include salts, clays, micro-organisms, 
natural organic matter and other colloidal materials (Mylon et al 
consumer, environmental exposure. 
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Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
2004).  At present these are not appropriate for use in a regulatory 
context. 
 
Where models were used in the case studies, these were mostly 
used without any additional consideration with respect to 
nanomaterials.  
 
Exposure models a key element of the exposure estimation 
process. The limited evidence of successful validation for 
occupational exposure indicates that model estimates should not 
be relied on alone without further confirmation of their validity in 
individual cases. In any case, model estimates should be used with 
caution. 
 
It is not possible to provide linkage to models which have been 
validated for nanomaterials. Cautionary statements should be 
added to the relevant parts of the guidance. 
Utility of exposure 
simulation studies 
Simulation studies provide a useful addition from which additional 
data on the potential release may be obtained. Typically such 
studies attempt to simulate, often at worse cases a process which 
may lead to a release. They provide a basis by which data can be 
collected relatively quickly under a more controlled set of 
conditions. This could provide the opportunity very determinants of 
exposure in a controlled way.  There are a number of examples in 
the literature.  For example Hsu and Chein (2007) designed an 
experimental setup for simulating the abrasive effect of sunlight, 
wind, and human in a closed chamber to examine the release from 
TiO2 nanoparticle coatings on wood, polymer and tile. [RNC/RIP-
ON/B3/2/FINAL (6.4.6)] Gohler et al. (2010) measured emissions 
from a sanding simulation using polyurethane coating and 
architectural paint containing two types of nanoparticles. During 
the abrasion tests, no significant difference was detected between 
the number concentrations of released particles of the pure 
coatings and of the coatings that were dosed with additives 
[RNC/RIP-ON/B3/2/FINAL (6.4.31)], However, larger particles, 
R.14.4.1 Include specific recommendation that 
simulation studies can be used to provide relevant 
exposure information 
Similar statements in R.16. A16-1 and R.17 A17.1 
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Issue Possible implications for the REACH guidance  Assessment guidance changes & research needs 
containing nanoparticles were observed. 
 
One of the case studies (CASE1 Nanocyl) considered the potential 
for fibre release in a simulation study from a composite material 
containing CNT. The method used as described by Gohler et al. 
(2010). Emissions were assessed by collection onto a filter for off-
line analysis by TEM. They reported that no fibres were observed. 
This study is expected to be published shortly in the scientific 
literature. 
 
Simulation studies of this type can be used to provide relevant 
exposure information development of the ES and can be used to 
provide input data to develop and validate exposure models. As 
with all such simulations sufficient justification of the reality of the 
simulation should be provided. 
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3.7 TASK C1: CASE STUDIES ON HOW NO EFFECT LEVELS COULD BE 
ESTABLISHED 
3.7.1 Human health 
3.7.2 In this report we have applied the methods in the REACH guidance to 
MWCNT, TiO2 and silver nanoparticles. However only relatively few studies 
exist which are sufficiently rigorous and exhaustive enough for the REACH 
approach of deriving a human exposure limit. Therefore, there needs to be 
further studies conducted at the same robust level as those outlined and 
analysed. The most robust way in which to establish if the REACH approach 
is sufficiently robust is the collection of human data, preferably 
epidemiological evidence based on worker populations. However, such data 
is rare within risk assessment (for nanomaterials and substances in general) 
and it is far preferable that negative effects are controlled meaning such data 
would not become available.  
3.7.3 The absence of evidence does not necessarily indicate an absence of an 
effect and, for nanomaterials, there exists still a great deal of uncertainty in 
relation to the long-term effects of exposure. Currently the most reliable 
evidence for effects is studies conducted by researchers such as Pauluhn 
(2010b) and Ma-Hock (2009) using internationally recognised test methods. 
However these studies were not intended to look for all effects, such as long 
term carcinogenicity, and therefore these studies may not fully address the 
potential hazard of the nanomaterials studied.  Indeed it is unrealistic to 
expect a single study to cover all potential endpoints.  Normally the approach 
would be to look for other studies using similar materials, which may not be 
suitable for derivation of a DNEL, but which can inform as to the likely effects 
of the materials (e.g. long-term effects, systemic effects etc.). However in 
relation to a number of nanomaterials (and other materials) there is 
insufficient evidence to apply such an approach. Another compounding factor 
of a weight of evidence approach based on the peer reviewed literature, 
which is relevant to nano- and non-nano materials, is that negative data is not 
always reported even though such data may be important in generating a 
balanced picture of materials toxicity.  
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3.7.4 A major question relating to the applicability of the REACH guidance is the 
applicability of the current assessment factors (AF) in relation to 
nanomaterials which is dealt with in the following section. The default AF used 
in the REACH guidance have been derived from classical (soluble) toxicity.  It 
is therefore important to investigate whether current scientific knowledge is 
mature enough to assess applicability and/or suggest deviations from these 
factors for nanomaterials.  In any case, as for substances in general, when 
deviating from the default, this should be scientifically justified based on 
substance-specific data.  
3.7.5 Assessment factors - Interspecies Differences 
3.7.6 The use of interspecies differences is to account for differences between the 
experimental subjects (such as a rat) to a human. The REACH guidance (R.8) 
states that the default assumption is that humans are more sensitive than 
experimental animals. This default assumption may be true for certain 
chemicals, but as expressed within some of the studies reviewed (Pauluhn 
2010a, Kobayshi et al. 2009a/b, Hanai et al. 2009), rats may be far more 
sensitive to particle effects.  This is due to the phenomena of lung overload, to 
which rats are far more sensitive than humans or indeed other test species 
such as hamsters. As such it may well be appropriate that the default 
assessment factor which already takes a conservative position (humans are 
more sensitive than animals) could be reduced. This was performed within the 
assessments by Christensen at al. (2010b) that reduced the default AF from 
the default of 2.5 to 1.5, which appears a valid position based on the use of a 
the most sensitive species.  
3.7.7 Within the study by Pauluhn (2010a) the driver of toxicity was reported as 
being due to lung overload. As the cell tasked with clearance of particles in 
the distal lung is the alveolar macrophage, Pauluhn (2010a) accounted for 
differences in susceptibility by dividing the volume of rat alveolar 
macrophages by that of human alveolar macrophages. From this it was 
concluded that, based on alveolar macrophage volume, humans are six times 
more resistant to lung overload. Within the calculation, considering other 
differences normalised by the body weight (1/10), this led to an overall 
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interspecies AF of 2 which appears reasonable based on their overload 
hypothesis. 
3.7.8 Assessment factors - Intraspecies Differences 
3.7.9 The use of intraspecies AF takes into account differences within a population, 
for example the relative sensitivities of the very young compared to the very 
old in the general population, such that all members of a population should be 
adequately protected. Within the studies investigated, the use of such factors 
for a worker population demonstrates the greatest difference to the REACH 
approach and as such is the source of the greatest variation between derived 
limits based on similar studies. An example of this is the approach used within 
the NEDO study (Kobayshi et al. 2009, Hanai et al. 2009). The approach 
within the NEDO study was to assume a healthy worker population with no 
sensitivities and as such no AF was applicable. The REACH approach applies 
a default factor of 5 to account for sensitivities within a healthy worker 
population as it is unrealistic to assume a population of individuals has 
completely perfect health and no sensitivities such as asthma. The approach 
of Pauluhn (2010a) was to use the default factor to scale to workers 
ventilation (10/m3 working day and adult) and to make no other account for 
intraspecies differences. This was based upon the lack of systemic 
bioavailability of Baytubes producing purely local effects and the fact that 
such an effects was thought to be independent of metabolism. As a 
hypothesis, there is little to suggest that the approach taken by Pauluhn is 
incorrect. However it may not take into account systemic effects such as 
cardiovascular disease which could potentially occur, not through direct 
translocation, but through other mediators leading to effects.  
3.7.10 In relation to MWCNT, and indeed other materials, it is still not yet clear as to 
the toxico-kinetics of MWCNT (although within the study of Pauluhn (2010b) 
no systemic effects were detected), specifically, the translocation of these 
materials into the pleural space. However there are indications appearing in 
literature that this may be possible for some types of MWCNTs (Mercer et al. 
2010; Ryman-Rasmussen et al. 2009).  Their persistence in this cavity could 
lead to pleural inflammation, fibrosis and possibly the generation of 
mesothelioma.  Pauluhn (2010b) showed accumulation of MWCNT in the lung 
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associated lymph nodes as part of lung clearance routes. However there is 
currently no evidence that the MWCNT, such as those used by Pauluhn 
(which tend to exist as loose bundles), will become untangled into individual 
fibres and translocate into the pleural space where it may be cleared to the 
outlying lymph nodes or be retained and cause adverse effects. Therefore 
further studies are needed to clarify this potential route of translocation, target 
tissue and the potential hazard and for which types of CNTs this may be 
relevant. 
3.7.11 As a precautionary approach, in the absence of better evidence it may be 
advisable to follow the REACH R.8 guidance approach and use the same 
intraspecies AF for local effects as it does for systemic effects.    
3.7.12 There does not seem sufficient evidence or cause to assume that the 
application of such an intraspecies AF to nanomaterials would be 
inappropriate. Indeed within a worker population there are likely to be those 
which are of increased susceptibility to NM, perhaps due to asthma or sub-
clinical cardiovascular disease which would place them at higher risk of 
adverse effects to nanomaterials.    
3.7.13 Differences in duration of exposure 
3.7.14 The REACH R.8 Guidance allows for substance specific adjustment of the 
assessment factors based on factors such as accumulation (which would 
require an increased AF). This may be very pertinent to certain forms of 
insoluble nanomaterials and potentially even more so for long straight fibres 
which may resist clearance and as such, with repeat exposure lead to an 
accumulation of dose (Donaldson 2009; Muller 2005). 
3.7.15 Issues related to dose response 
3.7.16 The use of AF to take into account dose response relationships appears 
equally valid for NM as for other materials. They relate to the nature of the 
dose response curve obtained, gaps between doses etc. and how these 
relate to the confidence one can have in the observed effects and limits 
proposed.  
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3.7.17 Quality of whole database 
3.7.18 In principle, there appears no reason to suggest that guidance is insufficient 
with regards to addressing issues with the quality of the whole database.  
However, certain aspects may benefit from clarification. Guidance does stress 
that increased uncertainty may exist in cases when using a low reliability 
study or alternative data such as in vitro studies, Quantitative Structure 
Activity Relationship (QSAR) and read across, which should be accounted for. 
This is particularly pertinent to the current situation for NM as there is 
currently little evidence to suggest that (Q)SAR or read-across approaches 
are applicable. Thus, such approaches should only be applied if scientifically 
justified on a case-by-case basis. However in the future, through further 
research, this approach may be appropriate and guidance is adequate to deal 
with both situations, although a statement in the guidance on the applicability 
of (Q)SAR and read-across to nanomaterials would be useful. 
3.7.19 Metric 
3.7.20 The question of which metric is most appropriate for the derivation and 
application of DN(M)EL is ongoing and is fully discussed in RNC/RIP-
oN3/D/2/FINAL.  In the examples discussed, the metric of mass has been 
used in the studies cited to show N(L)OEAC and this has been conserved 
throughout the derivation of DNELs. This does not propose to suggest that 
mass is the most appropriate metric, it is simply a practical metric (as 
reflected in the opinion of NIOSH (2005), further discussed in RNC/RIP-
oN3/C2/2/FINAL). Within the conclusions of NIOSH, a surface area metric 
was identified as the most accurate dose descriptor. The benefit of this as a 
dose descriptor is that a single limit can be applied irrespective of particle size 
which is important when considering the role of aggregation. In addition, 
NIOSH stated that convention and the availability of suitable equipment 
dictate that mass is still the most practical measurement. NIOSH (2005) 
suggested two Recommended Exposure Levels (RELs) based on two 
separate size fractions (fine and ultra fine for TiO2) in the place of a single 
surface area metric to account for alterations in particle toxicity based on 
particle size/ surface area,. The relative considerations of some of the metrics 
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discussed in RNC/RIP-oN3/D/2/FINAL are discussed below in relation to the 
studies used. 
3.7.21 Fibrous nanomaterials  
3.7.22 The question of fibre number concentration may be applicable to CNT but 
may also be applicable to other nanomaterials. There are various methods 
available for the formation of nanowires, nanotubes and nanorods from a 
range of materials and as such these materials may be rendered harmful by 
virtue of their shape (so long as they reach the minimum length of straight 
fibres and are biodurable). Indeed in the study by Hamilton et al. (2009), they 
tested long TiO2 nanobelts (15-30 µm) against short nanobelts (< 5 µm) and 
spherical TiO2 using murine alveolar macrophages and in vivo testing.  It was 
concluded that the long fibre-shaped TiO2 elicited inflammation in a manner 
similar to that of asbestos or silica. As such they suggested that any 
modification of a nanomaterial's shape, resulting in a wire, fibre, belt or tube, 
be tested for pathogenic potential (Hamilton et al. 2009).  
3.7.23 It is impractical to suggest an over-riding single metric for nanomaterials or 
even within a class of nanomaterials (e.g. CNT), as alterations can occur in 
the material (such as shape) that potentially alter the mode of toxicity. 
Instead, an understanding of the physico-chemical characteristics is required 
to establish potential hazard and tailor the use of the most appropriate 
exposure metric for setting exposure levels.   
3.7.24 Such a link between physico-chemical characteristics and potential hazard 
with suggested metrics is shown in Task B5 of the RIP-oN 2 project 
(RNC/RIP-oN2/B5/2/FINAL). Within this scheme, if a nanomaterial satisfies 
the traditional fibre pathogenicity criteria of being straight, long and biodurable 
it may act as a pathogenic fibre. As such the correct metric would be fibre 
number, which is the metric used to measure other pathogenic fibres such as 
asbestos.  This suggestion is also shown in the Safe Work Australia (SWA) 
document ‘Engineered Nanomaterials: Feasibility of establishing exposure 
standards and using control banding in Australia’ (SWA, 2010c). Within this 
document, the authors discuss the suggestion of benchmark exposure level 
(BEL) for fibres proposed in the BSI ‘Nanotechnologies’ document (BSI PD 
6699-2:2007). The BSI document proposed a level for fibrous nanomaterials 
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of 0.01 fibres/ml, in line with the current UK clearance limit in asbestos 
removal activities. The SWA approach was to suggest a BEL of 0.1 fibres/ml 
for fibrous nanomaterials, as there is no evidence that fibres are more toxic on 
a fibre-by-fibre basis. Indeed this is true, and whilst some studies have 
suggested that CNT can show inflammogenicity over that of asbestos (Poland 
et al. 2008), these have been performed on a mass basis and the increased 
inflammogenicity of CNT may simply represent an increased fibre number per 
unit mass. There are no studies to our knowledge that demonstrate CNT 
toxicity on a fibre number basis. Such a study would enable the comparison of 
fibre potency between CNT and other benchmark fibres such as asbestos.   
3.7.25 Non-fibrous nanomaterials  
3.7.26 The discussion of the relative merits of alternative metrics and their 
correspondence to toxicity outcomes is fully described in RIP-oN 3 task D 
report and we will not reproduce such evidence here. Of the studies 
investigated, mass was the metric reported in the NOAEL and we have 
conserved this through the derivation of a DNEL. However in relation to non-
fibrous nanomaterials, there is strong emphasis that a metric such as surface 
area may better describe the toxic effects seen with nanomaterials than other 
metrics such as mass. This has been shown in several studies such as that of 
Duffin et al. (2007), where materials of a similar surface reactivity but differing 
sizes, all generate a similar level of inflammation when based on the same 
surface area.  
3.7.27 However, the use of surface area as a metric raises several technical 
difficulties in measuring exposure, not least that the current convention of 
workplace exposure monitoring of coarse particles is based on a mass metric.  
This problem was raised by NIOSH (2005) who noted that surface area was a 
preferable metric, taking into account increasing particle toxicity with 
decreasing particle size (increasing surface area) but mass as a metric is 
more practical. As such, the NIOSH approach was to recommend two 
recommended exposure limits (REL) based upon size fractions (fine (<10 µm) 
and ultra-fine (<0.1 µm)) as this was considered most practical in relation to 
workplace exposure despite surface area being demonstrated to be a more 
appropriate dose metric than mass.  
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3.7.28 Using an approach based on this, BSI (BSI PD 6699-2:2007) suggest a BEL 
of 0.066 x WEL (workplace exposure limit) for a material, which for TiO2 would 
correspond to the NIOSH derivation (e.g. 1.5 mg/m3 x 0.066 = 0.1 mg/m3). 
Such an approach appears valid based in the assumption that the increased 
toxicity of a nanomaterial is related to that of the bulk material (e.g. an inert 
bulk material gives rise to a similarly inert nanomaterial) based purely on its 
increase in surface area. This approach would however underestimate the 
toxicity of a material if there were an additional alteration in the nature of the 
material in the nano-range over and above that of a simple increase in 
surface area.  
3.7.29 In relation to use of alternative metrics, these may be altered by the 
aggregation state of the NM which may be reflected in changes in the relative 
toxicity as discussed in the following section.   
3.7.30 Agglomeration and Aggregation  
3.7.31 Thermodynamically aggregation and agglomeration are two distinct 
processes. They have been described by Zhang et al. (1999) although he 
does not refer directly to the names of the processes. Aggregation is a 
process that can be described by the fact that material in the nano-phase is 
converted into material of the bulk phase. The process is irreversible with 
small forces. Consequently the surface area decreases (mass remains 
constant). Agglomeration is the process whereby (primary) particles 
agglomerate. This process can simply be described by an equilibrium 
reaction. Consequently the total surface area remains constant and the 
process can be reversed. Unfortunately both processes usually take place 
simultaneously. Thus, if the toxicity of a particle is dependent on the surface 
area, the effect will change if the primary particles aggregate. However such 
is also the case if the toxic effect is based on size since agglomeration is an 
equilibrium process of which the direction depends on the environment of the 
particles. As such it can be seen that the aggregation/ agglomeration state of 
a particle is an important issue when considering its toxicity. This is primarily 
the case when the driver of toxicity is an attribute that is altered during 
aggregation/ agglomeration (e.g. surface area, size) rather than conserved 
(e.g. mass).  
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3.7.32 Within experimental studies, considerable effort is often placed in gaining as 
stable and homogenous an aerosol as possible, centred around the primary 
particle size. However this may not necessarily reflect real life exposure, 
particularly with regards aggregate/ agglomerate formation (Oller & 
Oberdörster, 2010). As such, if the driver of toxicity was surface area, it is 
conceivable that experimental manipulations to decrease aggregation/ 
agglomeration (and as such increase surface area) may lead to over 
estimation of the potential hazard of a material if its natural form in the 
workplace is a much larger, aggregated/ agglomerate particle with a 
correspondingly lower surface area. 
3.7.33 Aggregation/agglomeration of a nanoparticle may also alter its zone of 
deposition e.g. deposition of larger particles is likely to occur to a greater 
extent in the upper ciliated airways where clearance is more rapid owing to 
the mucociliary escalator, whilst smaller (nano)particles may deposit further 
down the respiratory tract in the proximal-alveolar region. Within this region 
clearance is macrophage mediated and hence slower. Another interesting 
aspect is the nature of the aggregate/ agglomerate, such as if its composed of 
solid spherical nanoparticles forming a larger, denser agglomerate or, for 
example, if the sample is composed of loose agglomerates of carbon 
nanotubes which are geometrically large but may still posses a lower density 
and hence lower aerodynamic diameter and deposit in the distal airways. 
Based on the discussions by Pauluhn (2010a), low density agglomerates 
such as that of CNT may lead to volumetric overload of alveolar macrophages 
at a lower dose of a similar density, but smaller geometric diameter material 
such as carbon black. 
3.7.34 It is impossible to gauge the overall effect aggregation/ agglomeration can 
have, as this is likely to be different with different forms of nanomaterials and 
may be dependent on numerous factors such as surface charge, coating or 
surface forces (e.g. van der Waals forces in the case of CNT). Environmental 
factors may also influence the degree of agglomeration or separation (e.g. 
turbulent air flow) and as such the aggregation state is likely to be highly 
dynamic.               
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3.7.35 In conclusion, the REACH approach appears to be useful for calculating safe 
exposure levels for some nanomaterials such as silver and MWCNT. It is 
currently impossible to evaluate if the assessment factors are sufficiently 
conservative or overly so without the use of human data based in real 
exposure situations which is simply not available. The assessment factors 
used within the risk assessment have been derived for the conventional 
approach and were not developed with consideration for (nano)particles. 
Based on current scientific knowledge, it is unknown whether the same 
factors can be truly applied or not in case of a (nano)particle approach. Within 
the TiO2 studies evaluated, the derivation of a lower DNEL (on a mass-metric 
basis) than that of the bulk, non-nano form of TiO2 is in line with what the 
scientific literature shows us. That is, smaller particles have an increased 
surface area and, as such, a low toxicity (per unit surface area) material may 
show increased toxicity due to increased surface area. This is in line with 
what has been derived by NIOSH (2005), as shown in RNC/RIP-
oN2/C3/2/FINAL. 
3.7.36 The lack of a consensus on nanomaterial non-testing approaches such as 
QSAR or read-across means that at the current time it may only be practical 
to conduct risk assessment based on a case-by-case basis for individual 
nanomaterials. That is, individual sources, production methods etc. rather 
than individual classes of nanomaterials such as MWCNT. As such, for an 
experiment which has been conducted with only one type of nanomaterial and 
for which the dose-response curve has been established by a single metric, 
such as mass, the derived DNELs may only be valid for the used specific 
materials. The development of suitable non-testing approaches is important 
as it may reduce the burden of expensive and ethically challenging in vivo 
testing. In order to further develop non-testing approaches such as QSAR for 
nanomaterials to an acceptable level for REACH purposes, comparison of 
experimental results and physico-chemical characteristics of nanoparticles 
needs to be performed. Such comparisons are often performed on small 
panels of selected nanoparticles as part of research projects (e.g. the EU 
ENPRA project). Whilst these projects are very useful; larger scale 
comparisons of numerous materials may need to be performed e.g. in high 
throughput testing systems. Shared information from industry may be an ideal 
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source of detailed toxicological and physico-chemical data for a wide range of 
materials which would advance this process greatly.    
3.7.37 Environment 
3.7.38 As shown in RNC/RIP-oN3/C1/2/FINAL and in more detail in the ENRHES 
review (Stone et al., 2009), it is in principle possible to determine PNEC using 
the present methodology. However, by doing so the particle behaviour of 
nanoparticles is neglected and it is inherently assumed that nanoparticles 
behave like dissolved (organic) chemicals. 
3.7.39 In principle, there does not seem to be nano-specific arguments to change the 
way assessment factors are selected presently, i.e. that more available data 
from long-term tests can reduce the assessment factor from 1000 to 100, 50, 
and 10. 
3.7.40 However, the assessment factors were originally intended not only to cover 
the uncertainty related to the amount of available data, but also factors like 
inter- and intraspecies differences and extrapolations from laboratory to field. 
The value of the assessment factors are based on regulatory practice and 
empirical knowledge on ecotoxicological effects of chemicals. Since there is 
no history for evaluation of nanomaterials, it is at present not possible to claim 
that the use of the presently available assessment factors will ensure that 
species will be protected at concentrations below PNEC (RIVM, 2009). 
3.7.41 The so-called deterministic approach using species sensitivity distribution 
modelling would also, in principle, be acceptable for deriving PNEC values for 
nanoparticles. However, this approach requires at least ten high quality 
NOECs/EC10-values from different species belonging to eight taxonomic 
groups. This kind of data is not available for any nanomaterial at present and 
thus it remains to be shown that the deterministic approach for PNEC 
determination will actually be applicable to nanomaterials.  
3.7.42 A number of factors specific for nanoparticles have been found to influence 
the responses observed in the standard ecotoxicity tests preferred for 
determining PNECs. These are mentioned in detail in RNC/RIP-
ON/B3/2/FINAL (particle impurities, suspension preparation methods, release 
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of free metal ions, nanoparticle aggregation, and relevance of dose-
response), but not all of these can be claimed to be nano-specific.  
3.7.43 Thus, impurities, solvent interaction, and free ion toxicity are issues that have 
been dealt with for chemicals and procedures/recommendations that may be 
adapted to nanoparticles are available (see OECD 
ENV/JM/MONO(2009)20/REV, ENV/JM/MONO(2009)25). 
3.7.44 For the more general validity of the present approach to derived PNEC, 
nanoparticle aggregation/ agglomeration, problems of reproducibility of test 
results and non-monotonous concentration-response curves are of the 
highest importance (Hartmann et al., 2010).  
3.7.45 The extent that these factors influence the ecotoxicological impact of 
nanomaterials is unknown. Currently, even the scientific evidence for these 
factors is contradictory and varies from nanoparticle to nanoparticle (Baun et 
al., 2009). This impedes the reliability and interpretation of the available 
ecotoxicity data the direct use of the reported LC50, EC50 and NOEC for 
PNEC assessment.  
3.7.46 It is, at present, unclear whether aggregation/ agglomeration of nanoparticles 
in test media will result in higher or lower toxicities found in standard tests. It 
has been argued that the bioavailability of larger particles is lower than for 
smaller particles and therefore the toxicity could be expected to be lower 
when aggregation occurs. However, this may not be the case for filter feeders 
like D. magna that has a preferential filtration of certain particles sizes 
(generally above 500 nm). For these organisms, aggregation may result in 
higher uptake and disaggregation may occur during digestion in the daphnids, 
rendering smaller particles that may cross biological membranes. 
Biomodification of nanoparticles upon uptake in daphnids has been 
documented in the literature (Roberts et al, 2008; Baun et al., 2008). It is 
possible that the Daphnia-test may be sufficiently sensitive to measure 
possible aquatic toxic effects of nanoparticles also. 
3.7.47 It is clear that aggregation/agglomeration strongly affects the reproducibility 
and also the shape of concentration-response curves obtained in standard 
tests as shown e.g. by Hartmann et al. (2010). The understanding of the 
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aggregation process and the determining factors in standardised test media is 
very scarce at present, making it very difficult to give accurate advice on the 
best way to test nanoparticles. 
3.7.48 It must be expected that the aggregation/ agglomeration behaviour is different 
from test media to test media (e.g. there are large differences in the medium 
composition of the M7 media used in OECD Daphnia test and the OECD 
medium for algal testing). This makes it difficult to conclude on nanoparticle 
behaviour between different tests. 
3.7.49 One way forward may be to strive to test only on stable suspensions, however 
this may require that the addition of NOM (natural organic matter) is included 
in standard test protocols for testing nanoparticles. NOM has in many cases 
been found to stabilise aqueous suspensions of nanoparticles.  However, the 
biological impacts of the interaction between nanoparticles and NOM are not 
well described at present. 
3.7.50 In addition, it has recently been found that aggregation/ agglomeration 
behaviour in aqueous media might follow a non-linear concentration-
aggregation/ agglomeration relationship (Baalousha, 2009; Baun et al., 2009). 
This implies that traditional test designs in ecotoxicity tests, using a range of 
different dilutions, will give not only different concentrations (as intended), but 
also different degree and type of aggregation/ agglomeration (not intended). 
This may be one of the reasons for the non-monotonous concentration-
response curves encountered for some nanoparticles in ecotoxicity tests, 
since bigger aggregates/ agglomerates formed at high concentrations may be 
less toxic than smaller aggregates formed at low concentrations.  
3.7.51 If this is a general phenomenon, it will severely affect the paradigm of deriving 
PNEC by extrapolation from standardised tests that usually are carried out in 
high concentration regimes for hazard identification purposes. It is, at present, 
not certain whether effects from such tests can be extrapolated “downwards” 
(i.e. that the application of an assessment factor will in fact be protective). 
3.7.52 It seems too early to define the most appropriate metric for concentration-
response relationship applicable to all nanomaterials. The present metric 
used for bulk materials is mass per volume (or per mass in the case of 
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soil/sediment/sludge). Only very few studies have actually investigated 
alternative dose metrics at this point in time and correlated these with the 
observed effects. If another dose metric other than mass is chosen, this also 
implies that Predicted Environmental Concentration (PEC) estimations should 
be made in the same units and therefore that the choice of dose metric is not 
dependent on eco-toxicological considerations alone. 
3.8 TASK C2: HAZARD / RISK CHARACTERISATION – HARVESTING 
RESULTS FROM ON-GOING ACTIVITIES 
3.8.1 The objective of Task C2 was that of a review task pertaining to the 
characterisation of the hazards and risk of nanomaterials to humans and the 
environment. The information resources from this task were obtained from 
Task A of RIP-oN 3 and within this task our aim was to use and summarise 
examples of the analysis of the hazard and risk assessment approach taken 
by several bodies within different countries.  
3.8.2 An example of this, and in common with other studies and reports analysed, 
the NIOSH report addressing exposure risks associated with TiO2 (NIOSH, 
2005) concluded that particle surface area was the preferred metric for 
characterisation of particle hazard. However whilst surface area has been 
identified as the preferred metric, deficiencies exist in sampling technology 
and meaning it is currently not possible to measure exposure in the 
environment based on this metric. As such RELs were suggested by mass 
(assuming a known particle size distribution range) as a surrogate for surface 
area in two broad groups of fine and ultrafine particle size, with the latter REL 
being lower than the former REL, reflecting its increased toxicity. The NIOSH 
derivation reflects our own result in Task C1 and the wider literature, which 
suggests increased surface area of nano-TiO2 leads to increased toxicity and 
as such this should, where practicable, be reflected in the relevant exposure 
limit.  
3.8.3 Another source of information for consideration of hazard/risk characterisation 
was a nanosilver case study conducted by the National Institute for Public 
Health and the Environment (RIVM) which simulated a REACH registration for 
nanosilver. The authors found that, even though information about nanosilver 
toxicity and even toxicokinetics was available, it was almost impossible to 
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determine if nanosilver was behaving similarly to its bulk counterpart and only 
a rough risk assessment could be drawn, highlighting the difficulties faced 
when producing a risk assessment in with the current limited information. In 
performing a case-study for nanosilver, the authors have highlighted several 
problems in using proposed risk assessment framework. For example, the 
authors noted the need for adequate physico-chemical characterisation and 
comparative studies of bulk and nano forms of a material which may enable 
the validation of read-across approaches.  
3.8.4 In our evaluations of the NEDO studies addressing occupational exposure 
limits for TiO2 (Hanai et al. 2009) and MWCNT (Kobayashi et al. 2009b), a 
discussion was made of an alternative approach presented within the Hanai 
et al. paper for hazard characterisation. This approach was termed a bi-axial 
approach within the study and is suggested as a method by which acceptable 
levels of human exposure may be predicted for a material for which inhalation 
data does not exist. The approach uses ranking of a substances toxicity using 
data not suitable for derivation of a human exposure limit. This is then 
compared to the relative toxicity of a substance for which inhalation data does 
exist (and derived human exposure limit) and based on this benchmark 
inhalation data, an indicative interim human exposure limit established.   
3.8.5 As an approach, this raises many questions but is interesting and could be 
considered for further R&D and assessment for its suitability for REACH 
regulation.  
3.8.6 In reflection and discussion of the approaches for the derivation of exposure 
limits used by Pauluhn (2010a) and Hanai et al. 2009 (which appears 
representative of the NEDO approach), an alternative approach for 
extrapolating from experimental animals to humans for inhalation exposure is 
suggested, based on current particle toxicology literature. As this approach is 
a recent addition to the report and as such has not been part of the RIP-oN 3 
stakeholder review process, it is presented as an appendix to the report 
(Appendix 4 herein). The approach however is suggested for consideration 
and development in relation to its suitability for future incorporation into 
guidance. 
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3.9 TASK C3: ADVISORY REPORT ON HAZARD AND RISK 
CHARACTERISATION FOR NANOMATERIALS 
3.9.1 The outcome of the report was that, whilst the REACH guidance for hazard 
and risk characterisation has been written primarily for soluble substances, 
nonetheless they seem overall suitable for nanomaterials due to their wide 
applicability and generality. However the question of what parts of the 
guidance are also truly suitable for (dispersed) particles like most 
nanomaterials still needs to be addressed. 
3.9.2 However, some major points were emphasised in relation to nanomaterials 
and hazard and risk characterisation. Firstly, there is a large diversity of 
nanomaterials and information about the hazard and/or exposure to these 
materials is often scarce. Such a scarcity of information is not specific to 
nanomaterials and is often seen with chemicals, but due to the existence of a 
greater wealth of data surrounding analogous materials, other approaches 
such as read across or categorisation are available in chemical assessment. 
However the scientific understanding such as concepts of similarity or drivers 
of toxicity for a wealth of nanomaterials is not yet sufficiently mature to allow 
for such an approach to be taken in the absence of information with any 
degree of certainty. In these conditions, it is difficult to do a proper quantitative 
risk assessment analysis and the precautionary principle should be applied 
either via further testing or by taking a very conservative approach in relation 
to the application of assessment factors.  
3.9.3 Secondly, DNEL(s) for an exposure pattern are derived from relevant dose-
descriptors firstly by modification if required to a correct starting point followed 
by the application of assessment factors. These assessment factors whilst not 
developed specifically for nanomaterials, address numerous aspects of 
extrapolation and uncertainty that may be both applicable and appropriate for 
nanomaterials.  
3.9.4 The issue of metrics is a difficult one as no single metric can be said to 
adequately represent all materials. In the case of nanomaterials, whilst mass 
is commonly used for historical reasons and ease of use, and has been 
suggested as a driving force behind certain pathogenic process (Pauluhn 
2010a), it does not necessarily represent the best metric for all nanomaterials 
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and all effects. Indeed particle surface area has been suggested to more 
accurately reflect the particle dose leading to a response and as such in 
certain circumstances would be the most appropriate choice when deriving a 
DN(M)EL. In addition derived limits for fibrous nanomaterials, a fibre number 
metric may be more suitable than either a mass or surface area metric. As no 
single metric can be established, guidance ideally should reflect the presence 
of other additional metrics and allow their use by not being overly prescriptive 
towards a historical mass based metric.  
3.9.5 A further important point pertaining to the hazard and risk characterisation of 
nanomaterials is that the adequacy of exposure patterns should be 
particularly emphasised. Indeed, it has been stressed that exposure patterns 
in occupational or consumer settings (e.g. variable particle size distribution) 
might be different from exposure patterns in experimental settings (e.g. stable 
particle size-distribution). However, factors such as the size distribution/ 
agglomeration state of nanomaterials are known to be important in 
determining the hazard. Therefore, prior to any risk assessment, the 
relationship between external exposure levels in studied setting and exposure 
levels in experimental conditions used to derive toxicological reference values 
is needed. This comparability of the exposure patterns constitutes an 
additional challenge in the risk assessment of nanomaterials. 
3.9.6 The specific issues resulting in specific guidance changes as well as identified 
R&D priorities are discussed later in this report.  
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3.10 TASK D: METRIC(S) TO COMPARE IN THE RISK CHARACTERISATION  
3.10.1 The objective of Task D was to develop a working document on the 
identification of critical items on exposure/dose descriptors and related 
parameters, outlining needs for adequate metrics/parameters as appropriate 
for exposure assessment compatible with the ones used for hazard 
assessment. The underlying principal of metrics is the number of molecules 
expected to participate in the process in question. Most commonly mass is 
used as a proxy, but particle number or surface areaare increasingly 
suggested as more scientifically based metrics.   
3.10.2 The question of what is the best metric to measure the hazard and exposure 
of nanoparticles is frequently posed.  In practice there are many metrics, all of 
which include mass or number, which are currently used in the risk 
assessment (both regulatory and otherwise) across the three elements of 
exposure, toxicology and risk.  The most commonly used are identified in the 
table below: 
Target Route Exposure metric 
(example units) 
Toxicology /ecotoxicology dose 
metric  (example units) 
Human inhalation mass conc in air (mg/m3) 
mass per animal or per body part 
(m) 
inhalation fibre number conc in air (f/ml) 
fibres per animal or per body part 
(#f) 
dermal 
mass per surface 
area of skin 
exposed 
(mg/cm2) 
mass per animal or surface area 
(m) 
dermal 
mass per kg body 
wt per day 
(mg/kg/day) 
mass per animal or surface area 
(m) 
ingestion 
mass per kg body 
wt per day 
(mg/kg/day) 
mass per animal (m) 
Environment air/water/ soil 
release rates into 
compartment 
(kg/day) 
or release factors 
(%) 
compartment concentrations 
(mg/m3) 
3.10.3 The metrics can be units, concentrations, or ratios. They can be measured 
directly, for example the exposure metric, mass concentration in air or 
modelled for example risk evaluation metric compartment concentration.  Risk 
characterisation is based on a ratio between the exposures and toxicology 
metrics and is unit-less. 
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3.10.4 The most prominent alternative or additional metric identified for use in 
relation to the risk assessment of non-fibrous nanomaterials, are 
concentration metrics based on surface area. This is based primarily on 
toxicological evidence relating particle surface area to inflammation, an 
indicator of toxicity.  The evidence for this has been assessed in the Task 
report (RNC/RIP-oN3/D/2/FINAL).  Other parameters suggested as possible 
metrics include surface reactivity and charge.  Surface reactivity is clearly an 
important parameter although whether this could be considered as a potential 
metric or simply a unit to express the toxicological response is a matter for 
discussion.  Its use as a metric (in toxicology) would be as “units of reactivity 
per body part”.  This same is true of charge in which the metric would be 
coulomb/body part. However, these need further research and it is considered 
that the basis of these properties becoming “metrics” is not yet sufficiently 
advanced to a level at which use and guidance for REACH can be 
recommended.  
3.10.5 It is important to note that there are other parameters which can act as 
modifiers of the toxicity.  These include particle size, size distribution, density, 
aggregation and shape. These parameters would not generally be considered 
as scalable quantities and do not appear to conform to the current use of the 
term “metric” under REACH.  Therefore they have not been considered 
further in this discussion. 
3.10.6 Metrics in risk assessment need to be scalable quantities which may be used 
to express the levels of hazard, exposure or risk.  To date, conversion 
between mass, number and surface area has largely been based on simple 
assumptions, treating (nano)particles as spherical and using mean particle 
diameters.  It is considered advantageous to be able to provide functional 
conversions between the three metrics based on established and validated 
relationships.  Conversion between the metrics of mass, number and surface 
area remains challenging both within and between exposure, hazard and 
dose.  Measurement of surface area in relation to dose is still mostly indirect 
and is typically based on a mass assessment times a measure of specific 
surface area of the powdered material obtained by Brunauer, Emmet and 
Teller (BET) analysis or similar.  Encouragingly, in relation to inhalation 
exposure, measurement systems are available to measure mass, number and 
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surface area concentrations (e.g. ISO 2008).  Attempts have been made to 
assess relationships between these various metrics. 
3.10.7 For example, Wake et al. (2001) carried out a laboratory study to compare the 
performance of Matter LQ1-DC active surface area monitor, a TSI Model 
3934 Scanning Mobility Particles Sizer and an R&P Tapered Element 
Oscillating Microbalance. Using the three instruments described above, 
experiments were carried out in the laboratory with polydisperse aerosols, 
containing ultrafine particles, to establish what relationships exist between the 
three measurement parameters mass, surface area and number as 
determined by each instrument and how these relationships may be 
influenced by particle composition and morphology.  For each of the five 
aerosol types investigated, consistent relationships were found for mass and 
active surface area with increasing particle number concentrations for all the 
particle sizes investigated.  However, these relationships were not consistent 
with particle size.  Amongst Wake’s conclusions were that no simple 
relationship was found for predicting active surface area and mass from the 
results of measurements made with the benchmark instrument the SMPS.  
This instrument, therefore, should not be used to calculate surface area and 
mass unless a detailed knowledge of the aerosol is known. In view of this, the 
use of all three metrics, measuring in parallel, should continue to the extent 
feasible despite the difficulty in arranging this in the workplace.  Moreover, 
Wake considered it unwise to make measurements in terms of just one 
parameter, be it mass, active surface area or number/size, when assessing 
the potential for engineered nanoparticles to cause ill health when the causal 
factor has not yet been established.   
3.10.8 An advantage of mass over surface area (and virtually all other alternatives) is 
that the mass in a system is conserved i.e. remains constant (and could be 
assessed through mass balance), whereas surface area is not.  In other 
words, the actual surface area can change due to aggregation/de-aggregation 
which may occur following deposition of the nanoparticles and influence the 
interpretation of data.  The same is also true (to an even greater extent) for 
particle number.   
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3.10.9 However, there is nevertheless evidence that surface area is an important 
metric in describing the potential human health hazard of some types of 
nanoparticles.  For low toxicity low solubility materials, surface area of 
particles administered rather than mass burden of particles may be a more 
appropriate dose metric for pulmonary toxicity studies.  The same type of 
relationship has also been demonstrated for higher toxicity nanoparticles.  For 
dermal effects, any metric proposed to assess dermal exposure to 
nanoparticles should be biologically relevant and should relate to health 
effects.  It may be that for local effects, inflammation is the key driver in which 
it could be speculated that surface area would be the important metric.  
Further work including workplace studies and in-vivo/vitro assessment of 
penetration is required.  For the environment, it seems too early to tell 
whether a dose [concentration] - response relationship can be established as 
well as whether, for instance, number or surface area can be substituted with 
dose by mass. Too few studies have actually investigated alternative dose 
metrics at this point in time and correlated these with the observed effects. 
3.10.10 In relation to the guidance which can be given now on hazard assessment, it 
is considered important to continue with mass based measurement.  This is 
the basis of the current risk assessment process and the linkage to past work 
in both exposure and toxicology.  Based on the evidence available, it seems 
justified to additionally express the data in terms of surface area.  In practical 
terms, this would only require knowledge of BET and density results for the 
nanomaterial used.  For exposure assessment, both surface area and number 
concentration data are achievable and provide useful information and addition 
to the standard mass data, and should be collected.   
3.10.11 Further consideration of additional issues relating to metrics, as part of an 
ongoing international dialogue warrant acknowledgement in this final report: 
 There is no general rule for the choice of metric as the relevance may 
depend on the exposure route and even the material itself (e.g. aspect 
ratio), so it should be decided on a case-by-case basis by the 
registrant.  The mass metric may not always be the most appropriate 
or relevant metric.  However, given the historical and established use 
of the mass metric, which is the case in most if not all elements of 
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hazard, exposure and risk characterisation in a Chemical Safety 
Assessment (CSA) under REACH, it continues to be considered 
appropriate that even in cases where another metric is relevant and 
has been used, the mass metric description/data/result should 
continue to be provided.  
 It is clear that one, two or more metrics may be relevant to undertake 
the best possible CSA for different forms of a materials covered by 
one registration, including all exposure scenarios etc.  This is to be 
encouraged, albeit with a clear justification and transparency to 
ensure that the CSA can be understood.  The most relevant for 
determination of the Risk Characterisation Ratio (RCR) should be 
considered in such cases.   
 At present, evidence of the emergence of new metrics is strong in 
some case (e.g. surface area), but this is acknowledged as an 
evolving field.  It has been made clear in the RIP-oN 2 and 3 projects 
that there is evidence to recommend surface area as a metric 
appropriate in inhalation exposure but there is no conclusive evidence 
with regard to dermal exposure.  This has already been reflected in 
the guidance recommendations.  The choice of metrics is rightly left to 
the registrant, with the expectation that the choice is scientifically 
justified.  As stated above, as exposure scenarios differ, so can the 
choice of metrics for the related form and the individual scenario. 
 It should always be clear how different metrics have been used (in 
rare cases perhaps even from separate studies) or derived through 
transformation of final results of the same test etc.  It should be 
ensured that the whole CSA (hazard, exposure, risk characterisation 
ratio including any required risk management measures) is performed 
consistently.  If the Derived No Effect Level (DNEL) or Predicted No 
Effect Concentration (PNEC) are determined using one metric, so 
should the estimation of the Predicted Environmental Concentration 
(PEC) to characterise the risk ratio.  The basis for selecting and 
assessing the efficiency of RMM employed should be expressed in 
the same metric.  The same applies to the potential application of 
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models and to the justification of any read-across.  If there are 
transformations of metrics involved, they need to be transparent so 
the applicability of the data can be justified.   
 It is clear that a consideration of Assessment Factors needs to be 
performed for different metrics, separately, and including the 
uncertainty potentially arising from the transformation of metrics and 
from the differences in the tests performed.  
 There is more to the conversion between metrics than simply working 
in one metric and then expressing results in another.  Adequate 
characterisation and the scope of applicability of the test is required, 
along with consideration of the design of the test (e.g. selected doses, 
sample preparation to minimise uncertainty/bias) and the selection of 
the most appropriate instrumentation/method.  
 It remains that there are currently no definitive conclusions on the best 
metric.  However, there is growing consensus that if new animal tests 
on nanoforms are performed, there should be a sufficient 
characterisation of those forms to allow the dose-response to be 
expressed in the different metrics discussed - number, surface area 
and mass.  
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4 GUIDANCE ASSESSMENT 
4.1 RATIONALE 
4.1.1 The philosophy adopted for the development of specific recommendations for 
guidance updates and research & development (R&D) is as follows.  
4.1.2 The content of a recommendation for a specific update to guidance is 
consistent with the focus of current REACH Guidance document, its level, and 
language, such that: 
 where the need is for ‘strategic-level’ guidance applicable to 
nanomaterials (i.e. high-level or overarching principles), succinct 
contextual information and reference(s) to primary sources of 
information are provided; 
 where the need is for updated detailed pragmatic information on, for 
example methods, a synopsis of specific guidance with appropriate 
reference(s) are provided; 
 where there is simply a need identified to acknowledge an important 
relevance or limitation in existing guidance to nanomaterials, a 
simple wording clarification may be proposed.   
4.1.3 Recommendations for updates to Guidance are made on the basis of the 
findings of the RIP-oN 3 task activities, and where there is a recognised case 
for doing so.  Wide-scale acknowledgement confirming the general 
applicability of Guidance to nanomaterials has not been made.  For the 
avoidance of doubt however, with these changes, all clauses of the guidance 
document, unless explicitly stated otherwise, are now applicable to 
nanomaterials and should be used for that purpose. 
4.2 GUIDANCE REVIEWED 
4.2.1 This report focuses on the following parts of the guidance on Information 
Requirements and Chemical Safety Assessment: Part D (Exposure Scenario 
building), Part E (Risk Characterisation), Part F (Chemical Safety Report, incl. 
CSR format), Part G (Extending the SDS), Chapter R.12 (Use descriptor 
system), Chapter R.13 (Risk management measures and operational 
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conditions) and Chapters R.14, R.15, R.16 and R.17 (on exposure estimation 
in different groups).  It also considers the RMM library. In each case, for each 
issue, all of these documents have been reviewed to evaluate the need for 
guidance changes. 
4.2.2 The mapping between the various guidance documents and the issues 
identified from exposure assessment aspects (RNC/RIP-oN3/B4/2/FINAL) is 
shown in Appendix 2. This identifies each of the scientific issues identified in 
that report and the preceding reports, by reference to the tables in RNC/RIP-
ON3/B4/2/FINAL, and maps that to the point in the guidance indicating where 
they are relevant. 
4.2.3 The maps in Appendix 2 represent the intersection between identified 
scientific issues and a particular section of the guidance.  White, unfilled cells 
indicate where the specific identified scientific issue is not relevant to that 
particular section of the Guidance. Therefore no change to that section of the 
guidance is required because of that specific issue.  
4.2.4 Filled blue cells indicate where the specific identified scientific issue is 
relevant to that particular section of the guidance but the guidance applies 
equally well for nanomaterials as for substances in general and therefore, 
again, no change to the guidance is required.  
4.2.5 Filled yellow cells with a plus symbol cells indicate where the specific 
identified scientific issue is relevant to that particular section of the guidance 
but the guidance is not sufficient and needs to be amended to take account of 
the issue. Guidance recommendations have been made for these cells only. 
4.2.6 The matrices are not intended to be part of the guidance, they are merely to 
illustrate the decision making process which has led to the guidance and/or 
R&D recommendations. 
4.2.7 This same approach has been followed for each of the guidance documents. 
4.3 PART D EXPOSURE SCENARIO BUILDING 
4.3.1 This part of the guidance explains how to conduct exposure assessment, 
covering the development of exposure scenarios and exposure estimation. 
The main focus is on how ES can be developed. It also contains an overview 
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on exposure estimation however much more detailed guidance on exposure 
estimation can be found in Chapters R.14 to R.18. The exposure scenario 
guidance covers both the core content of information to be collected as well 
as the step-wise procedure to build the final exposure scenarios for a 
substance, as an integrated part of the iterative CSA. 
4.3.2 Considerations  
4.3.3 Almost all of the issues described in the proceeding tasks of RIP-oN 3 (B1, 
B2, B3, B4) have some relevance to the exposure scenario building document 
(Part D). In the main however the document is described at quite a high level 
and points to other documents for more detailed descriptions and guidance. 
The version of Part D which was reviewed is version 1.1 (May 2008). In 
carrying out the work however we also took account of the exposure scenario 
format document which was being developed in 2010. Version 2 of this 
document was published in May 2010.   
4.3.4 The mapping between Part D and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown Appendix 2. This 
identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the tables in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant.  
4.3.5 D.2 describes the contents of exposure scenarios, providing an overview of 
core information to be taken in to account in ES development (D2.2), 
examples of determinants of exposure (Table D2.1) a standard format for the 
final exposure scenario (Table D2.2), subsequently replaced by the May 2010 
full document on this issue and an overview of the exposure scenario 
development steps (D2.3) - information in this section is high level or points to 
other more detailed guidance.  It is considered that this is equally applicable 
to nanomaterials as for any substance in general.  The detail of the revised 
standard format is considered later.  No specific recommendations are made 
in relation to this section.  D.3 describes the overall workflow and dialogues, 
comprising in tabular format a diagram of the workflow in building exposure 
scenarios identifying steps in that workflow as well as the output of each step.  
This is entirely generic and is applicable to any substance including 
nanomaterials.  Also later in that section, “it will be on the DU to evaluate 
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whether in practice the measure is implemented as recommended by the MI 
e.g. a local exhaust ventilation of a certain effectiveness. The RMM library will 
aid the transparency of this process.”  The description of RMMs and their 
effectiveness in this document is at a generic substance independent level.  
As such it does not in itself suggest the requirement for changes to be made 
for nanomaterials.  However in the subsequent part of this report we have 
reviewed in more detail, the individual elements types of RMM etc. and have 
made recommendations for the document R.13 and for the RMM library itself.  
These recommendations have not been reproduced here.  It is considered 
that these recommendations will be sufficient to take account of any of the 
issues in this particular document.   
4.3.6 From the analysis of case studies it was considered that “these Case-Studies 
could serve as nanomaterial product-specific examples only and that no 
generalisation with regard to practices within an entire nanomaterial type-
specific branch could be based on these individual ES Case-Studies.”  This is 
not to indicate that generalisation of ES for nanomaterials will always be 
impossible. As with any substance the generalisation of the ES would need to 
be justified. What would be different for nanomaterials is that this would not 
just be based on the substance composition but would also need to take 
account of other parameters such as particle size distribution.  Based on this  
it is recommended that a paragraph is added to D.4.3.3: 
4.3.7 Generalisation of ES for nanomaterials, as with other substances will always 
need to be justified. For nanomaterials this would not just be based on the 
substance composition but would also need to take account of other 
parameters such as particle size distribution.   
4.3.8 D.5 is the section on exposure estimation.  Again this is provided largely at a 
substance independent level and does not go into any detail concerning the 
exposure measurement methods themselves.  The following change is 
recommended to take account of identified issues related to background 
discrimination. 
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4.3.9 Insert into D.5.2 the bullet point: 
4.3.10 Have background concentrations been taken into account for particle 
measurements. 
4.3.11 Data from measurements (D.5.3.1) is only a single small paragraph, which 
points to R.14 for more detail.  Much of this section is concerned with 
modelling approaches which are dealt with in more detail in R.14 and other 
documents.  We consider that the changes proposed elsewhere in relation to 
exposure measurement and estimation are sufficient to take care of the 
issues which have been identified.   
4.3.12 In appendix D.1, the strength and limitations of available Tier 1 exposure 
estimation tools are indicated.  It is recommended that a caveat is added to 
each of these tools to indicate a limitation in relation to the use for 
nanomaterials.  This limitation will indicate as follows: 
4.3.13 Please note that this tool has not been validated for use with nanomaterials.  
If the output of the model is used to estimate exposure for NMs, this should 
preferably be supported by measured data. There should be a clear 
description in the CSR of the uncertainties associated with the estimated 
values and the consequences for the risk characterisation.  
4.3.14 This would fall some way short of the statement which is made for some 
models e.g. for the Control of Substances Hazardous to Health (COSHH)– 
The Federal Institute for Occupational Safety and Health (BAUA) – tool the 
statement is made not suited for Carcinogenic, Mutagenic, or Reproductive 
toxin (CMR) substances.  However a requirement for an exclusion of this kind 
is not justified based on the evidence. 
4.3.15 In relation to the ES Format, a detailed analysis of this document was carried 
out as part of the ES Case studies. A report of the outcomes of this is 
available as Appendix 1 of the current report. Overall the analysis indicated 
that most of the document was not substance specific and could be applied to 
nanomaterials as well as for substances in general. 
4.3.16 It should be clear to the user of the ES for which forms (of the substance) the 
RMMs and OCs given will apply, i.e. protect the one using the materials. This 
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should be specified under the heading "Product Characteristics", already in 
the format. 
4.3.17 In Appendix D.1, in table D.2.2.3, under the entry “Product Characteristics” in 
which examples of product characteristics, add the example: 
4.3.18 (Nano)form(s) of the substance  
4.3.19 Issues which were identified related to the use of different measuring systems 
and the interpretation of the data obtained.  There are several aspects to this.  
One is, for nanomaterials what measurements should be taken with which 
instruments. It is suggested that it is more appropriate to change the R.14 
document in relation to this issue rather than the ES Format document which 
contains no similar detailed measurement advice. The type of changes 
indicated (for R.14) are the same as have been proposed based on the 
evaluation of the other evidence collected in RNC/RIP-ON/B3/2/FINAL.  
Hence, the case studies support the need for clearer general guidance to be 
provided. 
4.3.20 A second issue relates to the use of real time measurement devices, such as 
the CPC or SMPS which essentially provide a continuous output of data over 
a time period which, in most of the devices, can be logged.  The current 
guidance is clearly written from the perspective of multiple single offline 
measurements and combining these e.g. to develop summary statistics of the 
data obtained e.g. mean or 95th percentile.  There is almost no information on 
this issue in the guidance documents reviewed. This also illustrates the 
difficulties in trying to use pre-existing data in order to demonstrate 
compliance.  Again it is suggested that it is more appropriate to change the 
R.14 document in relation to this rather than the ES Format document which 
contains no similar measurement advice. 
4.3.21 A third issue relates to the use of different metrics. In the data provided by 
these case studies a range of metrics were used. A number of approaches 
led to estimates based on number concentration and there was no clear view 
as to how such measurements could be used for comparison with the DNEL 
(which was, in all cases expressed in terms of mass concentrations). This 
cross metric comparison would be possible if there were well established 
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relationships for conversion between these. However as indicated in the Task 
D report, such relationships are not available and are unlikely to be stable or 
generalisable. In the absence of this it is difficult to provide clear guidance on 
this issue. This may continue to be the case for some time. The key generic 
message here is that in that, in comparing DNELs with exposure estimate, the 
metrics used should be relevant and the same in each case. Although this is 
perhaps obvious, it seems to be worth stating. However, the appropriate place 
for such a statement to be made would be Part E, Risk Characterisation 
rather than Part D. These considerations have been carried forward to the 
next section. 
4.4 PART E RISK CHARACTERISATION 
4.4.1 Part E describes the risk characterisation and outlines the main steps in the 
process.  Identifying calculation of the risk characterisation ratios, and the 
need for iteration. 
4.4.2 The mapping between Part E and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown Appendix 2. This 
identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the tables in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
where the guidance is adequate for nanomaterials as for substances in 
general and where it has been necessary to recommend a change.   
4.4.3 The document is high level and process orientated. It is generic and therefore 
most of the provisions apply equally well to nanomaterials as for substances 
in general.  The document emphasises (in E3.1) the need to make the whole 
process as “transparent as possible with careful explanation and justification 
as to assumptions decisions uncertainties and adequacy of the available data 
set”.  The document also acknowledges that the whole risk characterisation 
process depends heavily on expert judgement. Both of these caveats would 
tend to give a steer towards expert input in the case of different or unusual 
substances, such as nanomaterials. 
4.4.4 The main section of relevance to exposure issues is E.3.4.3, “Step wise 
approach for the qualitative assessment, including development of exposure 
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scenarios (ES)”. This section points to the need to conduct exposure 
estimation/assessment according to Part D of the guidance.  It also 
emphasises (in Table E.3-1) suggestions for general risk management 
measures and operational conditions and PPE to be considered when 
developing exposure scenarios.  Examination of this table indicates that it is 
based on type of effects and R phrases, rather than substance specific.  For 
example types of effects may include very toxic, respiratory sensitiser, 
carcinogen, etc.  These are characteristics of particular substances rather 
than substance type groupings.  On that basis these provisions are substance 
generic and apply equally well to nanomaterials as to any substances in 
general.   
4.4.5 As discussed in Section 4.3 (Part D) it is worth emphasising that in comparing 
DNELs with exposure estimate, the metrics used should be the same in each 
case. Therefore it is recommended to update the Guidance by inserting the 
following as a footnote in Section E.1.2: 
4.4.6 In calculating the RCR both the exposure estimate and the PNEC or DNEL 
should be expressed using the same relevant metric(s).  
4.4.7 Other than for this issue, in relation to exposure issues no specific 
recommendations for guidance changes are being made.  
4.4.8 Research recommendations 
4.4.9 Mention is made in E.3.5.1 of potential applications of bio-monitoring data.  
One of the useful challenges for nanomaterials would be to develop effective 
biomarkers of exposure which could be reliably measured.  This would require 
information on the exposure biomarker response relationship to be developed 
for a range of different nanomaterials.  Where such relationships would be 
available this would be highly effective and useful in relation to risk 
assessment of nanomaterials.   
4.5 PART F CHEMICAL SAFETY REPORT INCLUDING APPENDIX TO PART 
F CSR TEMPLATE 
4.5.1 The REACH Part F is a high level guidance document which provides notice 
of general requirements in relation to the chemical safety report (CSR).  
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Specifically in F2.2 it points the user to the template which is the appendix of 
the guidance.  The CSR template provides further guidance on how to detail 
and structure the information required in the CSR (based on the standards 
headings of Annex 1 of REACH).  The CSR is intended to document the 
outcomes of the CSA process.   
4.5.2 The template as an appendix to Part F basically provides the structure of this 
CSR.  It is intending to be generic and be applicable to all substances and 
materials.   
4.5.3 The mapping between Part F and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown Appendix 2. This 
presents each of the scientific issues identified in that report and the 
preceding reports, by reference to the tables in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
where the guidance is adequate for nanomaterials as for substances in 
general and where it has been necessary to recommend a change.   
4.5.4 The general provisions of this document are considered to be equally 
applicable to nanomaterials as they are to substances in general.   
4.5.5 Units are specified in some of the tables e.g. in the exposure concentration 
fields of the risk characterisation chapter (chapter 10) inhalation exposure is 
indicated to be in the units of mg/m3.  Consideration should be given for the 
inhalation aspects that relevant additional data in relation to number or 
surface area would be provided. This would also apply to the tables where 
these units (for inhalation) are recorded. The suggested change would be to 
add the following footnote at all points in the document where the units of 
inhalation are provided in terms of mg/m3: 
4.5.6 For nanomaterials it may be appropriate to also consider other relevant units 
e.g. in terms of surface area concentration cm2/m3 or number concentration 
n/m3.  
4.5.7 Research recommendations 
4.5.8 As this is a high level document which outlines the whole CSR process it does 
not in itself suggest any new requirements for research.   
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4.6 PART G EXTENDING THE SDS 
4.6.1 This chapter provides guidance to M/I on how to integrate the final exposure 
scenario for a substance into a safety data sheet (SDS) to make it an 
extended SDS (eSDS).  This includes: i) general guidance on how the 
exposure scenarios and the main body of the eSDS can be combined in a 
useful way, and ii) specific guidance on the relationship between the Sections 
1.2 (identified uses), 7 (handling and storage), 8 (exposure controls) and 13 
(disposal considerations) of the SDS and the exposure scenarios in the 
annex. The chapter does not provide complete guidance on all sections of the 
eSDS, and it does not cover safety data sheets for substances for which no 
CSR is required. 
4.6.2 The mapping between Part G and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown Appendix 2. This 
identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the table in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
where the guidance is adequate for nanomaterials as for substances in 
general and where it has been necessary to recommend a change.   
4.6.3 It provides in Table G2 an overview of the relationship between the SDS 
chapters and standard entries of the exposure scenario.  This table and the 
rest of the document is highly generic and its provisions apply as well to 
nanomaterials as to substances in general. As discussed in RNC/RIP-
oN3/B4/2/FINAL it is appropriate to add in some guidance to ensure that data 
relevant to the different nanomaterial form is included. It is recommended to 
insert the following as a bullet point at the end of G3: 
4.6.4 Where (a) particulate form(s) is (are) covered by the Extended Safety Data 
Sheet (eSDS), the M/I should ensure that the data are relevant to this (these) 
form(s) in the relevant particle size ranges (e.g. for nanomaterials). 
4.6.5 No further changes to this guidance are recommended.   
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4.6.6 Research recommendations 
4.6.7 As this is a high level document it does not in itself suggest any new 
requirements for research.   
4.7 R.8 CHARACTERISATION OF DOSE [CONCENTRATION]-RESPONSE 
FOR HUMAN HEALTH 
4.7.1 The R.8 document provides guidance to enable the generation of no-effect-
levels for human health based upon the integration of all available hazard 
data generated. The approach for generation of derived no effect levels 
(DNEL(s)) or derived minimum effect levels  (DMEL(s)) is outlined within the 
guidance as follows: 
4.7.2 STEP 1: Gather typical dose descriptors and/ or other information on 
potency 
4.7.3 STEP 2: Decide on mode of action (threshold or non-threshold and which 
next steps(s) to choose 
4.7.4 STEP 3: Derivation of effect levels (DNEL (step 3-1) or DMEL (step 3-2) 
or the use of a qualitative approach (step 3-3). 
4.7.5 STEP 4: Select the leading health effect 
4.7.6 The approach taken within the recommendations for guidance amendments in 
this report is the identification of amendments within the introductory section 
of R.8 followed by an evaluation of each step as outlined above.  
4.7.7 Considerations  
4.7.8 When considering the R.8 guidance document for nanomaterials, for the most 
part, the guidance provided applies equally well to nanomaterials as for 
substances in general. However, some issues have been raised within tasks 
C1 and C2 and these are reflected in discussions and recommendations for 
alterations for nanomaterials in the following sections. 
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4.7.9 Metrics 
4.7.10 One of the major issues with nanomaterials is the determination of the most 
relevant and most practical dose-metric to study their biological effects. 
Classically, a mass-based metric is used for dose-response studies with 
chemicals. However, for nanomaterials, other metrics might be more relevant 
to assess their hazard. Indeed, particle number or surface area or surface 
reactivity have been described in some cases as better metrics, to describe 
dose-response (Duffin et al. 2007, Warheit et al. 2007, Oberdörster 2010). In 
addition, the best dose metric might depend on the physico-chemical 
characteristics of each type of nanomaterials, such as its solubility 
(Oberdörster 2010). Therefore, there are still on going debates about the best 
dose-metric for nanomaterials.  
4.7.11 This uncertainty about the best dose metric to be used for dose-response 
analysis of nanomaterials leads to uncertainties about the comparability of 
risk assessment on different nanomaterials. As such it has been suggested 
within the RNC/RIP-oN3/D/2/FINAL report that for inhalation, in addition to 
mass, surface area and particle number (especially for fibres) as a metric be 
recorded and reported also. It should be noted that current assessment 
factors used within the derivation of exposure levels are typically based on 
mass based metrics. For the most part, the alteration of metric is not 
considered to impact on the use of some assessment factors or the suitability 
of their default values. However for some, such as interspecies factors, there 
may be some impact on the use of these assessment factors. Therefore 
where alternative metrics are considered, the impact of the use of an 
alternative metric factor on the suitability of the assessment factor(s) should 
be considered and amended, with justification, if necessary.   
4.7.12 The R.8 guidance document is from this point on considered by a section by 
section basis in reflection of guidance.  
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4.7.13 R.8.1 Introduction 
4.7.14 R.8.1.1 Overview of legislative requirements 
4.7.15 In our evaluation we considered that the introduction represents a valid 
overview of the REACH approach which is both equally valid for 
nanomaterials and non-nanomaterials alike. This is because within section 
R.8.1.1 (Overview of legislative requirements), it informs that DNEL(s) should 
reflect likely exposure routes, duration and frequency and in our view this is 
just as pertinent for nanomaterials as for substances in general and is not 
overly prescriptive. Indeed the list of factors to be taken into account when 
establishing a DNEL covers uncertainty, specifically mentioning intra- and 
inter-species variation, nature and severity of effect and sensitivity of relevant 
populations. All of these are relevant to nanomaterials and in particular 
uncertainties arising from variability in data and inter-species variation may 
also be an issue for nanomaterials and are adequately addressed here in this 
introductory section.  
4.7.16 Under the use of OELs for the derivation of DNELs, the Guidance document 
refers registrants to Appendix R.8-13. Alterations to this appendix have been 
suggested (see paragraph 4.7.119), although no changes are required at this 
point in Guidance.  
4.7.17 In addition to introducing the derivation of a DNEL based on threshold effects, 
the introduction also addresses those situation for which no test data are 
needed based on exposure arguments, technical impossibility of testing, or 
the substance being classified as an isolated intermediate. These sections 
would also be applicable for nanomaterials, should a nanomaterial fall into 
one of these categories.  
4.7.18 The description of the situations whereby the derivation of DNEL is not 
possible and a qualitative or semi-quantitative approach must be taken, 
particularly in relation to mutagenic and carcinogenic effects would also be 
applicable for nanomaterials based on the non-descriptive, introductory nature 
of the section.  
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4.7.19 R.8.1.2 Overview of aspects to be considered in derivation of DNEL(s)/ 
DMEL(s) 
4.7.20 Examination of this section indicates that for the most part, the guidance 
provided applies equally well to nanomaterials as for substances in general. 
Within the summary introduction of the units (R.8.1.2.7 page 17) it describes 
how DNELs should be expressed ideally as external values so that they are 
more easily interpreted in compliance assessment to ascertain if the DNEL is 
being exceeded. Whilst certainly applicable to nanomaterials, the exposure 
units are given based upon a mass metric (i.e. mg/m3). As discussed earlier in 
this report and in RNC/RIP-oN3/C3/2/FINAL and RNC/RIP-oN3/D/2/FINAL 
(chapter 11), several other metrics are considered to also be potentially 
applicable to nanomaterials and indeed may correlate better with observed 
effects. It is not possible at this stage to identify a single metric that is 
applicable to all nanomaterials but the incorporation of other metrics in 
addition to mass, namely surface area should be considered. In relation to 
fibrous nanomaterials, particle (fibre) number may be a more appropriate 
metric although the technical feasibility of this has yet to be established. As 
such this is suggested for further R&D of a high priority. Therefore we would 
suggest the following amendment to Table R.8-1 footnotes on page 18 of R.8 
Guidance (alternations shown underlined): 
4.7.21 1 Units for systemic exposure are mg/m3, cm2/m3 (relevant for 
nanomaterials) and nanoparticle number/m3 (especially relevant for fibres) 
for inhalation, and mg/kg bw for oral and dermal exposure. Other metrics 
may also be used if this is scientifically justified and a comparable 
exposure metric is available to enable a risk characterisation ratio to be 
derived. In addition, when expressing metric information it should be 
stated on what the size distribution is based e.g. as-produced, as-
exposed or as-interacted. 
4.7.22 2 Units for local effects are mg/m3, cm2/m3 (relevant for nanomaterials) 
and number/m3 (especially relevant for fibres) for inhalation; and for 
dermal exposure: mg/cm2, mg/person/day. Other metrics may also be 
used if this is scientifically justified and a comparable exposure metric is 
available to enable a risk characterisation ratio to be derived. In addition, 
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when expressing metric information it should be stated on what the size 
distribution is based e.g. as-produced, as-exposed or as-interacted. 
4.7.23 R.8.2 Step 1: Gather typical dose descriptors and/or other 
information on potency 
4.7.24 Within this section the issues considering dose-response assessment in the 
derivation of a no/lowest observable adverse effect level (N(L)OAEL) and 
benchmark dose (BMD) are discussed. The approach surrounding the 
generation of N(L)OAEL, its accuracy in relation to a true NAEL and current 
methodological issues in establishing a BMD using standardised methods are 
all apparent for nanomaterials and no new information is available for 
addressing the issues. 
4.7.25 The crux of the issues identified relates to the appendices to which the 
guidance section refers and these are outlined below.  
4.7.26 The guidance refers users to Appendix R.8-1 for details on the derivation of 
different dose descriptors for non-threshold carcinogens and again the units 
within these tables (R.8-14; R.8-15; and R.8-16) are given based on a purely 
mass metric which may not be the most appropriate metric for all forms of 
nanomaterials and other such as surface area or number (especially for 
fibres) should be considered alongside mass.  
4.7.27 Within the dose descriptor for acute toxicity, guidance refers users to 
appendix R.8-8 which gives a detailed overview of the process of establishing 
an acute DNEL. Within the process, as summarised by a decision tree for 
setting an acute inhalation toxicity DNEL, the appendix purports the use of 
read-across or performing testing in the absence of substance specific data. 
As discussed the understanding surrounding such a non-testing approach is 
not yet sufficiently developed for nanomaterials and suggestions for 
amendments have been made in the relevant section of this report (paragraph 
4.7.115).   
4.7.28 R.8.3. Step 2: mode of action (threshold or non-threshold) 
4.7.29 For non-carcinogenic or non-mutagenic effects, it is assumed that a threshold 
has to be exceeded before any effects arise. Therefore a threshold is to be 
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defined and DNEL(s) are set for each threshold endpoint. If a substance 
exerts its effects at a level at which no threshold can be ascribed, then the 
substance is to be considered as having a non-threshold mode of action and 
a qualitative/semi-quantitative risk characterisation should be conducted. A 
DMEL should be derived if data allow.  
4.7.30 As a consequence, it is important to determine if a mutagenic and/or 
carcinogenic material is acting according to a threshold and/or a non-
threshold mechanism. Therefore, as defined in the guidance (R.8.3), step 2 
consists of determining if the studied compound is a non-threshold mutagen 
or a non-threshold carcinogen. For nanomaterials, as with substances in 
general, this distinction might still be difficult to assess despite the generation 
of data from a testing approach. The REACH guidance R.8.3 acknowledges 
that a decision on threshold or non-threshold effects may be difficult to reach 
and as such, if it is not clear if an effect is threshold or non-threshold in nature 
“…the assumption of a no-threshold mode of action would be the prudent 
choice.” (R.8.3, page 22, paragraph 4 second sentence). In relation to 
particles and particularly nanoparticles (due to their large surface area and in 
certain forms, volume) carcinogenic effects may occur as a result of the 
threshold phenomena, lung overload in experimental systems. This should be 
borne in mind when deciding a mode of action and is discussed further in the 
following section. 
4.7.31 Example of physical process causing secondary carcinogenic effects - Lung 
overload 
4.7.32 Within this section it may be pertinent to bring attention to carcinogenic effects 
which may also occur by threshold mechanisms. In relation to (nano)particles, 
one should consider the generation of lung overload (as described in 
RNC/RIP-oN2/FPR/1/FINAL) which can lead to tumour formation via indirect 
mechanisms not attributed to the direct action of the particle itself. Indeed the 
situation of lung overload and its relation to risk assessment was discussed 
within the NIOSH TiO2 study (NIOSH, 2005). The authors of the study 
concluded after analysing the available evidence that:   
4.7.33 “….the tumourgenic effects of TiO2 exposure in rats did not appear to be 
chemical specific or acting via a direct action of the chemical but rather as a 
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consequence of particle size and surface area acting through secondary 
genotoxic mechanisms.” 
4.7.34 These route by which secondary genotoxic mechanisms occur is well 
described within the NIOSH (2005) report and was summarised as such:  
4.7.35 “…plausible mechanism of action for TiO2 in rats can be described as the 
accumulation of TiO2 in the lungs, overloading of lung clearance mechanisms, 
followed by increased pulmonary inflammation and oxidative stress, cellular 
proliferation, and, at higher doses, tumorigenesis. These effects are better 
described by particle surface area than mass dose. The observed 
inflammatory response is consistent with a threshold mechanism.”   
4.7.36 Exposure to Poorly Soluble, Low Toxicity (PSLT) particles such as TiO2 at 
concentrations below the level at which overload occurs is not associated with 
pathogenic effects. However once this overload threshold has been crossed, 
approximately 200-300 cm2 of lung burden as suggest by Tran et al. (2000), 
there is a sudden increase in lung burden leading to adverse health effects. 
As such, the phenomenon of lung overload occurs as a threshold effect and 
pathogenic effects arising from this, such as secondary genotoxicity leading to 
tumour formation, would naturally also be threshold in nature. Therefore in 
generating exposure levels based on such data, it would be prudent to derive 
a DNEL rather than a DMEL which is more commonly used for carcinogenic 
effects.  
4.7.37 It is not the intention here to suggest that as a matter of course a DNEL 
should be used in replacement of a DMEL for all nanoparticles or that a 
threshold effect should be presumed. The use of a DNEL based a threshold 
effect for an observed endpoint such as carcinogenicity should only be done 
where experimental evidence of overload is apparent or where sufficient 
weight of evidence indicates overload at the test concentration for the 
(nano)particle in question. Our suggestion of consideration of lung overload 
when addressing the question “is the mode of action threshold or non-
threshold?”, does not supersede the statement already present in guidance 
that if the mode of action is not clear, then a  non-threshold approach would 
be the prudent choice. As such our placement of a suggested guidance 
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amendment attempts to reflect this and we suggest the following insertion 
after the first bullet point of section R.8.3 page 22: 
4.7.38 Substances may exert carcinogenic/ mutagenic effects either via direct 
mechanisms or by mechanisms secondary to a threshold effect (e.g. 
threshold induction of chronic inflammation leading to genotoxicity and/ or 
carcinogenicity). In the case of carcinogenic/mutagenic effects occurring 
secondary to a threshold stimulus such as inflammation, it could also be 
considered threshold in nature and as such a DNEL can be derived. A 
possible example of such a driver is the induction of lung overload in 
experimental animals exposed to poorly soluble low toxicity (nano)particles 
leading to chronic inflammation, oxidative stress and culminating in lung 
tumour formation. 
4.7.39 R.8.4 Step 3-1: derivation of DNEL for threshold endpoints 
4.7.40 In the derivation of a DNEL for threshold effects observed, a series of further 
steps are taken with the data obtained to derive a DNEL. These include: 
1) Selection of the relevant dose-descriptor(s) for the endpoint 
concerned (R.8.4.1) 
2) Modification, when necessary, of the relevant dose descriptor(s) 
per endpoint to the correct starting point (R.8.4.2)  
3) The application, when necessary, of assessment factors to the 
correct starting point (R.8.4.3) 
4.7.41 Within section R.8.4.2 there exists a list of occasions where starting point 
modification may be necessary. Point 2. states:  
4.7.42 “if for a given human exposure route there is not a dose descriptor for the 
same route (in experimental animals or humans)”.   
4.7.43 Within the explanatory section for this point (R.8.4.2, Ad2, page 24-25) the 
guidance suggests that generation of substance-specific data on absorption 
via different routes are preferred over the use of default values (equally 
applicable to nanomaterials) and that such information may be generated 
based on consideration of chemical structure.  
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4.7.44 This may well be the case for numerous nanomaterials as aspects of its 
physico-chemical properties such as size, hydrophilicity, shape and solubility 
could potentially all play vital roles in the materials adsorption and distribution 
kinetics. There is, however, still a need for further R&D to generate an 
improved understanding of which physico-chemical attributes affect 
absorption kinetics, how and to what extent. With this knowledge, generation 
of substance specific values may be possible based on analogous materials 
and scientific understanding but this is not yet realisable. We do not feel this 
requires an amendment to the current guidance text as it is not overly 
prescriptive but should be acknowledged for further R&D. 
4.7.45 Other factors are also addressed within this section including route-to-route 
extrapolation and the general principles appear appropriate for nanomaterials 
also. In particular the assumption that, in general, dermal adsorption will not 
be higher than oral adsorption appears justified as, despite their small size, 
nanomaterials would not necessarily be expected to penetrate dermal layers 
more than that of the gastric mucosa. Route-to-route extrapolation is an 
approach whereby if experimental data for the relevant route of exposure is 
absent, data from another route may be substituted with appropriate 
extrapolations. As stated within guidance, this can only be considered for 
systemic effects, not local effects and not consisting of first past systemic 
effects and this is certainly also the case for nanomaterials.   
4.7.46 Guidance states that where route-to-route extrapolations are made, 
differences in kinetics and metabolism need to be made but such information 
may be difficult to obtain. This again is certainly the case for nanomaterials 
and only limited absorption values exist for a small number of nanoparticles 
via different routes of exposure.  
4.7.47 The current guidance document in its discussion of route-to-route 
extrapolation is cautionary in its stance and emphasises that obtaining route 
specific data be considered and the use of substance specific data for 
extrapolation be used wherever possible. Whilst there is insufficient scientific 
grounds for challenging the suggested default factors used within route-to-
route extrapolation, these have not been developed for nanomaterials. As 
such the incorporation of the following cautionary statement is suggested for 
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inclusion at the end of the Ad 2 section on page 25 of the R.8 guidance 
(section R.8.4.2) and also within appendix R.8-2 appended to the first 
paragraph: 
4.7.48 The use of a route-to-route extrapolation in determining health hazards for 
nanomaterials may not be considered suitable at this time as the use of this 
approach has yet to be established for nanomaterials. Therefore the use of 
route-to-route extrapolation for nanomaterials must be scientifically justified 
on a case-by-case basis. 
4.7.49 Further investigation of the effects of certain physico-chemical parameters 
such as size and surface charge on the absorption and toxicokinetics is 
needed and should be considered a research and development priority. In 
particular, sensitive methods of detection are needed. This would be useful 
not just for informing route to route extrapolations, but also for PBPK 
modelling and increasing awareness of potential sites of systemic 
accumulation and/or effects.     
4.7.50 The 3rd point in deriving a DNEL relates to the application of assessment 
factors to areas of uncertainty, variability or deficiencies within a data set 
which cannot adequately be addressed elsewhere. These consist of 
assessment factors to address:  
 interspecies differences  
 intraspecies differences 
 differences in duration of exposure 
 issues related to dose-response  
 quality of the whole database 
4.7.51 The outcome of the RNC/RIP-oN3/C3/2/FINAL report and as agreed in the 3rd 
SCG meeting 15-16 December 2010 in relation to these assessment factors 
is broadly that they should not be changed for nanomaterials as there exists 
insufficient evidence to suggest a need for an alteration in the default 
assessment factors. However, it was agreed that there might be scope for 
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providing more specific guidance on when and how the defaults factors could 
be modified for nanomaterials. 
4.7.52 Interspecies differences  
4.7.53 The default assumption within this section is that humans are more sensitive 
than animals. This, as a starting assumption, is a conservative approach and 
one would assume is aimed at encompassing all likely modes of action of 
toxicity, at least for other substances. For the most part the guidance 
addressing interspecies differences is applicable to nanoparticles and 
sufficient. Perhaps the most relevant section when considering the current 
knowledge surrounding particles that would allow the use of substance 
specific information, is the section surrounding uncertainty in respiratory 
effects. Within the guidance, it is stated that: 
4.7.54 “…there could be significant quantitative differences in deposition, airflow 
patterns, clearance rates and protective mechanisms between humans and 
animals and where there is no data…” 
4.7.55 Indeed in relation to (nano)particle exposure, there is a great deal of data 
reporting the differences between humans and various animal species in 
relation to ventilation rates/ respiratory volumes, airflow patterns and in 
particular deposition fractions in different respiratory zones based on particle 
aerodynamic diameter as well as clearance kinetics. Thus, such historical 
information could be used when addressing interspecies adjustments as, in 
relation to particle inhalation exposure, the difference in retained dose 
between two species is the most important parameter when accounting for 
interspecies differences. A suggested approach for performing an 
interspecies extrapolation using physiological and experimental parameters 
commonly reported within high quality studies can be found in Appendix 4 of 
this report. As this approach is a recent addition to the RIP-oN project and 
has not been discussed within the stakeholder consultation process, it is 
presented within the appendix for consideration of further development and 
assessment for its suitability for incorporation into guidance, potentially within 
appendix R.8-2 or as a stand alone appendix within the R.8 chapter.  
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4.7.56 In the interim, the following text is proposed for incorporation into the R.8 
Guidance within section R.8.4.3.1, page 33 between the 3rd and 4th 
paragraphs:   
4.7.57 In deviating from the default assessment factor during the derivation of a 
DN(M)EL for (nano)particles, a calculation of the actual lung dose could be 
performed. However as there are considerable differences in ventilation rates, 
deposition patterns, and clearance rates between humans and animals, all of 
these factors should be taken into account.  
4.7.58 If performing an extrapolative calculation based upon physiological 
parameters such as ventilation rates, this should be assessed against other 
calculations performed in the derivation of a DN(M)EL. This is to address 
potential for duplication of calculations. For example in the calculation of the 
inhaled dose rate, a species respiratory volume and duration of exposure is 
taken into account and as such, a starting point modification for these 
parameters would not need to be performed.  
4.7.59 When considering lung deposition, the aerodynamic diameter not the true 
(stokes) diameter dictates the fractional deposition of a (nano)particle (see 
Miller 2000 for further explanation of lung deposition). When calculating the 
deposited dose, this may also be performed for the zone within the lung 
showing signs of adverse effects or particle accumulation (e.g. alveolar 
region) and this could be supported with histopathological findings.  
4.7.60 When considering the clearance rates it should be noted that clearance half 
times refer to insoluble particles and as such these values should not be used 
for soluble particles. 
4.7.61 Once a calculation of the retained dose within the lung has been made for an 
experimental animal, this can be normalised to a physiological parameter. 
Sufficient consideration should be given to the use of alternative physiological 
parameters to body weight, e.g. lung weight, lung surface area or the surface 
area of the proximal alveolar region (Donaldson et al. 2008). However the use 
of alternative parameters should be scientifically justified. In addition the use 
of additional exposure metrics such as (nano)particle surface area or number 
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concentration (especially for fibres) should be considered when performing 
analysis which should also be scientifically justified. 
4.7.62 The aim of this inserted section is to inform registrants of issues surrounding 
extrapolation from experimental animals to humans using 
inhaled/deposited/retained dose as a parameter. Further guidance based 
upon Appendix 4 of this report could be considered for further development.      
4.7.63 Intraspecies differences 
4.7.64 Within guidance, assessment factors are used to account for differences 
within a population, such that the most sensitive member of a population 
exposure to a substance will be protected. For the general public this 
considers both those healthy individuals and those with increased sensitivity/ 
susceptibility such as pregnant women, children, the very old or those with 
pre-existing disease. In order to account for such differences, a default 
assessment factor of 10 is applied in the derivation of a DNEL for the general 
population and there is no evidence to suggest that this would not be an 
appropriate default for nanomaterials.  
4.7.65 When considering a worker population, the range of sub-groups (e.g. 
children) is reduced and generally consists of ‘healthy’ adult workers and 
does not consist of the very old or those with severe disease. However within 
even a healthy population there may still exist considerable variability. For 
example the presence of sub-clinical disease (e.g. cardiovascular disease), 
clinical disease which does not prevent employment (e.g. asthma) or 
unknown genetic polymorphisms that could result increased sensitivity to a 
particular substance. As well as physiological differences, other factors may 
also increase variability such as smoking status, which is known to contribute 
to the occurrence of certain diseases (e.g. bronchogenic carcinoma).  
4.7.66 For these reasons, in deriving a DNEL based on a ‘healthy’ worker population 
for substances, including nanomaterials, the use of an assessment factor to 
take account of this variability is prudent. This approach is not consistently 
taken by all risk assessors, e.g. the approach taken by Hanai et al. (2009) 
within the NEDO approach where this factor was not considered necessary. 
The approach taken for both TiO2 and carbon nanotubes was to apply no 
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uncertainty (assessment) factor for their worker population as “this 
assessment is targeted at workers who are probably in good health and are 
not sensitive”.  
4.7.67 In our view such an approach is not supported as within this population there 
is certainly likely to exist variability in health status and sensitivity (e.g. 
smokers who due to reduced lung clearance efficiency may be more prone to 
particle accumulation). As such it is suggested herein that there is not 
sufficient data available to challenge the use of the default assessment 
factors for a worker population and where a reduced AF (e.g. 1) has been 
used within the available literature, this has not been adequately supported.  
4.7.68 As such we propose the following appendage to final paragraph of the 
‘intraspecies differences’ section on page 34 of the R.8. Guidance:   
4.7.69 It is to be noted that, as is the case for interspecies assessment factors, 
relevant substance-specific information on intraspecies variations should 
always be used to adjust or substitute the default factors (see e.g. World 
Health Organization (WHO)/ International Programme on Chemical Safety 
(IPCS), 2005).  In the case of (nano)particles, the consideration of lowering 
the default assessment factor due to perceived sensitivities/ insensitivities 
within a population must be scientifically justified. 
4.7.70 In order to deviate from the default assessment factors, a greater 
understanding of the relative sensitivities of certain individuals/ populations 
and how these may relate to nanoparticle is perhaps required. For example, 
whilst several studies either assume a local effect or did not detect 
translocation/ systemic effects after nanoparticle exposure (Hanai et al. 2009, 
Pauluhn 2010a/b), one may need to take into account other systemic effects 
(not necessarily occurring as a result of direct particle translocation). An 
example of this is an increase cardiovascular events (e.g. myocardial 
infarctions) which have been observed in the wider population during 
episodes of high particulate matter (PM) concentration in the ambient air. 
Such R&D is still required to address relative sensitivities. 
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4.7.71 Differences in duration of exposure 
4.7.72 Assessment factors to account for differences in experimental exposure 
duration (typically months to occasionally years) and actual human exposure 
duration are suggested within guidance and summarised in table R.8-5, page 
35 of the R.8 document.  There is no current evidence to suggest that the 
default assessment factors for duration extrapolation would not be equally 
applicable for nanomaterials. However within this section, there exists 
guidance on how, with substance-specific data, the defaults may be modified. 
The lowering of the default assessment factors with evidence of no increase 
in severity/ incidence of effects with increasing exposure duration is certainly 
valid for nanomaterials in relation to dermal exposure and due to the reduced 
sensitivity to lung overload in humans in comparison to rat models, it is also 
likely to be valid for inhalation exposure. 
4.7.73 The guidance also suggests that a higher assessment factor may be 
appropriate if there is the potential for accumulation of dose. Accumulation 
may impact on the incidence and severity of an effect by leading to the 
accumulation of a substance to a critical (threshold) dose leading to an effect 
and/or through the lack of clearance of a substance. This may result in 
continual interaction of the substance with the biological environment causing, 
for example chronic inflammation. This may be especially prudent for 
exposure routes such as the lung and certain poorly soluble particles/  
morphologies associated with reduced clearance, e.g. long straight, 
biopersistent fibres which are likely to be retained if deposited in the non-
ciliated airways leading accumulation of dose with repeated exposure.  
4.7.74 The inclusion of this description of situations where it may be appropriate to 
deviate from the default assessment factors is equally applicable to 
nanomaterials as to substances in general. We would however suggest that 
the final sentence of the section be modified to more accurately reflect the 
situation of lung overload and provide reference to further information within 
guidance. The sentence found at the end of bullet point 3, page 35 of the R.8 
Guidance document could be altered as follows (alterations shown 
underlined):  
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4.7.75 In relation to inhalation of poorly soluble, low toxicity (PSLT) particles, 
exposure at high doses can lead to accumulation within the alveolar spaces, 
lung interstitium and lung associated lymph nodes which may result in a 
further increase in toxicity following long term exposure (Morrow, 1988). For 
further information see Guidance R.7a. 
4.7.76 Dose response relationships 
4.7.77 When considering the dose response relationship, guidance provides a great 
deal of information in relation to the issues surrounding dose descriptors and 
comments on these and alterations required are given within this report. 
Within this section there is not sufficient reason or evidence to suggest that 
the default factors presented would not be sufficient for nanomaterials. Issues 
surrounding the use of BMD in replacement of a LOAEL and its incompatibility 
with current testing standards are also addressed within section R.8.2 and no 
further amendments for nanomaterials are necessary.    
4.7.78 Quality of the whole database 
4.7.79 When looking at the quality of the whole database used to calculate a DNEL, 
an extra assessment factor can be applied to account for deficiencies within 
the data set including gaps, inconsistencies between studies, or deficiencies 
in study design. The application of such extra assessment factors is also 
applicable to nanomaterials and may be particularly relevant due to the 
general paucity of information surrounding nanomaterials.  
4.7.80 In view of the potential study deficiencies, current R.8 Guidance directs users 
to evaluating the quality of the testing method, sample size, study design, 
biological plausibility etc. All of these factors would be equally applicable and 
measurable for a study of nanomaterial as other materials and there is 
sufficient scope within the guidance to account for deficiencies within these 
areas through the use of a more stringent assessment factor. There also 
appears no evidence to suggest that deficiencies in experimental design, 
sample number etc. would cause any more or less uncertainty than for 
substances in general.  
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4.7.81 However when looking outside a study, across the wider literature and 
addressing issues such as consistency with other studies and similarity of 
effects within the body of data, there can be additional uncertainty. 
4.7.82 Within the nanotoxicological literature, there appears a spectrum of the depth 
of toxicological information for nanomaterials. For certain nanomaterials, e.g. 
very new forms and or commercially less well developed forms, there appears 
very little toxicological information and as such the overall database would be 
viewed as possessing additional uncertainty. However for other forms, such 
as TiO2 or carbon black nanoparticles, a relatively large amount of data exists 
with which a registrant could assess their data for reliability and consistency in 
relation to other studies. Perhaps the largest area of uncertainty is the long-
term effects of nanoparticle exposure, especially carcinogenic endpoints. Due 
to this variation and the constantly evolving nature of the nanotoxicology 
literature, it would be impractical to suggest a ‘one-size-fits-all’ approach to 
dealing with uncertainty within nanomaterials. Indeed, such uncertainty is also 
prevalent when considering other new materials and the current guidance has 
been developed with sufficient scope to account for deficiencies when 
considering a nanomaterial as with any substance. The final sentence of the 
Quality of whole database section (page 37) states that a larger assessment 
factor can be applied on a case-by-case basis. This should also be 
considered for nanomaterials, with each derivation assessed on it own merits 
in relation to the specific study and the wider literature.  
4.7.83 It is however suggested that the greater certainty may be achieved where 
data addressing longer term endpoints, especially carcinogenic endpoints is 
available. In addition, information on absorption, systemic availability and 
organ accumulation (including any associated effects) could be seen as 
reducing uncertainty for nanomaterials and potentially substances in general. 
As such we suggest the following amendments (underlined) to the fourth 
paragraph of page 37 of section R.8.4.3.1:    
4.7.84 “……This approach requires a critical evaluation of the entire body of 
available data for consistency and biological plausibility. In addition the 
availability of chronic data (in particular addressing carcinogenic endpoints), 
and data addressing absorption, systemic availability and accumulation would 
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be seen as reducing uncertainty. Potentially relevant studies should be judged 
for quality and studies of high quality given more weight than those of lower 
quality….” 
4.7.85 When considering the entire database of a material, a question raised in 
relation to nanomaterials is to what extent data on the bulk form can be 
considered when addressing the quality of whole database for a 
nanomaterial. This is an important question but also raises many of the issues 
associated with read-across from bulk materials to nano-forms. The main 
issue is to what extent are the bulk and nano-forms similar or different. As is 
the suggested case for read-across approaches, the use of bulk data for 
informing nano hazard assessment may be associated with more uncertainty 
than for substances in general and must be scientifically justified. As such it is 
suggested that as part of R&D into the use of read-across between bulk and 
nano-forms, that consideration be given to the use of bulk data in assessing 
the quality of whole database. In addition we propose the following text 
addition to R.8 Guidance appended to the fourth paragraph of page 37:   
4.7.86 When assessing the consistency and biological plausibility of study data 
against the wider body of literature for nanomaterials, the use of data on the 
bulk or other forms of the material in place of nano-specific data must be 
scientifically justified and may be associated with additional uncertainty.  
4.7.87 Endpoint-specific issues on AF 
4.7.88 This section refers registrants to appendices R.8-8 to R.8.-12 for further 
information and any alterations to these appendices is given at the end of this 
R.8 section.   
4.7.89 R.8.4.3.2 Use of Physiologically-Based Pharmacokinetic (PBPK) 
modelling for Engineered Nanoparticles 
4.7.90 Section R.8.4.3.2 describes how physiologically based pharmacokinetic 
(PBPK) models can be used in the derivation of DNEL/DMEL. The confidence 
in PBPK modelling is based on a rigorous process of verification; validation, 
sensitivity testing and model documentation. These are generic steps and are 
applicable to all PBPK models. A large subset of the model parameters are 
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identical for (nano)-particles as well as chemicals. They are: (1) Physiological; 
(2) Anatomical; (3) Physico-chemical parameters. However currently, the 
rates of translocation of nanoparticles in different anatomical compartments 
are generally unknown. It is expected that these parameters will vary from 
particle to particle and will be related to the physico-chemical properties of 
these nanoparticles. The existing method for extrapolation to other species, 
as stated in the document (Schneider et al, 2004), may be applicable for 
nanoparticles but this needs to be verified. For intraspecies variability, the 
probabilistic techniques such as Monte Carlo sampling are equally applicable 
to nanoparticle PBPK modelling. 
4.7.91 Just as in chemical toxicology, extrapolation from high dose to low dose in 
order to derive NOAEL is equally important for nanoparticles and will be 
adopted. Of equal importance is the route to route extrapolation. The step 
described in guidance is equally valid for nanoparticles. 
4.7.92 Finally the application of PBPK models as part of the toolbox for Risk 
Assessment is equally justified with nanoparticles as it is justified with 
chemicals in the Guidance. As with chemicals the issues such as 
extrapolation high to low dose, intra- and inter- animal variation extrapolation 
are equally of importance to nanomaterials.  Currently PBPK models are few 
and are substance specific. The development of generic models for classes of 
nm based on their similar physico-chemical structure is an important research 
need. As such based on the caveats already introduced within guidance 
(which are equally relevant to nanomaterials), no alterations to guidance are 
warranted at this time.  
4.7.93 R.8.4.3.3 Overall assessment factor and its application to the correct 
starting point 
4.7.94 The summation of the assessment factors used and the application of an 
overall assessment factor is valid for nanomaterials and as no alterations to 
default assessment factors are proposed, no alteration to this section of 
guidance is required either.  
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4.7.95 R.8.5 Step 3-2: derivation of DMEL for non-threshold endpoints 
4.7.96 In the derivation of DMEL for non-threshold effects, a similar approach in 
many ways to that of deriving a DNEL is taken. Where similarities exist, 
registrants are generally referred to the appropriate section of guidance 
instructing the derivation of a DNEL. However certain deviations or alternate 
approaches are used within the derivation of the DMEL and these are 
considered in the following sections.    
4.7.97 R.8.5.1 Deriving a DMEL for a non-threshold carcinogen, with adequate 
human cancer data.  
4.7.98 This section of the guidance document R.8 has recently been amended and 
now refers registrants to appendix R.8-15, section B for guidance.  
4.7.99 R.8.5.2 Deriving a DMEL for a non-threshold carcinogen, with adequate 
animal cancer data.  
4.7.100 Within guidance, there are two mathematical models suggested for the 
derivation of the DMEL for a non-threshold carcinogen with adequate animal 
cancer data. Due to the current paucity of data surrounding the carcinogenic 
potential of various nanomaterials, it is impossible to state if these 
approaches would be unsuitable for nanomaterials. However based on the 
generalised nature of these approaches, taking into account the wide variety 
of materials to which they are to be applied, there is little reason to suggest 
that these would not be suitable for nanomaterials.   
4.7.101 R.8.5.2.1 The ‘Linearised’ approach 
4.7.102 The linearised approach is based upon the assumption that a linear dose 
response relationship between tumour formation and exposure exists. The 
approach, as with the derivation of a DNEL, follows 3 main phases: 
4.7.103 a) select the relevant dose descriptor(s) 
4.7.104 b) Modify, when necessary, the relevant dose descriptor(s) to the correct 
starting point 
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4.7.105 c) derive from this correct starting point a DMEL for each relevant 
exposure pattern essentially by linear high to low dose extrapolation, 
and by the application of assessment factors (when necessary). 
4.7.106 In the case of modification of the dose descriptor for deriving a DMEL, the 
modifications are applicable in the same situations as those described for a 
DNEL with the addition of an extra situation, namely “Differences between 
occupational and lifetime conditions of exposure.” The Guidance document 
refers registrants to the relevant section of starting point modification for 
DNELs and whilst no alteration to these sections has been proposed, R&D 
requirements are suggested (paragraph 4.7.126).  
4.7.107 The additional situation for which a starting modification maybe required is 
adjusting for differences in occupational and lifetime exposure conditions. 
Specifically this relates to the fact that within guidance, human environmental 
exposure (24 hours per day, 7 days a week for 75 years) is considered 
equivalent to that of a life-time exposure of an experimental animal. Because 
occupational exposure is for a shorter duration than environmental exposure 
(8 hours per day, 5 days per week, 48 weeks per year for 40 years), the 
animal data which is equivalent to environmental exposure needs to be 
adjusted accordingly.   
4.7.108 In the final step of deriving a DMEL, assessment factors are applied when 
necessary to account for differences between the experimental data and real 
human exposure situations. These are performed in the same way as for the 
derivation of a DNEL and registrants are referred to the relevant section of the 
R.8 guidance covering DNELs for information. As such we refer readers to the 
relevant part of this report (paragraph 3.7.5) which address these assessment 
factors in relation to their occurrence in guidance.     
4.7.109 The amendments to the application of an interspecies and/or intraspecies 
factor due to the use of a linear approach also could be considered sufficiently 
conservative for nanomaterials as it is for substances in general. Also a 
consideration of issues related to dose-response as discussed in guidance is 
incorporated into the various dose descriptors used (T25, BMD10 and 
BMDL10) and is sufficiently prudent for nanomaterials.   
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4.7.110 The approach taken for extrapolating from high dose levels associated with 
high cancer risk to low levels associated with a very low risk of human cancer 
is equally relevant and equally conservative (thought to in some cases lead to  
an overestimation of risk) for nanomaterials. Indeed the linearised multistage 
model (LMS) has been in the derivation of a REL by NIOSH for ultra-fine 
(nano) TiO2 (NIOSH, 2005).      
4.7.111 R.8.5.2.2 The ‘Large Assessment Factor’ approach (“EFSA” approach) 
4.7.112 As described in guidance, the large assessment factor or EFSA approach 
applies basically the same steps as that of the linearised approach. The steps 
taken in the selection of the relevant dose descriptor and modifications the 
correct starting point mirror that of the linearised approach and are equally 
appropriate.  
4.7.113 The application of assessment factors marks the main point of deviation from 
that of the Linearised approach.  The EFSA approach recommends the use of 
a large assessment factor of 100 to account for differences in interspecies 
(10) and Intraspecies (10) differences.  The factor of 10 for an interspecies 
assessment factor could be considered conservative for both nanomaterials 
and substances in general. The use of a factor of 10 for intraspecies 
differences is based somewhat on the potential impact genetic 
polymorphisms may have on compound metabolism and cancer susceptibility. 
It is unknown as to what effect genetic polymorphisms may have on the 
susceptibility to nanoparticle effects but as removal of nanoparticles is likely to 
be based on cellular based clearance (e.g. alveolar macrophages, liver 
kupffer cells) rather than metabolism; one could presume that nanoparticle 
susceptibility may be less influenced by genetic polymorphisms in drug 
metabolising enzymes. However insufficient evidence exists to challenge the 
default assessment factor at this time.  
4.7.114 The EFSA approach also uses an additional assessment factor of 10 to 
account for inter-individual variability in cell cycle control and 
Deoxyribonucleic acid (DNA) repair; two important cellular processes that can 
affect cancer susceptibility. The use of a second assessment factor to 
account for differences in inter-individual variability (although based on 
separate aspects) is also conservative. However the approach of considering 
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differences in aspects such as DNA repair efficiency between individual of a 
population (irrespective of health status) is sound and perfectly applicable to 
nanomaterials. At this time no evidence exists to suggest that a more 
stringent factor would be required than that applied to substances in general.    
4.7.115 It is considered here that guidance allows the scientifically justified alteration 
(e.g. reduction) of the assessment factors in relation to substance specific 
information. Therefore for the assessment factors outlined in the guidance 
document, more stringent default assessment factors are not considered 
necessary. As such, no alterations to this approach are deemed necessary.   
4.7.116 R.8.5.2.3 Alternatives to the conventional extrapolation procedures 
4.7.117 This section of guidance simply refers users to the PBPK modelling approach 
(section R.8.5.2.1 of guidance) which is dealt with in paragraph 4.7.69 of this 
document.   
4.7.118 R.8.5.3 Deriving the DMEL for a non-threshold carcinogen/ mutagen, 
without adequate cancer data  
4.7.119 In the absence of proper data for the derivation of the DMEL, guidance 
suggests other approaches which may be explored to derive a DMEL 
including read-across, use of sub-chronic studies or the threshold of 
toxicological concern (TTC) concept. As previously reported within the RIP-oN 
projects and extensively in RNC/RIP-oN2/B5/2/FINAL in relation to the R.7a 
guidance document, the use of read-across needs further R&D for 
nanomaterials. This is because it is not clear and no consensus exists as to 
what attributes concepts of similarity should apply to when considering a 
nanomaterial and its analogue. This is not to say that this not possible, indeed 
future research may provide grounds for such an approach. However, 
scientific justification for the use of read-across would need to be provided. As 
such we propose the following statement for inclusion into Page 51, 
appended to the final paragraph of the section ‘read across’ section of R.8.5.3 
of guidance.  
4.7.120 The use of a read across approach in addressing data gaps for nanomaterials 
may not be considered suitable at this time as the use of such approaches for 
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nanomaterials has yet to be established. Therefore the use of read-across 
and other non-testing approaches for nanomaterials in deriving an 
assessment of hazard for humans must be scientifically justified.  
4.7.121 The use of the TTC approach is also not appropriate yet for nanomaterials as 
it is based on a form of read-across from other structural classes for which 
extensive databases exist. The relevance of these databases or points of 
comparison/ similarity to nanomaterials has not been established. In addition 
this approach is only applicable to the oral route and whilst some nanoparticle 
exposure may occur via the oral route, the predominant route of exposure in 
the occupational setting (likely to be most relevant when considering high 
exposure levels) is potentially via the inhalatory route and dermal route. The 
guidance section on TTC (page 52) currently points out that further 
development and stakeholder agreement is still required and this is certainly 
the case for nanomaterials.  Due to the uncertainty expressed within guidance 
addressing use of subchronic studies and TTC approaches, and the 
requirements of further R&D and expert judgement, further information 
regarding nanomaterials specifically is not considered warranted.      
4.7.122 Due to the difficulties in generating regulatory relevant robust hazard  data 
(incl. carcinogenicity) for many substances, not only nanoparticles, it would be 
important to consider further R&D into non-testing approaches such as read-
across, (Q)SAR etc. Research and development for QSAR, grouping 
approaches (REACH Guidance R.6.) and in silico approaches (general 
applicability) are also considered within the RNC/RIP-oN2/FPR/2/FINAL as a 
high priority that should be addressed within the short term. It is 
recommended that the advice provided be considered for further development 
of a possible new sub-section on nanomaterials under R.6.2.5 Guidance on 
specific types of categories.   
4.7.123 Within this section, the use of data derived from transgenic animals is also 
described. The approach suggested is considered appropriate for animal 
testing using nanomaterials.  
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4.7.124 R.8.6 Step 3-3: qualitative approach  
4.7.125 No changes are considered to be needed although further R&D is required in 
developing at least qualitative approaches to indentifying respiratory 
sensitizers as discussed in section 4.7.162.  
4.7.126 R.8.7. Step 4: Selection of leading health effects  
4.7.127 R.8.7.1 Selection of the critical DN(M)EL 
4.7.128 When considering the critical DN(M)EL, the recommendations of guidance 
appear equally suitable for nanomaterials. In relation to dusts, the section also 
refers to the general dust limits for nuisance dusts and how, in relation to 
these limits, a DNEL may need to be lowered. This means that if a DNEL is 
derived for a particle indicating no effect above that of the general dust limit, 
then the dust limit would apply rather than the DNEL. Where the DNEL is 
lower than the dust limit, the DNEL would apply (as one cannot adjust a 
DNEL upwards). This approach is prudent as if a substance/ nanoparticle 
shows toxicity below this level, this would result in a DNEL below this level 
which must be adhered to (and hence any identified health effects should be 
controlled). If the substance does not show toxicity below this level and a 
DNEL is derived which is in excess of the dust limit, the dust limit would apply 
(meaning any identified health effects should still be controlled). Guidance 
also states that the general dust limit is not to be used as a surrogate DNEL in 
situations where no substance specific information is available. This is 
certainly also the case for nanomaterials and there appears no grounds to 
lower the general dust limit for nanomaterials as any increased toxicity should 
be detected and reflected in a lower DN(M)EL.    
4.7.129 R.8.7.2 Endpoints for which no DNEL/DMEL can be derived  
4.7.130 Similarly, the qualitative approach described for risk characterization, when no 
DN(M)EL value can be derived, seems appropriate for nanomaterials.  
4.7.131 R.8.7.3 Using DN(M)EL for human exposure patterns  
4.7.132 Guidance considering the use of derived DN(M)ELs to human exposure 
patterns is considered applicable and appropriate for nanomaterials.  
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4.7.133 Within the R.8 guidance document appendices, the following alterations are 
suggested and only those appendices for which an alteration is suggested are 
shown. For all others these have been assessed as being suitable for 
nanomaterials with no alterations required.  
4.7.134 APPENDIX R. 8-8  
4.7.135 This appendix outlines the approach taken in generating a DNEL for acute 
toxicity and to the most part applies equally to nanomaterials and substances 
in general. In particular, the appendix under the section ‘identification of the 
typical dose descriptor’ outlines that whilst acute toxicity tests traditionally 
used mortality as an endpoint this may not provide the most rational starting 
point for deriving a DNEL. This is because toxicity occurs as a continuum to 
which lethality is the most severe expression and if taken as an endpoint, 
does not allow the consideration of other, clinical or sub-clinical signs of 
toxicity. This issue has been raised in the RNC/RIP-oN2/B5/2/FINAL 
document (paragraph 6.2.5) and the suggestion has been made for further 
development of current acute toxicity testing guidelines to include further 
pathological and histological examination to detect more sensitively adverse 
effects. As such a change is both relevant to all substances tested and relates 
to further development of test methods, no guidance alteration is considered 
necessary.    
4.7.136 Whilst the guidance appendix provides a detailed overview of the issues and 
approach to setting an acute DNEL, within box 9 of the decision tree (figure 
R.8-5 page 111) and in the following discussion of this approach (page 113, 
paragraph 2) it states that: 
4.7.137  “…if acute data are available for a substance(s) with a similar structure and 
physico-chemical properties (and toxicity profile if such data are available) it 
can be used for setting the acute toxicity DNEL.” 
4.7.138 As it is not yet sufficiently understood on what basis a similarity should be 
established between forms (nano-nano, bulk to nano or some other 
analogue), we would suggest the insertion of a caveat in the explanatory 
section in Appendix R.8-8 on page 113 appended to paragraph 2. The 
suggested inclusion is: 
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4.7.139  The use of non-testing data such as read-across, grouping or (Q)SAR 
approaches in addressing data gaps for nanomaterials is very limited at this 
time. In addition to this the use of such in silico models for nanomaterials has 
also yet to be established. Therefore the use of non-testing approaches for 
nanomaterials in deriving an assessment of hazard for humans must be 
scientifically justified. 
4.7.140 APPENDIX R. 8-13  
4.7.141 This section outlines the approach taken in relation to developing a DNEL in 
situations where an occupational exposure level already exists, specifically in 
the case of an EU indicative occupational exposure limit (IOEL), EU binding 
occupational exposure limit (BOEL) and a nationally adopted occupational 
exposure limit. Currently, there are no EU occupational exposure limits for 
nanomaterials and as such the subject of this appendix is not yet apparent for 
nanomaterials. However, should an EU IOEL or BOEL become available then 
the contents of this appendix may be required. As such we have felt it prudent 
to offer proposed amendments where we see deficiencies lie in relation to 
nanomaterials.    
4.7.142 The appendix chapter outlines that for an IOEL, a registrant can use an 
existing limit in place of a DNEL specifically where: 
 The exposure route, duration and exposure population or 
vulnerable sub-population are the same  
 Where no newer scientific information exists, or that which does, 
supports the IOEL 
4.7.143 In situations where an exposure route/ duration, population differs from that of 
the IOEL or where newer conflicting scientific data exist, then a new DNEL 
specific to the route(s) etc must be generated. Such an approach is equally 
applicable to nanomaterials. However in addition, it should be noted that 
difference in physico-chemical attributes for example size, shape and 
crystallinity may have an impact on the (adverse) toxicological effects as 
discussed within the RRNC/RIP-oN3/C2/2/FINAL report (section 2) and 
RNC/RIP-oN2/B5/2/FINAL report (section 4). As such, an IOEL developed for 
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a nanomaterial with particular physico chemical characteristics would not 
automatically be appropriate for another material with the same chemical 
composition but differing physico-chemical characteristics (e.g. differing 
shape/ size/ surface functionality). In such a situation, a DNEL should instead 
be derived for the specific material in question (a case-by-case approach). As 
such we propose the following insertions into Appendix R.8-13: 
4.7.144 Page 142: Registrants obligations, paragraph 2, first sentence (insertion 
shown underlined): 
4.7.145 A registrant is allowed to use to use an IOEL as a DNEL for the same 
exposure route, duration and (particle) physico-chemical characteristics, such 
as particle size distribution, shape and surface area unless new scientific 
information……     
4.7.146 Page 143: Registrants obligations, appended to paragraph 1: 
4.7.147 For nanoparticles alterations in physico-chemical attributes such as size, 
crystallinity, shape (e.g. spherical or fibrous), and surface functionality/ 
attributes may impact on the relative toxicity of materials of the same 
chemical composition. As such, the use of an IOEL in place of a DNEL is only 
suitable where the material physico-chemical attributes are the same as that 
of the material in question. In situations where such physicochemical 
characteristics are not the same and read-across is not scientifically justified, 
a DNEL should be generated for the same form/material that reflects the true 
physic-chemical properties of the substance. 
4.7.148 The information for using a BOEL in place of DNEL is applicable to 
nanomaterials with no alterations required (should the use of any future BOEL 
be made).  
4.7.149 The information for using a national OEL in place of DNEL is also applicable 
to nanomaterials with no alterations required (should the use of any future 
national OEL be made).  
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4.7.150 Research Recommendations 
4.7.151 Within the RNC/RIP-oN3/C3/2/FINAL report several R&D requirements were 
identified which could either address gaps in the current approach for 
derivation of exposure limits or provide useful additions to the current 
understanding of nanomaterials and these are suggested in the following in 
addition to those already highlighted within the text above.  
4.7.152 Metrics 
4.7.153 Further research and development is needed in order to establish the most 
appropriate methods and metric(s) for which to base a derived exposure limit 
on. This may be different depending on the nature of the material (e.g. 
reactive surface vs. fibre based toxicity) and should, where possible relate to 
the biologically effective dose driving an adverse effect. For a number of 
nanomaterials, surface area is seen as an important metric for measuring 
inhalation exposure and deriving limits, but other metrics such as fibre 
number may also be considered. As a component of this R&D suggestion, 
methodological approaches would need to be developed in order to utilise 
other metrics in combination with mass. For example current methods to 
detect fibres in the air are not designed to deal with complex nanofibres such 
as carbon nanotubes and as such may need further modification or 
development.  
4.7.154 Toxicokinetics 
4.7.155 Further R&D is suggested to generate an improved understanding of which 
physico-chemical attributes effecting absorption kinetics, as well as how and 
to what extent this occurs. Specifically the generation of such information 
could allow the use of substance specific values based on analogous 
materials and scientific understanding. Such information would allow 
improvements in both addressing the issues of uncertainty in starting point 
modifications and also for use in PBPK modelling. As an R&D priority, this 
could be considered a high priority of the short term.   
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 143 -
4.7.156 Non-testing Approaches 
4.7.157 In tackling the issue of data gaps in establishing hazard and risk 
characterisation, further R&D is required concerning the drivers of toxicity and 
how these relate to physico-chemical attributes. This may enable the use of 
non-testing data based on approaches such as categorisation of 
nanomaterials, read-across between differing nanomaterials based upon 
certain physico-chemical similarities and (Q)SAR.  The understanding of how 
nanomaterials behave, how they differ from bulk materials and their drivers of 
toxicity is crucial in understanding important parameters such as absorption 
and distribution kinetics as well as establishing rates of translocation which 
relate to several aspects of hazard and risk characterisation. These include 
the generation of accurate PBPK modelling and establishing threshold and 
non-threshold mechanisms of nanomaterials toxicity, which impact on 
improving data reliability and establishing more accurate exposure limits. As 
non-testing approaches are potentially of enormous benefit to hazard 
assessment, a greater understanding to enable their use in relation to 
nanomaterials is highly desirable. As such, R&D into this area could be 
considered a high priority of the short/medium term.     
4.7.158 Risk Characterisation 
4.7.159 An approach for risk characterisation by Hanai et al. (2009) is discussed with 
the RNC/RIP-oN3/C2/2/FINAL report. This approach uses a bi-axial 
framework by which acceptable levels of human exposure may be predicted 
for a material for which inhalation data does not exist. The approach uses 
data that is not suitable for extrapolation to human exposure limits (e.g. lung 
instillation data or potentially in vitro data) to rank a materials toxicity in 
relation to a material for which inhalation data does exists. Based on this 
ranking, an assessor can judge if a material is more or less toxic than the 
form for which inhalation data exists and set an interim exposure limit which is 
higher or lower than limit derived using the inhalation data. 
4.7.160 This approach is interesting as, whilst there are many questions surrounding 
the confidence one may have in the final predicted human exposure level, it 
opens up a range of data and testing approaches that are unencumbered by 
issues surrounding read-across based upon physico-chemical characteristics. 
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As such, this approach could be used to help in the development of an interim 
approach to using non-inhalation data to address the current situation of a 
wealth of nanoparticles but few suitable inhalation studies for the derivation of 
acceptable human exposure levels.   
4.7.161  The development and assessment of this approach for its suitability for 
incorporation into REACH could be considered as an obtainable short term 
goal if based upon non-inhalation methods which more closely represent 
inhalation exposure such as instillation methods. The use of other, non-
physiological means of assessing toxicity such as in vitro methods would 
require considerably further development and validation as well as greater 
evaluation before being used in this approach. The bi-axial approach 
described thus far has been based upon inhalation as a route of exposure. 
This is because it has been set in the context of the approach taken within the 
Hanai et al. (2009) paper and also because inhalation is considered one of 
the foremost routes of exposure to nanoparticles in the occupational setting. 
However the bi-axial approach may be equally relevant to other exposure 
routes/target organs such as dermal toxicity based upon extrapolation to 
human exposure levels using an appropriate testing method, and ranking of 
another particles based upon other test methods (note this does not suggest 
that lung instillation could be used to rank nanoparticle toxicity for dermal 
toxicity or any form of route to route extrapolation).   
4.7.162 Qualitative Hazard Characterisation  
4.7.163 When considering the hazard/risk characterisation process, REACH 
Guidance indentifies various tools with which to evaluate hazard/risk and how 
to use this information to control such identified risks. Whilst substance 
specific, in depth toxicological evaluation of each substance is most certainly 
preferable in a hazard characterisation of a material, it is often not available or 
sometimes not practical. As some form of evaluation still must be performed, 
a more qualitative characterization of hazard can be used to generate 
information with which to evaluate a material.    
4.7.164 Within RNC/RIP-oN3/C2/2/FINAL, there are several schemes outlined for 
making a qualitative assessment of hazard. However, none are yet 
considered to provide a robust framework for incorporation into Guidance on 
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adopting a qualitative approach for nanomaterials in the absence of 
quantitative data. They may provide a degree of informative context to 
elements of the qualitative approach, specifically in Part E Guidance (Section 
3.4.3).   
4.7.165 Specifically, acknowledging the aforementioned schemes would enhance the 
guidance’s recommendation that the implementation of risk management 
measures (RMMs) and operational conditions (OCs) needs to be proportional 
to the degree of concern for the health hazard presented by the substance.  In 
particular, Steps 2 and 4 in the “Step-wise approach for the qualitative 
assessment, including development of exposure scenarios (ES)” (Guidance 
Part E, Section E.3.4.3) refer specifically to the use of information on physico-
chemical properties.   
4.7.166 The particular references to physico-chemical properties in the steps could 
provide a basis for a recommendation of updating the Part E Risk 
Characterisation (Section E.3.4.3) guidance with a statement and reference to 
the availability of qualitative hazard assessment schemes (based on physico-
chemical properties) for nanomaterials (RNC/RIP-oN3/C2/2/FINAL).  
4.7.167 As such, we can see that as part of a ‘tool kit’ for hazard characterisation, the 
development of improved qualitative approaches such as those discussed 
within RNC/RIP-oN3/C2/2/FINAL report is important. This is not least to 
reduce the burden of animal testing, but also to provide a rapid interim 
evaluation of potential hazard so that these may be controlled. However such 
schemes for nanomaterials have yet to be widely accepted or tested and as 
such alteration to guidance at this time may be premature. It is therefore 
considered that the development of such qualitative schemes should be given 
credence when considering future R&D priorities for hazard evaluation of 
nanomaterials and could be considered a high priority over the short term. In 
practical terms, this would provide a more holistic route to the evaluation of 
nanomaterials for which REACH Guidance is intended, and a route which is 
already available for some other materials. Indeed when considering the 
range of nanomaterials and the associated testing burden, the development 
of accepted qualitative approaches would be a powerful tool for a rapid 
evaluation which is much needed.  
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4.7.168 Respiratory Sensitisation 
4.7.169 Within the R.8 Guidance (Appendix R.8-11) there is a description of 
respiratory hypersensitivity reactions resulting in allergic airways diseases 
such as asthma. However in relation to determining the induction or elicitation 
thresholds with which to establish a DNEL, the guidance currently identifies 
that there are no validated or widely accepted animal or in vitro test protocols 
for detecting respiratory sensitisation. Indeed, the current method of hazard 
identification is based upon the presence of human data and as such is 
ineffective at preventing adverse human effects in the first place. In relation to 
nanomaterials, there are some studies which suggest that certain 
nanomaterials can elicit severe allergic-type inflammation within the lung (Cho 
et al. 2010).     
4.7.170 Whilst certainly nano-relevant, this issue is not nano-specific as methods for 
addressing potential respiratory sensitisation using quantitative and qualitative 
approaches does not yet exist for substances in general either. This as an 
issue impacts on several aspects of REACH guidance including R.7a (and 
identified as a R&D priority in the RNC/RIP-oN2/FPR/1/FINAL report), 
guidance part E as well as guidance R.8. Due to the debilitating nature of 
allergic airways disease and the current lack of methodologies with which to 
identify respiratory sensitizers for both nanomaterials and other substances, it 
seems prudent to conduct research and development into methods with which 
to evaluate respiratory sensitizers. Indeed this may be through the 
development of quantitative approaches which allow the identification of 
threshold levels suitable for the evaluation of DNELs or at least allow a 
qualitative evaluation for hazard characterisation.   
4.7.171 Experimental/ Exposure conditions 
4.7.172 An issue raised in the paper by Oller and Oberdörster (2010) is the potential 
impact differences in exposure situations may have on the toxicity of a 
(nano)particle. Within experimental conditions, a great deal of effort is often 
placed upon obtaining well dispersed aerosols with fewer large agglomerates. 
However such dispersions may not accurately reflect real exposure conditions 
and as parameters such as particle/ agglomerate size can effect the 
respirability, deposition and clearance of (nano)particles, changes in the size 
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distribution may impact on the scavenging of nanoparticles and received 
dose. Further R&D is required to gain a better understating of how 
representative experimental conditions are of real human exposure 
conditions, what parameters differ and how these may effect the resultant 
dose received and observed toxicity.       
4.7.173 Assessment Factors 
4.7.174 Whilst the assessment factors have been considered in relation to 
nanomaterials and to the most part there is little scientific evidence to suggest 
that current default assessment factors are or are not sufficient for 
nanomaterials. Where deficiencies or alternative approaches lie, these have 
been discussed and amendments/ further R&D suggested. It would also be 
prudent to suggest that further R&D is required to further investigate the 
suitability of the current default assessment factors for nanomaterials as well 
what substance specific data should be available and what methods used 
when deviating from defaults. In addition, further research should look into the 
effect different metrics would have on the application of assessment factors.   
4.8 R.10 CHARACTERISATION OF DOSE [CONCENTRATION]-RESPONSE 
FOR ENVIRONMENT 
4.8.1 The R.10 guidance chapter provides guidance on how to characterise the 
dose (concentration) – response for the different environmental 
compartments. In other words it is mainly guidance on how to quantitatively 
assess the effects of a substance on the environment by determining the 
concentration of the substance below which adverse effects in the 
environmental compartments of concern are not expected to occur. This 
concentration is known as Predicted No-Effect Concentrations (PNECs). 
4.8.2 When considering the available data and quality of the data both within a 
study (e.g. statistical power) and between studies, for consistency and 
biological plausibility, greater certainty and a correspondingly lower 
assessment factor is gained where greater numbers of data sets are available 
and experimental data is available for a longer experimental duration (giving a 
more realistic picture of effects during an organisms life cycle). This approach 
is succinctly summarised within the R.10 Guidance document (page 17) 
which states: 
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4.8.3  “The sparser the available data, the higher is the assessment factor which is 
applied”.  
4.8.4 Such an approach may also be suitable for nanomaterials, as when more 
information is available, greater certainty can be had in a predicted no effect 
concentration. One issue however that still remains is to what extent data on 
the bulk form can be considered when addressing the quality of the whole 
database for a nanomaterial. This raises an important question of to what 
extent are the bulk and nano-forms similar or different. As such, the use of 
bulk data for informing nano hazard assessment may be associated with 
additional uncertainty and should be scientifically justified. It may also be 
prudent that R&D is undertaken to assess the use of bulk data in assessing 
the quality of the whole database for nanomaterials. In addition we propose 
the following text addition to R.10 Guidance after the second sentence of the 
first paragraph of the section ‘Assessment factor methods’ (page 17)    
4.8.5 ‘In relation to nanomaterials where there is uncertainty due to the absence of 
available data, the use of read-across from available data on bulk or other 
forms of the material in place of specific data for the nanomaterials being 
assessed must be scientifically justified and may be associated with additional 
uncertainty.’ 
4.8.6 In addition, the following changes are recommended: 
4.8.7 R.10.5.2.1 Calculation of PNEC for freshwater sediment using equilibrium 
partitioning 
4.8.8 The following text is recommended to be added to the first paragraph in 
R.10.5.2.1 (R.10, pg. 32), following the sentence ending "… coefficient as 
inputs (OECD, 1992b; Di Toro et al., 1991).":  
4.8.9 For some nanomaterials the Equilibrium Partitioning Method may not be 
applied provisionally for the calculation of PNEC for freshwater sediment as 
the method has limited applicability for very adsorptive compounds which do 
not enter equilibrium.  
4.8.10 R.10.5.3.1 Calculation of PNEC for marine sediment using Equilibrium 
Partitioning Method 
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4.8.11 The following text is recommended to be added as to the first paragraph in R. 
10.5.3.1 (R.10, pg. 35), following the sentence ending "… provisionally be 
calculated using the equilibrium partitioning method ":  
4.8.12 For some nanomaterials the Equilibrium Partitioning Method may not be 
applied provisionally for the calculation of PNEC for marine sediment as the 
method has limited applicability for very adsorptive compounds which do not 
enter equilibrium.  
4.8.13 R.10.6.1 Calculations of PNEC for soil using equilibrium partitioning  
4.8.14 The following text is recommended to be added as to the second paragraph in 
R. 10.6.1 (R.10, pg. 39), following the sentence ending "… through food (Van 
Gestel, 1992)":  
4.8.15 For some nanomaterials the Equilibrium Partitioning Method may not be 
applied for the calculation of PNEC for soil as the method has limited 
applicability for very adsorptive compounds which do not enter equilibrium.  
4.9 R.12 USE DESCRIPTOR SYSTEM 
4.9.1 This guidance document provides a system of use descriptors to standardise 
the description of the use of substances. The use descriptor system is based 
on five separate descriptor-lists which in combination with each other form a 
brief description of use or an exposure scenario title.   
4.9.2 The sector of use category (SU) describes in which sector of the economy the 
substance is used.  The chemical product category (PC) describes in which 
types of chemical products (= substances as such or in mixtures) the 
substance is finally contained when it is supplied to end uses (by industrial, 
professional or consumer users).  The process category (PROC) describes 
the application techniques or process types defined from the occupational 
perspective.  The environmental release category (ERC) describes the broad 
conditions of use from the environmental perspective. 
4.9.3 The article category (AC) describes the type of article into which the 
substance has eventually been processed. 
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4.9.4 The use descriptors will help suppliers and users to structure their 
communication with each other. They are intended to facilitate, the 
identification of uses to be provided in the registration dossiers, the building of 
an ES by suppliers, based on communication up and down the supply chain 
and the building of short titles for exposure scenarios. 
4.9.5 Considerations 
4.9.6 Technical issues described in the case studies under taken as part of Task B1 
(further evaluated in task B4) are those which are most relevant to proposals 
for changes to R12. Specifically the case study providers used this guidance 
to support development of the exposure scenarios. In this respect they 
developed/ allocated SUs, PROCs and ERCs based on the guidance. 
Assessment of these is also based on the review of exposure studies carried 
out in task B3 (RNC/RIP-oN3/B3/2/FINAL). 
4.9.7 The mapping between R.12 and the issues identified from exposure 
assessment aspects (RNC/RIP-oN3/B4/2/FINAL) is shown Appendix 2. This 
shows each of the scientific issues identified in that report and the preceding 
reports, by reference to the table in RNC/RIP-ON3/B4/2/FINAL, and maps 
that to the point in the guidance indicating i) where they are relevant, ii) where 
the guidance is adequate for nanomaterials as for substances in general and 
iii) where it has been considered necessary to recommend a change.   
4.9.8 Examination of R12 indicates that for most of the document the guidance 
provided applies equally well to nanomaterials as for substances in general. 
As a general statement, the use descriptors can be applied to any substance 
depending on the physical nature of that substance.  
4.9.9 Appendix R.12-1 provides a list of Sectors of Use (SU). All of the case study 
providers were able to allocate SUs in the development of the ES. No 
uniquely nano-specific SUs were identified in the case studies or in the review 
of the literature in task B3 (RNC/RIP-oN3/B3/2/FINAL).  
4.9.10 Appendix R.12-2.1 provides a list of product categories (PC). The categories 
listed are meant to structure the market of a substance according to product 
types. PCs were not specifically addressed in the case studies. No uniquely 
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nano-specific PCs were identified the review of the literature in task B3 
(RNC/RIP-oN3/B3/2/FINAL). 
4.9.11 Appendix R.12-4.1 provides a list of environmental release categories (ERC).  
All of the case study providers were able to allocate ERCs in the development 
of the ES. No uniquely nano-specific ERCs were identified in the case studies 
or in the review of the literature in task B3 (RNC/RIP-oN3/B3/2/FINAL). 
4.9.12 Appendix R.12-5.1 provides a list of article categories (AC). The categories 
listed are meant to structure the market of a substance according to product 
types. PCs were not specifically addressed in the case studies. No uniquely 
nano-specific PCs were identified the review of the literature in task B3 
(RNC/RIP-oN3/B3/2/FINAL). 
4.9.13 Appendix R.12-3.1 provides a list of process categories (PROC). All of the 
case study providers were able to allocate SUs in the development of the ES. 
No uniquely nano-specific SUs were identified in the case studies or in the 
review of the literature in task B3 (RNC/RIP-oN3/B3/2/FINAL). 
4.9.14 In any case, the guidance states “This list is not complete with regard to uses 
potentially to be described under REACH. Describe other uses as 
appropriate” which allows considerable flexibility for the user to augment 
these lists as appropriate. 
4.9.15 In addition to their description function, some of the descriptor-lists are 
intended to support identification of the suitable exposure estimation entries in 
one or more of the available Tier 1 exposure estimation tools (see Section D.5 
in Guidance Chapter D). Please note, that this does not automatically mean 
that those Tier 1 tools can be applied. The efficacy and application of these 
models for estimating nanomaterials exposure and guidance 
recommendations arising from that are dealt with in the review and 
assessment of R.14, R.15, R.16. 
4.9.16 This assessment of R.12 indicates that in this document guidance provided 
applies equally well to nanomaterials as for substances in general. There are 
therefore no recommendations for guidance amendments in relation to this 
document.   
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4.9.17 No additional requirements for change for this part of the guidance, beyond 
those already indicated, were identified from the evaluation of the hazard 
assessment (RNC/RIP-oN3/C3/2/FINAL). 
4.9.18 Research recommendations 
4.9.19 As this is a high level document which outlines the whole CSR process it does 
not in itself suggest any new requirements for research.   
4.10 R.13 RISK MANAGEMENT MEASURES AND OPERATIONAL 
CONDITIONS INCLUDING THE RMM LIBRARY 
4.10.1 Chapter R.13 provides supporting guidance on the most common types of 
use conditions having an impact on exposure. This includes an overview on 
operational conditions (OC) and risk management measures (RMM) related to 
exposure of workers (R.13.2.2), to consumers (R.13.2.3) and to the 
environment (R.13.2.4). Sections R.13.2.5 and R.13.2.6 provide guidance on 
how to address OC and RMMs related to the life cycle stages subsequent to 
manufacture and identified downstream and consumer uses: article service 
life and waste life stage. Each of these sections includes an overview on 
RMM and OC and guidance on how to use the RMM and the available Tier 1 
tools for exposure estimation when carrying out iterations.  
4.10.2 Section R.13.3 provides guidance on how the effectiveness of risk control 
measures can be taken into account. It does not present any information 
about the effectiveness of risk control measures. These are provided in the 
RMM library.3 In Section R.13.4 the set-up of the RMM library is explained in 
more detail, and how to work with it. 
4.10.3 Considerations 
4.10.4 Technical issues described in RNC/RIP-ON/B2/2/FINAL (further evaluated in 
RNC/RIP-ON3/B4/2/FINAL) are those which are most relevant to proposals 
for changes to R13 and in the RMM library. Information obtained from case 
studies is also relevant. 
                                                
3 http://cefic.org/Industry-support/Implementing-reach/Libraries/ 
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4.10.5 The mapping between part R13 and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown Appendix 2. This 
identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the tables in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
where the guidance is adequate for nanomaterials as for substances in 
general and where it has been necessary to recommend a change.   
4.10.6 Examination of R.13 indicates that for most of the document the guidance 
provided applies equally well to nanomaterials as for substances in general. 
For workers, general descriptions of the OC (duration and frequency, applied 
amount, temperature, containment and capacity of the surroundings) and 
RMM in R.13.2.2 are equally applicable. Similarly for consumers (R.13.2.3) 
the environment (R.13.2.4), substances and articles (R.13.2.4) and waste life 
stage (R.13.2.5). The examples in R13 of conversion from risk management 
library to iteration at tier 1 provided appear to be generally applicable 
(however the question of the validity of this and other models is described 
separately in the discussion of R.14).   Statements which are already included 
e.g. “Solid substances or preparations may be supplied as fine light powders 
(implies high dustiness)…” (R.13.2.1) provide emphasis which would highlight 
the need to take to particular care with nanomaterials. 
4.10.7 In R.13.3 general statements concerning the effectiveness of RMMs are 
applicable and emphasise the need to justify effectiveness values chosen, for 
example on page 20 “List all known, published RMM effectiveness values for 
the RMM in question, including specific conditions under which the 
effectiveness is established”. The importance of substance properties is 
emphasised including for example the bullet point “Influence of substance 
properties (p21)”. In R.13.4 the aims, general description and categorisation 
are all equally applicable and do not require special adaptation. Again 
statements in these sections draw attention to the user of the need to take 
particular care about substance properties specifically (R.13.4.2.2). 
4.10.8 In R.13.4.2.5, estimation and documentation of RMM effectiveness in the 
library, the guidance appears to be equally applicable. However there is an 
opportunity to further strengthen the consideration of nanomaterial properties 
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by insertion of an additional paragraph as paragraph 4 of this section. The 
recommended change is as follows; 
4.10.9 Inset as paragraph 4 of R.13.4.2.5:  
4.10.10 Specifically in relation to nanomaterials, particle size can affect the 
performance of RMM and the effectiveness should not be assumed to be the 
same for nanomaterials as for substances in general, without justification.  
4.10.11 This generic point should be further supported with specific information in the 
RMM library. This is detailed in the next paragraphs. 
4.10.12 The RMM library is an EXCEL spreadsheet that is ‘made up’ of three parts: 
The library containing RMMs / OCs and details of their effectiveness lists of 
information sources for consumers, environment and occupational measures; 
and a practical guide to use of the library 
4.10.13 In terms of structure, the library is organised according to the occupational 
hygiene concept of ‘hierarchy of control’ as outlined in the Chemical Agents 
Directive. The reason for adopting this as the structural basis for the Library is 
that it allows for one library containing occupational, consumer and 
environmental measures, as well as also ensuring that occupational RMMs 
can still be selected according to the priority order governed by the ‘hierarchy 
of control’ concept. For consumer and environmental measures, the hierarchy 
is purely an organisational system for the RMMs. 
4.10.14 Effectiveness of individual RMMs is quantified in the library in those cases 
where technical/scientific evidence is available. The following changes are 
recommended based on the analysis in RNC/RIP-ON3/B4/2/FINAL. 
4.10.15 In relation to the RMM “Enclosure”, this has been mostly observed as an 
RMM for synthesis processes. Evidence reported in RNC/RIP-
ON3/B2/2/FINAL indicates that emissions to the workplace are substantially 
reduced if a process involving engineered nanomaterials is performed in a 
properly designed enclosure/containment. However this is not always the 
case. Emissions to the workplace have been reported which were 
subsequently attributed to a leak in the system and during activities such as 
product recovery and cleaning. From the RMM library, in relation to process 
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control, RMM W8.01 and W8.02 under the heading Automation and enclosure 
are most relevant. These have default values of H (High) which is still justified 
based on the evidence. The following change is recommended: 
4.10.16 RMM library, Sheet Individual Measures,  for W8.01 and W8.02 insert: 
4.10.17 For nanomaterials, evidence suggests that this RMM may not always be 
completely effective. Therefore for nanomaterials the effectiveness of this 
control approach should be directly assessed.  
4.10.18 In relation to the RMM “Respiratory protective equipment (RPE)”, evidence 
reported in RNC/RIP-ON3/B2/2/FINAL generally supports that the 
performance of respiratory protective equipment (RPE) will be effective 
against nanomaterials in that the claimed protection factors are likely to be 
achieved or exceeded.  This applies to both P3 and P2 respirators. There is 
no requirement to develop new types of filters. However use of a 
precautionary approach suggests that, to provide added protection, only the 
higher level respirators (P3) should be used.  There are 33 unique RMM 
measures related to RPE numbered W30.2 to W30.34. The following changes 
are recommended to be added in the “remarks” column, referring to these 
devices which offer lower protection than P3: 
4.10.19 RMM library, Sheet Individual Measures, for W30.03, W30.04, W30.06, 
W30.07 insert: 
4.10.20 Not suitable for use with nanomaterials. Respirators of this grade are likely to 
be technically effective against nanomaterials. However, a precautionary 
approach would suggest a higher level of protection. 
4.10.21 In relation to the RMMs “Hand Protection” and “Body Protection” Some 
evidence reported by the European project NANOSAFE2 suggests that 
nanoparticles can penetrate through cotton fabrics and other commercially 
available gloves and recommends that two layers of gloves (double gloving) 
are worn. The following changes are recommended to be added in the 
“remarks” column; 
4.10.22 RMM library, Sheet Individual Measures for CW29.01 insert: 
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4.10.23 Users should consider the use of double gloving provided that this in itself 
does not cause further problems such as manual dexterity issues. Cotton 
gloves and other woven materials are not suitable for use with nanomaterials. 
4.10.24 In addition, insert reference to the publication NANOSAFE (2008) into RMM 
library, Sheet Occupational References. 
4.10.25 RMM library, Sheet Individual Measures for W28.03, W28.04 insert: 
4.10.26 Suits manufactured from cotton or other woven fabrics are not suitable for use 
with nanomaterials. 
4.10.27 In addition, insert reference to the publication NANOSAFE (2008) into RMM 
library, Sheet Occupational References. 
4.10.28 In relation to the RMM “Health Surveillance”, there is no specific requirement 
for this to be used for nanomaterials. To provide the latest information the 
following change is recommended: 
4.10.29 Insert reference to the publication Schulte et al (2008) into RMM library, Sheet 
Occupational References. 
4.10.30 There are a number of other RMM (e.g. ventilation) where there is evidence 
that the RMM can effectively be used for nanomaterials. One option 
considered was that in these circumstances a note could be added to 
specifically identify this. However, this would appear to be a departure from 
process with other materials since positive affirmations do not generally seem 
to be used. Therefore, this option is not recommended. 
4.10.31 No additional requirements for change in this part of the guidance, beyond 
those already indicated, were identified from the evaluation of the hazard 
assessment (RNC/RIP-oN3/C3/2/FINAL). 
4.10.32 Research recommendations 
4.10.33 There are several research needs that have been identified for RMM and OC.  
Two types of research are envisaged. The first is the assessment of the 
effectiveness of a whole range of risk management measures needs to be 
established for use with different types of nanomaterials.    In relation to this, 
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the type of research envisaged includes both development and elaboration of 
underlying theoretical aspects and the collection of practical measurement 
data on the effectiveness of RMM as implemented in industrial settings, and 
on a laboratory or simulation based type of study.  In particular more 
information is required on RMMs such as enclosure, LEV, and the 
effectiveness of dermal protective equipment. Also in relation to exposure by 
inhalation (in an industrial setting) tests of the effectiveness of face seal 
leakage would be appropriate.  Secondly, there needs to be collection of 
fundamental information about how RMM and OC are actually implemented 
through industrial practice. 
4.10.34 For consumer exposure, there is almost no published information on the 
efficacy of any of the consumer RMMs for substances containing 
nanomaterials.   
4.10.35 In relation to environmental exposure more information is required on the 
effectiveness of prevention of release to air, and to water, and in relation to 
release to soil.   
4.10.36 From knowledge of the research programmes currently underway very little of 
it is focussed on to these aspects.  It is not anticipated that there is likely to be 
much in the way of significant publications in the next eighteen months or so.  
4.11 R.14 OCCUPATIONAL EXPOSURE ESTIMATION 
4.11.1 This chapter provides support for estimating occupational exposures dealing 
both with measurements and modelling approaches. It describes what 
information is needed for the assessment at different levels (Tiers) and how to 
deal with it.  The first tier exposure estimations are meant to be conservative 
and may well be above actual exposure levels.   
4.11.2 Information is given to support collection of exposure information for 
establishing the final exposure scenarios (ES), the information needs for 
different tiers and estimation or calculation of exposures.   
4.11.3 Considerations  
4.11.4 Technical issues described in RNC/RIP-ON/B3/2/FINAL (and further 
evaluated in RNC/RIP-ON3/B4/2/FINAL) are those which are most relevant to 
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proposals for changes to R14.  Information obtained from the case studies 
(RNC/RIP-ON3/B1/2/FINAL) is also relevant.  
4.11.5 The mapping between R.14 and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown Appendix 2. This 
identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the tables in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
where the guidance is adequate for nanomaterials as for substances in 
general, and where it has been necessary to recommend a change.   
4.11.6 Examination of R.14 indicates that much of the guidance that the document 
provides applies equally well to nanomaterials as for substances in general.  
However there are opportunities to improve the specificity of the guidance in a 
number of areas.   
4.11.7 In R.14.2 types and routes of exposure are described.  Information is provided 
at a high level.  Most of the information provided is equally relevant for 
nanomaterials as for substances in general.  There are three short 
paragraphs describing inhalation exposure (again at a fairly general level).  
Metrics are discussed to the extent that an example is provided of the 
measurement of inhalation exposure as the amount per unit of air volume 
inhaled with the example given of mg/m3.  The recommended change is as 
follows: 
4.11.8 Insert as the last paragraph of R.14.2 – Inhalation exposure: 
4.11.9 Inhalation exposure can be described by the concentration of the substance 
in air and the duration and frequency of exposure.  It is generally expressed in 
ppm (parts per million) or amount per unit air volume inhaled, averaged over 
the duration of the relevant task or shift (e.g. mg/m3 8hr Time Weighted 
Average (TWA)).  For measurement of exposure to nanomaterials information 
in relation to number concentration (especially for fibres) and surface area 
concentration are also considered to be of benefit (i.e. n/m3 or cm2/m3).  
4.11.10 The paragraphs on dermal exposure and oral exposure in this section are 
suitably general and no specific changes are recommended to these. 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 159 -
4.11.11 Section R.14.4 provides more detailed information on exposure estimation for 
both measurements and modelling approaches.  In relation to measurement 
approaches R.14.4.1 to R.14.4.6 are the sections where most of the 
information in relation to collection of measurements is provided.  However 
these sections provide little in the way of technical guidance as to how 
measurements should be made or used.  As such it may be questionable as 
to whether there should be further information of that type included in this 
chapter.  In seeking to make guidance amendments we have tried where 
possible to make the recommended changes consistent with the style and 
level of detail provided in the relevant chapters.  This has not always been 
possible however.  In these chapters additional recommendations are made 
which are at a level of detail beyond that which is currently in the guidance.  
An alternative to making these changes at this point in the guidance would be 
to make changes in R.7 as originally recommended in RNC/RIP-
ON3/B4/2/FINAL.  This could be still considered as a separate option.  
4.11.12 The first change relates to providing encouragement towards the use of 
simulations in the estimation of exposure levels as recommended in 
RNC/RIP-ON3/B4/2/FINAL.   
4.11.13 Insert as replacement in R.14.4.1 (page 5): 
4.11.14 For estimation of exposure the following preferential hierarchy should be 
applied to exposure data for estimation of exposure level: 
 Measure data including the quantification of key exposure 
determinants; 
 Appropriate analogous data, (including data derived from 
simulations) including the quantification of key exposure 
determinants; 
 Modelled estimates. 
4.11.15 In addition, added as a footnote: 
4.11.16 As an example of simulation studies, Gohler et al. (2010) measured emissions from a 
sanding simulation using polyurethane coating and architectural paint containing two 
types of nanoparticles. During the abrasion tests, no significant difference was 
detected between the number concentrations of released particles of the pure 
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coatings and of the coatings that were dosed with additives. However, larger particles 
containing nanoparticles were observed. 
4.11.17 A further change in relation to this issue is in Table R.14.1 under the heading 
Data Characteristics. 
4.11.18 Insert in Table R.14.1; workplace exposure assessment rating criteria, in the 
column data characteristics, in the cell medium quality data an additional 
bullet point which states: 
4.11.19 Data derived from simulations which mimic the task or activity under 
controlled conditions. 
4.11.20 Section R.14.4.3 is quite generic.   
4.11.21 In Section R.14.4.4 a similar point is recommended to draw the attention to 
the user of the potential for simulation studies.  The recommended change is 
to insert at R.14.4.4, bottom of page 8 as the third bullet: 
4.11.22 simulation studies replicating the task or activity of concern  
4.11.23 Otherwise this section is applicable.  It is noted that the statement is made 
that particle sizes of produced solid and dustiness and practical use is not 
very well related.  This is consistent with the limited evidence available for 
nanomaterials.  
4.11.24 In Section 14.4.5, selection and interpretation of measured data it is proposed 
to insert a paragraph drawing attention to the technical issues relating to the 
measurement of nanomaterials and to provide linkage to further guidance on 
this issue the recommended change is as follows:  
4.11.25 Measurement of exposure to nanomaterials provides particular challenges.  
These have been highlighted in several publications (e.g. Brouwer 2009, 
2010).  They include discrimination from background particles, collection and 
analysis of size information, effective high spatial and temporal variability, 
choice of metrics and measurement instruments, and measurement of high 
aspect ratio nanomaterials.  The state of knowledge on these issues is 
continuing to develop.  Further information on current approaches is provided 
in BSI 6699/3 (2010), OECD (2009) and in Annex R.14.X 
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4.11.26 In addition, as indicated above, it is recommended that an appendix is added 
R.14 which with the title “Considerations in relation to measurement of 
exposure to nanomaterials”. Rather than a method statement, this is a 
discursive document which outlines the main issues to be considered. 
Technically such an appendix does not fit within the current shape of the 
guidance at this point.  However in relation to the guidance chapters intended 
to be reviewed and assessed as part of RIP-oN 3, this provides probably the 
most appropriate place.  This document broadly is a digest of the information 
contained in Chapter 3.5 of this current report.  The proposed content of this 
appendix is added as an appendix to the current report being the same title 
(Appendix 3).   
4.11.27 In order to ensure that this is fully visible to the user, this Appendix should 
also be added to the guidance document R.7. The rationale for adding it into 
R.7 is that this is the only guidance document in which any information 
regarding particle measurement is provided (R.7.1.14).  Although R.7.1.14 
primarily refers to granulometry it also contains references for example to 
inhalable and respirable sampling.  The issue of whether this appendix should 
be added and the specific location of where it best fits within the guidance 
document is a point for discussion with the SCG.   
4.11.28 Information provided on dermal data, biological monitoring and uncertainty 
and statistics in this section are equally applicable to nanomaterials as for 
other materials.  In Section R.14.4.6 the acute exposure is equally applicable 
to nanomaterials as for substances in general.   
4.11.29 Sections R.14.4.7 to R.14.4.9 deal with the use of (first tier) exposure 
estimation tools as previously discussed in reports RNC/RIP-ON/B3/2/FINAL, 
RNC/RIP-ON3/B4/2/FINAL.  There have been only limited attempts at the 
validation of models for assessment of exposure to nanomaterials and such 
attempts at validation have generally not provided confidence in the accuracy 
of modelled estimates.  However, within the current REACH guidance there is 
already in relation to use of these models, acknowledgement of the limitations 
in the validation.  For example in R.14.4.7 there is a statement “while limited 
comparisons of tool predicted exposure with available data show a 
reasonable correlation for the tools.  Nevertheless there is room for 
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improvement.  This is especially the case for inhalation exposure to particles 
or aerosols which is more complicated to model and predict.  Moreover 
particulates have not been investigated as much as volatiles, leading to a 
more uncertain prediction of exposure, including potential underestimation of 
worst case exposure concentrations for particular activities (or process 
categories)”. 
4.11.30 It is appropriate at this point to introduce a further caveat to alert the user to 
the limitations of the usefulness of exposure estimation tools for 
nanomaterials.  However it is not possible to make a positive statement as to 
how these could be improved, or how the user should proceed.  Therefore the 
recommended change is as follows: 
4.11.31 Insert as paragraph 4 of R14.4.7: 
4.11.32 Please note that this tool has not yet been validated for use with 
nanomaterials. If the output of the model is used to estimate exposure for 
NMs, this should preferably be supported by measured data. There should be 
a clear description in the CSR of the uncertainties associated with the 
estimated values and the consequences for the risk characterisation.  
4.11.33 No additional requirements for change for this part of the guidance, beyond 
those already indicated, were identified from the evaluation of the hazard 
assessment (RNC/RIP-oN3/C3/2/FINAL). 
4.11.34 Research recommendations 
4.11.35 There are a number of potential research needs which have been identified 
through this review. 
4.11.36 There is a need for development of improved measurement tools for 
assessment of exposure to nanomaterials.  These would include tools which 
give the possibility of multi-metric approaches.  Linked to this issue is the 
need for development of a personal sampler.  There are already a number of 
activities in this direction, including the European project NANODEVICE and a 
range of commercial initiatives some of which have been identified in 
RNC/RIP-ON/B3/2/FINAL.  There is some evidence to suggest that some 
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improved methods will be available over the next two year period, however 
whether they will result in a personal device remains to be seen.  
4.11.37 Improved methods and approaches for discrimination from background nano 
aerosols are required.  These could take the form of measurement or 
analytical solutions or improved validated strategic approaches (experimental 
design approaches) which would enable discrimination to be more clearly 
demonstrated and achieved.   
4.11.38 Overall there is a need for a much improved sampling strategy to be 
implemented to take account of the multiple needs and the issues which have 
been identified.  In the context of REACH, the development of a strategy 
specifically for REACH compliance issues is necessary.  Currently available 
strategies are not focussed on this end point.  The strategy would enable (in 
the absence of personal sampling devices) estimation of personal exposure to 
nanomaterials to be developed from a range of experimental measurements 
and techniques by implementing and using the instrumentation already shown 
to be available and new instrumentation emerging. 
4.11.39 There is also a need to collect the evidential base about the potential for 
release from a whole range of types of activities and processes.  This would 
include measurements made in actual industrial scenarios but also laboratory 
based simulation experiments would provide the basis for more rapid 
gathering of data and information.  Further development of such simulations 
should be considered to be a high priority.  Within the collection of this data 
there is also a need to more effectively share this information.  This would 
include the publication of additional contextual data along with actual 
quantitative measurement data.   
4.11.40 Collection of available evidential data concerning release and exposure is 
necessary. These would include quantification and characterisation of the 
release in terms of the various metrics discussed, composition, and particle 
size distribution and how these varied in time and in different 
environments/media. This data would enable much more extensive validation 
of models to be carried out if required and, based on these validation 
exercises, new model approaches could be developed.  One promising 
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approach is that of the Advanced REACH Tool (ART) model, referred to in 
RNC/RIP-oN3/B3/2/FINAL. 
4.11.41 Information on who is exposed to what in which scenarios would also be 
desirable. This would be an important preliminary activity towards the 
development of understanding of the links between exposure and health 
effects, and as a complementary activity to medical surveillance.  
4.11.42 Most of the published data reported in RNC/RIP-oN3/B3/2/FINAL was for 
synthesis/manufacturing processes.  There is a clear need for more 
information to be gathered from other points of the life cycle.  For example, 
uniform release of nanomaterials during the use of products containing 
nanomaterials (e.g. spraying and subsequent maintenance of paints and 
coatings, nano-impregnated textiles wear & tear) is currently almost 
completely absent from the literature. Other examples would include 
occupational exposure to emissions in waste management in recycling, 
landfills and incineration. 
4.12 R.15 CONSUMER EXPOSURE ESTIMATION 
4.12.1 This chapter describes a step-wise and iterative procedure for the estimation 
of consumer exposure to substances on their own, in preparations or in 
articles. It consists of the following sections: 
 Workflow for consumer exposure assessment (Section R.15.1.2) 
 General considerations related to assessment of consumer 
exposure (Section R.15.2) 
 Calculation of consumer exposure at Tier 1 level (Section R.15.3) 
 Tools for supporting exposure scenario building at Tier 1 level 
(Section R.15.4 and Section R.15.5), 
 Higher tier models and measured data (Section R.15.6), 
 Risk characterisation (Section R.15.7), 
 Overview on information sources and available tools (Section R.15.6 
and Appendices R.15-3, R.15-4 and R.15-5 
4.12.2 The document describes how consumer exposure estimation can be 
performed by a tiered assessment, beginning with a screening estimation 
(Tier 1). If the result of the screening is that exposure is below the accepted 
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thresholds then there is “no concern” and the risks of the product can be 
considered to be controlled. Most of the document is concerned with the 
calculation of exposure (R.15.3 onwards). It is noted in the document that 
“consumer exposure estimation is often difficult due to limited data 
availability”. 
4.12.3 Considerations 
4.12.4 Technical issues described relating to choice of metrics (RNC/RIP-
ON3/B3/2/FINAL, RNC/RIP-ON3/B4/2/FINAL), Exposure modelling 
(RNC/RIP-ON3/B3/2/FINAL, RNC/RIP-ON3/B4/2/FINAL) and consumer RMM 
(RNC/RIP-ON3/B2/2/FINAL, RNC/RIP-ON3/B4/2/FINAL) are those which are 
most relevant to this document.  
4.12.5 The mapping between R.15 and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown in Appendix 2. 
This identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the table in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
where the guidance is adequate for nanomaterials as for substances in 
general and where it has been necessary to recommend a change.   
4.12.6 Analysis of R.15 indicates that for most of the document the guidance 
provided applies equally well to nanomaterials as for substances in general.  
R.15.1 is a generic introduction and description of the process, which applies 
equally well to nanomaterials. R.15.2.1 describes the scope of the consumer 
exposure estimation. This includes both articles that can be purchased from 
retail outlets by members of the general public and exposure as a result of 
being near where a substance is being used or has been used. R.15.2.2 
describes reasonable worst-case situations. Again these sections are generic 
and apply equally well to nanomaterials as for other types of substances. 
4.12.7 In R.15.2.3 routes of exposure (inhalation, dermal, oral) are described with 
some inconsistency in the way the metrics (all based on mass) are described. 
For example mg/m3 is given as an example in relation to inhalation an stated 
as an absolute in relation to dermal exposure (mg/cm2 (or as external dose,  
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mg/kg body weight/day). To clarify this and to include the possibility the 
following update to Guidance is recommended: 
4.12.8 Insert as the last paragraph of R.15.2.3 – Inhalation exposure: 
4.12.9 Inhalation exposure is expressed in terms of external exposure, as a 
concentration, usually as mg/m3. For measurement of exposure to 
nanomaterials information in relation to number concentration (especially for 
fibres) and surface area concentration are also considered to be of benefit 
(i.e. n/m3 or cm2/m3).  
4.12.10 In relation to dermal exposure and oral exposure, no clear recommendations 
about alternative metrics were able to be made in the Task D document. 
Therefore, current guidance which suggests expressing dermal exposure in 
terms of mass per surface area or mass per body weight is adequate for 
dermal exposure to nanomaterials. Similarly for oral exposure mass per body 
weight per day seems appropriate.   
4.12.11 Information provided in R.15.2.4, R.15.2.5 and R.15.2.6 is equally applicable 
to nanomaterials as to substances in general. In R.15.2.7, reference is made 
to the potential of the emission by mechanical abrasion, indicating that this 
should be considered. Also in this section, it is noted that effective risk 
management measures for consumer are usually product integrated 
measures. The limitations in relation to consumer instructions and personal 
protective equipment are noted. In these sections the information provided is 
equally applicable nanomaterials as for substances in general, no special 
provisions are required and no recommendations for change are made.   
4.12.12 Section 15.3 is concerned with calculation of exposure and refers to the use 
of Tier 1 tools. This section describes the algorithms used in these tools 
referring to further discussion regarding the tools in section R.15.4 and 
R.15.5. The applicability of these tools was assessed as part of the Nanex 
project and was discussed in RNC/RIP-oN3/B2/2/FINAL and RNC/RIP-
ON3/B4/2/FINAL. The conclusions from the Nanex project was that there 
were limitations in the applicability of these two models for estimation of 
consumer exposure by inhalation and estimates should only be used with 
care. Therefore the following guidance update is proposed: 
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4.12.13 Insert at the end of the first paragraph in R.15.3.1: 
4.12.14 Please note that this tool has not yet been validated for use with 
nanomaterials. If the output of the model is used to estimate exposure for 
NMs, this should preferably be supported by measured data. There should be 
a clear description in the CSR of the uncertainties associated with the 
estimated values and the consequences for the risk characterisation.  
4.12.15 Modify the paragraph beginning “When the inhalable and or respirable 
fraction is known” as follows: 
4.12.16 When the inhalable and or respirable fraction is known it should be taken into 
account. If the product contains releasable nanomaterials then the 
assumption should be made that it is entirely within the respirable fraction if 
not otherwise known.   
4.12.17 From the Nanex project (NANEX 2011) it is concluded that the models for 
estimating consumer exposure by the dermal route might be used (if the use 
pattern can be considered to be the same) as the underlying equations do not 
appear to rely on nano specific properties and would not need to be changed 
to address such properties. On this basis no further recommendations in 
relation to the dermal or oral models are made at this time.  
4.12.18 No additional requirements for change for this part of the guidance, beyond 
those already indicated, were identified from the evaluation of the hazard 
assessment (RNC/RIP-oN3/C3/2/FINAL).  
4.12.19 Research Recommendations  
4.12.20 Substantial additional work requires to be done in order to validate the models 
for use with nanomaterials.  Therefore research would require to assess, 
possibly through the use of simulations, actual exposures resulting from a 
range of types of products, e.g. paints and coatings, textiles, cleaning 
products etc. for which there may be nanomaterial based applications.  
Generation of exposure data using these is a priority. Based on the 
establishment of such a data set, appropriate validation of the models could 
take place. Based on the outcomes of such validation, the need to develop 
further more detailed models may be appropriate. On this basis consideration, 
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particularly for inhalation exposure, should be given to whether or not it is 
necessary to develop models for which other exposure metrics may be 
estimated e.g. number concentration or surface area concentration.   
4.12.21 The use of modelling approaches particularly in relation to consumer 
exposure is extensive and therefore full validation of the models used should 
be considered a priority research need.  
4.13 R.16 ENVIRONMENTAL EXPOSURE ESTIMATION 
4.13.1 This chapter provides guidance on how to estimate environmental exposure. 
It deals with estimation of the releases to air, water (either wastewater and/or 
surface water), and soil at local and regional scale, fate and distribution of the 
releases in environmental compartments (air, soil, surface water, sediment, 
biota) and sewage treatment plants and calculation of exposure 
concentrations in environmental compartments and man via the environment.  
4.13.2 Considerations 
4.13.3 The mapping between R.16 and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown in Appendix 2. 
This identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the table in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
where the guidance is adequate for nanomaterials as for substances in 
general and where it has been necessary to recommend a change.   
4.13.4 Only a limited number of studies are available in regard to fate and behaviour 
of nanomaterials such C60, CNT and nano-metals and nano-metal-oxides, but 
consistent findings are that behaviour of nanomaterials in the environment is 
dependent on type, form and physico-chemical characteristics of the 
nanomaterial in question, as well as those of the receiving environment 
(Stone et al. 2009). Nanomaterial transport and distribution are influenced by 
a number of factors, such as Brownian diffusion, inertia effects, gravitational 
influences, thermal influences, pH, ionisation, and presence/absence of 
Natural Organic Matter (NOM). These interactions ultimately affect the 
processes the nanomaterial consequently undergoes in its transport and 
subsequent fate (Stone et al. 2009).   
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4.13.5 As noted by Stone et al. (2009) traditional predictions of fate and transport are 
based on inherent properties such as phase transfer properties (e.g. boiling 
point, vapour pressure, partition coefficients), reactivity (e.g. photo-reactivity 
and hydrolysis) and biological degradation behaviour (Mackay and Hendry, 
2009).  
4.13.6 Many of these inherent properties are reported on for regular chemicals under 
REACH or can be derived via information about the octanol-water partition 
coefficient and vapour pressure of the substances. However, we know at this 
point that these properties are not adequate to understand and predict the 
fate and behaviour of nanomaterials (Stone et al, 2009).  This is further 
complicated by our current lack of understanding of the novel physico-
chemical properties exhibited by many nanomaterials and the effect these 
have on particle behaviour. In addition, it is most likely that those 
nanomaterials released into the environment will also exist as modified forms 
of their primary counterpart (SCENIHR, 2009). 
4.13.7 While there is information available on models nanoparticle transportation, 
aggregation and deposition available in the literature deriving primarily from 
the colloid literature, this is either theoretical and/or based on idealised 
relatively simple model systems (e.g. Weisner and Bottero 2007). The models 
have not been adapted for the large number of components present in natural 
water which may include salts, clays, micro-organisms, natural organic matter 
and other colloidal materials (Mylon et al 2004). At present these are not 
appropriate for use in a regulatory context. 
4.13.8 It is clearly conceivable that fugitive emission from processes in which 
nanomaterials are produced, could potentially lead to increased air 
concentration of these nanomaterials. As well as environmental exposure in 
these circumstances, it is possible that the general public, as well as the 
environment, would become exposed. 
4.13.9 Some attempts at modelling environmental exposure have been carried out, 
most notably by Boxall et al. (2007) and by Mueller and Nowack (2008), 
based on a substance flow analysis from products to air, soil, and water using 
model inputs such as: estimated worldwide production volume, allocation of 
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the production volume to product categories, particle release from products, 
and flow coefficients within the environmental compartments. 
4.13.10 In relation to the guidance it follows that the partitioning and degradation 
behaviour which are based on models which rely on molecular weight, water 
solubility, vapour pressure, octanol-water partition coefficient and information 
on ready biodegradability for the substance cannot be relied on. These 
models include the use of a number of partitioning coefficients (air-water, soil-
water, water-sediment, suspended matter-water, etc.), Henry's laws constant, 
vapour pressure and water solubility of the substances (R.16.5). Based on 
current understanding, it is not possible to provide validated adaptations or 
alternative to these models for nanomaterials. The following change is 
recommended. 
4.13.11 Insert at R.16.5 as a last paragraph in the introductory section: 
4.13.12 There are significant limitations in the applicability of any of the environmental 
fate models (e.g. fugacity models for various compartments and overarching 
models like EUSES) which depend on LogKow and Henry's law for use with 
insoluble nanomaterials (and other insoluble particles or substances). As no 
broadly accepted and scientifically valid models are available for estimating 
environmental fate of nanomaterials, M/Is are advised to collect measurement 
information on environmental release and content in the environment where 
possible. 
4.13.13 Other than for these aspects it seems that the provisions of R.16 apply as well 
for nanomaterials as for substances in general assuming that mass (kg/day) 
is the proper metric to describe the release rate (kg/day) to the environmental 
compartments (R.16.3.2.1).  
4.13.14 Research recommendations - environment 
4.13.15 Much more work is required to assess the potential emissions to the 
environment relevant to nanomaterials. This would include the development 
of methods for measuring the release of nanomaterials in waste streams on 
the emissions from various processes as well as quantifications of these 
releases for a wide range of material and process types. As part of this, 
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"characterisation" of what is released is of key importance. This should be 
considered a high priority for research. This applies both to release and 
exposure for humans and for the environment. Based on the collection and 
assembly of such data the efficacy of the various models could be assessed 
and where appropriate, further adjusted.  
4.13.16 There is a fundamental need for an analytical method capable of verifying the 
actual exposure concentration in the soil and over time. There is also a need 
to develop an analytical method to verify nanomaterial concentrations, 
aggregations/agglomeration behaviour and stability of nanomaterials in soil.  
4.14 R.17 EXPOSURE ASSESSMENT OF SUBSTANCES IN ARTICLES 
4.14.1 R.17 describes how to assess exposure to man and the environment from 
substances in articles.  Substances in articles can be assessed as part of the 
life cycle stage of a substance, as part of a registration for substances in case 
where substances in the articles are intended to be released further details 
are available in the document guidance for articles.  In general the applicable 
life cycle stages are “use” and “service life” e.g. wear and tear and 
maintenance of textiles.  The document provides general considerations for 
exposure estimation and information relating to developing estimates for 
inhalation dermal ingestion and migration based primarily on tier one models.  
There is some encouragement towards the use of measured data if available 
in R.17.2.  
4.14.2 Considerations 
4.14.3 Technical issues described relating to choice of metrics (RNC/RIP-
ON3/B3/2/FINAL, RNC/RIP-ON3/B4/2/FINAL) exposure modelling (RNC/RIP-
ON3/B3/2/FINAL, RNC/RIP-ON3/B4/2/FINAL) are those which are most 
relevant to this document.  
4.14.4 The mapping between R.17 and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown Appendix 2. This 
identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the tables in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
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where the guidance is adequate for nanomaterials as for substances in 
general and where it has been necessary to recommend a change.   
4.14.5 For most of the document the guidance provided applies equally well to 
nanomaterials as for substances in general.  The main concern however 
would be the limited applicability of the models used (or rather limited 
validation of the models used) particularly in relation to inhalation.  As noted in 
previous sections a statement should be added indicating this to the 
guidance.  The following is recommended: 
4.14.6 Insert at the end of paragraph 1 of R.17.2: 
4.14.7 Please note that this tool has not been validated for use with nanomaterials. If 
the output of the model is used to estimate exposure for NMs, this should 
preferably be supported by measured data. There should be a clear 
description in the CSR of the uncertainties associated with the estimated 
values and the consequences for the risk characterisation.  
4.14.8 Section R.17.4 considers release and exposure estimation for the 
environment.  Provisions in this section appear to be equally applicable to 
nanomaterials or articles containing nanomaterials as for other types of 
substances.  Almost no data is available by which the models for estimation of 
emissions can be tested.  Although a few studies have been reported the 
results are not yet generalisable.  It may be useful to give some 
encouragement to users to measure actual emissions by providing some 
indicators to these studies.  However the current state of development of 
these studies does not provide the basis for guidance recommendations.  In 
any case there is no indication from these studies that the worst case 
assumptions provided by the model would be insufficiently conservative.  All 
of the models consider only release in mass terms.  It is appropriate therefore 
to add a cautionary caveat: 
4.14.9 Insert in Section R.17.4.1 and R.17-1: 
4.14.10 Please note that this tool has not been validated for use with nanomaterials.  
As such any estimates obtained from these models should be scientifically 
justified. Consideration should be given to the use of simulation studies to 
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generate additional data on emissions. If the output of the model is used to 
estimate exposure for NMs, this should preferably be supported by measured 
data. There should be a clear description in the CSR of the uncertainties 
associated with the estimated values and the consequences for the risk 
characterisation.  
4.14.11 No additional requirements for change for this part of the guidance, beyond 
those already indicated, were identified from the evaluation of the hazard 
assessment (RNC/RIP-oN3/C3/2/FINAL). 
4.14.12 Research Recommendations  
4.14.13 Much more work is required to assess the potential emissions from articles 
which contain nanomaterials or are coated with nanomaterials.  This would 
include the use of simulation type studies (in practice simulation studies are 
probably the only way by which useful data can be obtained).  Based on the 
collection and assembly of such data the efficacy of the release models could 
be validated. As part of this, "characterisation" of what is released is of key 
importance. This should be considered a high priority for research.  This 
applies both to release and exposure for humans and for the environment.  
4.15 R.18 EXPOSURE ASSESSMENT FOR THE WASTE LIFE STAGE 
4.15.1 R.18 aims to illustrate and exemplify how exposure scenarios for the waste 
life stage may be defined. Based on that, the chapter outlines the basic 
workflow and methodology how Tier 1 emission estimates can be derived. It 
also explains the basic approach of how to handle the interface between the 
REACH regime and the waste regime in practical terms. Guidance on the 
legal status of substances in recycling streams is not provided. 
4.15.2 Considerations  
4.15.3 Technical issues described in RNC/RIP-ON/B3/2/FINAL (and further 
evaluated in RNC/RIP-ON3/B4/2/FINAL) are those which are most relevant to 
proposals for changes to R.18. Information obtained from the case studies 
(RNC/RIP-ON3/B1/2/FINAL) is also relevant. 
4.15.4 The mapping between R.18 and the issues identified from exposure 
assessment aspects (RNC/RIP-ON3/B4/2/FINAL) is shown Appendix 2. This 
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identifies each of the scientific issues identified in that report and the 
preceding reports, by reference to the tables in RNC/RIP-ON3/B4/2/FINAL, 
and maps that to the point in the guidance indicating where they are relevant, 
where the guidance is adequate for nanomaterials as for substances in 
general and where it has been necessary to recommend a change.   
4.15.5 Examination of R.18 indicates that much of the guidance which the document 
provides applies equally well to nanomaterials as for substances in general.   
4.15.6 R.18.2 describes the types waste streams may be generated at each stage in 
the supply chain, and indicates the type of information the M/I is required to 
collect on operational conditions of waste generation and existing/suitable 
waste management routes 
4.15.7 These are quite generic and may be applied to any substance. Units are not 
discussed but the assumption is that they will usually be expected to be 
expressed in mass terms.  
4.15.8 R.18.3 describes the waste operations recovery and disposal. R.18.4 
describes the general workflow in M/I’s assessment related to waste stage. 
R.18.5 describes Tier 1 emission estimation and includes discussion on pre-
sets for the emission pattern in time and space, examples for treatment pre-
sets and other waste operations. Assumptions made appear to be quite 
conservative. 
4.15.9 Sources of possible information for environmental release for 14 widely 
applied waste treatment techniques. 
4.15.10 Everything is considered in mass terms. 
4.15.11 There is very little information in the public domain regarding environmental 
release. There is certainly not enough which could be used to provide better 
estimates of release or to challenge the assumptions.  
4.15.12 The following caveat is recommended at the end of section 18.5.2 similar to 
the approach taken with other modelling.  
4.15.13 Please note that this approach has not been validated for use with 
nanomaterials. As such any estimates obtained from this approach should be 
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scientifically justified. Consideration should be given to the use of simulation 
studies to generate additional data on emissions. If the output is used to 
estimate exposure for NMs, this should preferably be supported by measured 
data, including the consideration of the most appropriate metric. There should 
be a clear description in the CSR of the uncertainties associated with the 
estimated values and the consequences for the risk characterisation.  
4.15.14 Research recommendations 
4.15.15 Much more work is required to assess the potential emissions from waste 
disposal processes relevant to nanomaterials. This would include the 
development of methods for measuring the release of nanomaterials in waste 
streams on the emissions from various treatment processes as well as 
quantifications of these releases for a wide range of material types.  This 
would include the use of simulation type studies (in practice simulation studies 
are probably the only way by which useful data can be obtained).  Based on 
the collection and assembly of such data the efficacy of the Tier 1 models 
cold be assessed could be validated. As part of this, "characterisation" of 
what is released is of key importance. This should be considered a high 
priority for research.  
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6 APPENDIX 1 – ADDITIONAL ANALYSIS OF THE ES CASE 
STUDIES 
6.1 The case studies were intended to provide an assessment of the 
effectiveness of the ES guidance, including the ES format.  The studies were 
planned and developed prior to the publication of the Version 2 document in 
May 2010.  However the study team had access to an earlier draft of that 
document and it was that which was used as the basis of the ES case study 
work. The case studies are described in detail in RNC/RIP-oN3/B1/2/FINAL.  
In this section the general learnings from the case study in relation to the ES 
format have been assessed. Exposure scenarios were built by the volunteer 
companies with support of experts and with greater knowledge of 
nanomaterials issues.  The assessment of the exposure scenario format is 
now presented.  The scenarios which were built related almost exclusively to 
uses of substance by workers and it is to that aspect that most of the 
comments are addressed.  The ES template used was almost identical to that 
provided on page 8 of the May 2010 document Exposure Scenario Format.  
For ease of understanding in relation to the current version, comments are 
arranged according to that format rather than to the format which was used to 
collect the comments.  Comments are arranged according to the main 
headings in that scenario format. 
6.2 Title of exposure scenario No. x 
6.3 No problems were identified with this section.  All of the case studies 
identified appropriate ERCs, PROCs and SUs as required.  Additional 
comments were used in some of the case studies to further expand the 
descriptions. No significant issues identified.  No recommendations for 
change.   
6.4 Exposure Scenario 
6.5 Contributing Scenario (1) Controlling Environmental Exposure For 
6.6 Initially there was some confusion in relation to the naming of this but it 
became clear that the name here needed to refer to the whole process that 
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was being considered. This is not particularly clear from the guidance, 
however but it is certainly not a nano issue. 
6.7 Product Characteristics 
6.8 Most of the products were identified as some form of powder. Information was 
also provided in this stage for example about packaging or the composition of 
the material.  No difficulties were experienced, guidance applies equally to 
nanomaterials as for substances in general. However, it is important that the 
ES should relate to the specific nanoform and this should be explicitly 
mentioned in the ES. This should be reflected in the guidance..  
6.9 Amounts Used  
6.10 The providers were able to provide information on the amounts used on both 
a daily or annual basis.  Amounts used ranged from a few kilograms to 
hundreds of tonnes per year.  No difficulties were experienced, guidance 
applies equally to nanomaterials as for substances in general, no 
recommendations on this issue. 
6.11 Frequency and Duration of Use  
6.12 Case study providers were all able to provide this information.  No difficulties 
were experienced, guidance applies equally to nanomaterials as for 
substances in general, no recommendations on this issue.  
6.13 Environmental Factors not Influenced by Risk Management  
6.14 Here the sub information is “flow rate of receiving surface water”.  Only two of 
the case studies completed this, the other two considered it was not relevant 
since no water was used in relation to the process, and there was no 
discharge.  No difficulties were experienced, guidance applies equally to 
nanomaterials as for substances in general, no recommendations on this 
issue. 
6.15 Other given Operational Conditions affecting Environmental Exposure  
6.16 The case study providers gave a variety of responses to this ranging from a 
simple statement of “indoor use”, “closed and dry process” to statements 
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which gave much more detailed information about the actual process.  
Although there was some confusion initially about what needed to be stated 
here, this was not related to any aspect of the nanomaterial.  No specific 
issues relating to the nanomaterials were identified, and no recommendations 
are being made in relation to this.   
6.17 Technical Conditions and Measures at Process Level (a source to prevent 
release) 
6.18 Providers did not produce a great deal on information here.  Statements 
ranged from “full containment” to more detailed explanations of why 
containment was considered to be effective.  One of the cases provided 
statements regarding a sewage treatment plant, plus additional exposure 
estimates generated in relation to fresh water, sediment, soil, marine water 
etc.  These were developed using Ecetoc TRA.  The guidance here appears 
to work as well for nanomaterials as for substances in general, no specific 
guidance recommendations are being made.  
6.19 Technical On-site Conditions and the Measures to Reduce or Limit 
Discharges, Air Emissions and Releases to Soil  
6.20 Case studies provided a range of information relating for example, to filtration, 
waste treatment, how waste was collected and taken off site and how it was 
subsequently disposed off.  Other providers simply stated closed process, 
packaging designed to limit exposure.  No difficulties were identified, the 
guidance works as well for nanomaterials as for substances in general, no 
recommendations for change being made.  
6.21 Organisational Measures to Prevent / Limit Release from Site 
6.22 There was some differences in the response between the providers in this 
case. Two of the providers gave information relating to the fact that it was a 
closed gas phase process adding that it was a requirement for system 
operation that the process was closed.  Additional information about the 
cooling system being a closed process was also provided. In another case 
they simply stated that there was a valve system to prevent emission.  It is 
clear that there were different expectations in the level of detail required in the 
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response on this particular question however again this was not in any way 
related to the use of nanomaterials but more simply a need to generally 
provide more information.  The guidance appears to work as well for 
nanomaterials as for substances in general, no changes are proposed in 
relation to this.   
6.23 Conditions and Measures related to Municipal Sewage Treatment Plant 
6.24 This was not relevant for all cases and was described as such.  In the case 
where this was used the default value was given (2000 m3/d) was used. The 
guidance appears to work as well for nanomaterials as for substances  in 
general, no changes are proposed in relation to this.   
6.25 Conditions and Measures related to External Treatment of Waste for Disposal  
6.26 Provider responses ranged from “contract with specialist waste treatment 
company, with a requirement for incineration of waste” to “not relevant”. It’s 
not clear why not relevant was considered an appropriate response in relation 
to that particular scenario. The guidance applies equally well for 
nanomaterials as for substances in general, no changes to the guidance are 
proposed.   
6.27 Conditions and Measures related to External Recovery of Waste 
6.28 Two of the providers stated that this was not relevant the other two providers 
provided information relating to recycling of the material.  The guidance 
applies equally well for nanomaterials as for substances in general, no 
changes to the guidance are proposed.   
6.29 Additional Good Practice Advice (for environment) beyond the REACH CSA  
6.30 Two of the providers gave additional information to this question.  The 
additional information was towards specific good practice activities, training 
activities or standardisation / quality control activities.  No nano specific issues 
were identified, the guidance appears to work as well for nanomaterials as for 
substances in general, no recommendations are being made.  
6.31 The preceding sections refer to the information required for the environmental 
exposure contributing scenario.  As a general statement although there were 
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some difficulties and misunderstanding as to where and at what level of detail 
information was required to be produced in general, these entries did not 
create any issues which were considered to be specific for nanomaterials.  
Therefore no recommendations are being made to the guidance based on the 
experience of the case study providers for these elements.   
6.32 Contributing Exposure Scenario (to controlling worker exposure) 
6.33 Appropriate names for the exposure scenarios were identified in all cases.  
Further specification was also provided describing this scenario.  No 
difficulties were identified, the guidance appears to work as well for 
nanomaterials as for substances in general, no recommendations for 
guidance changes are being made.  
6.34 Product Characteristics 
6.35 Cases provided information about the product characteristic.  This included 
that the product was in one case a solid powder, in another case a liquid 
preparation in another pure solid nanomaterial, with high dustiness.  Another 
of the cases provided information in this box in relation to aspects of the 
measurement programme which was useful information but not appropriate at 
that point although the guidance appears to be clear enough on this issue.  It 
appears to apply as well to nanomaterials as for substances in general, 
However, it is important that the ES should relate to the specific form 
(nanoform) of the material and this should be reflected in the guidance.  
6.36 Amounts Used  
6.37 All cases were able to provide information in relation to this.  The guidance 
appears to work as well for nanomaterials as for substances in general, no 
guidance changes are proposed.  
6.38 Frequency and Duration of Use / Exposure  
6.39 The information provided in relation to this task includes the request for 
duration per task / activity and frequency of exposure.  In practice the case 
providers had some difficulty in identifying what comprised a specific task or 
activity.  This was compounded somewhat by the fact that at least in some 
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cases the providers were trying to fit their tasks around exposure 
measurements which had been taken prior to this ES building activity and had 
not been specifically collected in relation to REACH.  The providers were 
supported by occupational hygiene experts both externally and within the 
project team who helped to resolve these issues. It is clear that this is an 
issue but not one that is related specifically to nanomaterials.  Although the 
guidance could be improved, this is a very generic need.  The guidance 
applies equally well for nanomaterials as for substances in general, no 
changes to the guidance are proposed  
6.40 Human Factors not Influenced by Risk Management  
6.41 Responses received ranged from “not relevant (detailed personal protective 
measures are prescribed)” to descriptions of PPE used.  Also there was some 
confusion over exactly what was required as an entry here. Although the 
guidance could be improved, this is a very generic need.  The guidance 
applies equally well for nanomaterials as for substances in general, no 
changes to the guidance are proposed  
6.42 Other given Operational Conditions affecting Workers Exposure 
6.43 Responses range from processes conducted in a fully closed reactor to 
description of the work room etc.  No specific difficulties were encountered, 
the guidance works as well for nanomaterials as for substances in general, no 
guidance changes are proposed.  
6.44 Technical Conditions and Measures to Control Dispersion from Source 
towards the Worker  
6.45 Extensive descriptions of the types of measures used were provided.  These 
included descriptions of specific types of valves which were used to permit 
emission, separation of control rooms from sources, description of the system 
as being an enclosed process, details were often provided in an annexe. The 
guidance applies equally well for nanomaterials as for substances  in general, 
no changes to the guidance are proposed. 
6.46 Organisational measures to prevent limit releases, dispersion on exposure. 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 191 -
6.47 Respondents most often referred to issues to do with work organisation 
activities such as those enclosed in an operational handbook e.g. training, 
and use of PPE in one case the response of not relevant was received.  Other 
different types of responses were received no particular difficulties were 
identified.  The guidance appears to work as well for nanomaterials as for 
substances in general, no guidance changes are proposed.   
6.48 Conditions and Measures related to Personal Protection, Hygiene and Health 
Evaluation 
6.49 Respondents provided a range of information about PPE how it was used, 
how it was disposed and provided linkages to operational handbooks and 
programmes.  Detailed information about the PPE was not typically provided 
(although in some cases it was available in the company literature.  Also the 
sub question on advice about how long the protective equipment can be used 
before replacement was not answered.  In general more detail would have 
been useful on this point.  However guidance appears to be as appropriate for 
nanomaterials as for substances in general, no changes to guidance are 
proposed.  
6.50 The preceding paragraphs are concerned with occupational exposures. Two 
of the case study providers also developed exposure scenarios based on the 
standard exposure scenario format for uses by consumers.  Again in relation 
to these the guidance appears to work as well for nanomaterials as for 
substances in general, no specific guidance recommendations relating that 
are proposed.   
6.51 The final stages of development of the overall exposure estimate bring 
together the various contributing scenarios.  Here there was a range of 
approaches taken.  These have been detailed more extensively in the B4 
report and will not be reproduced here.  Generally, the issues identified 
related to the use of measurement systems and how data which they 
generated could be interpreted.  Broadly a range of measurement approaches 
were taken including almost all of the measurement methods described in the 
current RNC/RIP-ON/B3/2/FINAL report. This included measurement of mass 
concentration, number concentration, size distribution, analysis of different 
size fractions and employing a wide range of different methods including 
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CPC, SMPS and cascade impactors. In most of the cases the providers used 
some external support or consultancy.  In many cases the programme had 
more of an investigative flavour rather than development of measurement 
data for the purposes of compliance.  In other cases new techniques were 
being developed which have subsequently appeared in the public domain.  
They therefore did not in any case really represent a provider going out 
carrying out a measurement programme specifically with the purpose of 
compliance.  This, coupled with the fact that at the current time there is no 
clear single route or protocol agreed as to how such nanomaterials can be 
measured contributed to the diversity of approaches and data taken.   
6.52 In relation to this there does seem to be a clear need to provide additional 
information in relation to this. There are several aspects to this.  One is, for 
nanomaterials what measurements need to be taken. To some extent these 
issues should be addressed by changes to the R14 document as well as 
other parts of the guidance (potentially).  The type of changes indicated are 
the same as have been proposed based on the evaluation of the other 
evidence collected in the RNC/RIP-ON/B3/2/FINAL report.  Hence, the case 
studies support the need for clearer guidance to be provided. 
6.53 A second issue relates to the use of real time measurement devices, such as 
the CPC or SMPS which essentially provide a continuous output of data over 
a time period.  The current guidance is clearly written from the perspective of 
multiple single offline measurements and combining these e.g. to develop 
statistical indices of the data obtained e.g. mean or 95th percentile.  There is 
almost no information on this issue the guidance document reviewed. This 
also illustrates the difficulties in trying to use pre existing data in order to 
demonstrate compliance.   
6.54 A third issue relates to the use of different metrics. In the data provided by 
these case studies a range of metrics were used.  A number of approaches 
led to estimates based on number concentration and there was no clear view 
as to how such measurements could be used for comparison with the DNEL 
(which was, in all cases expressed in terms on mass concentrations). This 
cross metric comparison would be possible if there were well established 
relationships for conversion between these, However as indicated in the Task 
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D report, such relationships are not available and are unlikely to be stable or 
generalisable. In the absence of this it is difficult to provide clear guidance on 
this issue. This may continue to be the case for some time.   
6.55 A final issue identified was the selection of the DNEL against which the 
exposure estimate could be compared.  Two of the case study providers 
compared their exposure assessments with research derived potential DNELs 
for different materials (TiO2 and CNT), therefore trying to go beyond current 
information.  In these cases derived exposure values where below the 
(research based) DNEL. This did not provide any additional information as to 
how DNELs could be derived but such recommendations will arise from the 
Task C reports of RIP-oN 3.  
6.56 Overall in relation to the case studies it was considered that “these Case-
Studies could serve as nanomaterial product-specific examples only and that 
no generalisation with regard to practices within an entire nanomaterial type-
specific branch could be based on these individual ES Case-Studies.”  This is 
not to indicate that generalisation of ES for nanomaterials will always be 
impossible. As with any substance the generalisation of the ES would need to 
be justified. What would be different for nanomaterials is that this would not 
just be based on the substance composition but would also need to take 
account of other parameters such as particle size distribution. 
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7 APPENDIX 2 - MAPPING OF EXPOSURE ISSUES TO 
GUIDANCE 
7.1 Introduction 
7.1.1 The maps in this appendix represent the intersection between identified 
scientific issues (arranged vertically on the left of the matrix) and a particular 
section of the guidance (arranged horizontally across the top of the matrix).  
White, unfilled cells indicate where the specific identified scientific issue is not 
relevant to that particular section of the Guidance. Therefore no change to 
that section of the guidance is required because of that specific issue.  
7.1.2 Filled blue cells indicate where the specific identified scientific issue is 
relevant to that particular section of the guidance but the guidance applies 
equally well for nanomaterials as for substances in general and therefore, 
again, no change to the guidance is required.  
7.1.3 Filled yellow cells with a plus symbol cells indicate where the specific 
identified scientific issue is relevant to that particular section of the guidance 
but the guidance is not sufficient and needs to be amended to take account of 
the issue. Guidance and/or R&D recommendations have been made for these 
cells only. 
7.1.4 The matrices are not intended to be part of the guidance, they are merely to 
illustrate the decision making process which has led to the guidance 
recommendations. 
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7.2 Part D Exposure Scenario building 
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Hierarchy of control
Existing methods (in general)
Modification and substitution
Enclosure
Ventilation, LEV, including fume hood, cabinets
Filtration
Administrative controls
Respiratory protective equipment - RPE
Other PPE, gloves suits etc
Control banding
Development of OELs
Medical surveillance
Safety Data Sheets
Consumer RMM
Environmental RMM
Operational Conditions
Discrimination from background nanoparticles x
Measurement of size distribution x
Maximum relevant size x
Effect of high spatial and temporal variability x
Choice of metrics and instruments x
Emerging measurement strategy x
Assessment of high aspect ratio nanomaterials  
Exposure modelling x
Utility of exposure simulation studies
Clause relevant to the issue but applies to NM as for other substances
Clause relevant to the issue and change required x
Clause not relevant to the issue
Table 4.3
Table 4.1
Table 4.2
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7.3 Part D ES Format 
D-ES Format Issue D.
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7.4 Part E Risk Characterisation 
Part E Issue E.
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7.5 Part F Chemical safety report including appendix to part F CSR template 
Part F Issue F.
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7.6 Part F-Annex 
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7.7 Part G Extending the SDS 
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7.8 R.12 Use Descriptor system 
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7.9 R.13 Risk management measures and operational conditions including the 
RMM library 
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Table 4.2
Table 4.1
Table 4.3
 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 203 -
7.10 R.14 Occupational exposure estimation 
R.14 Issue R.
14
.1
. I
nt
ro
du
ci
to
n
R
.1
4.
2 
Ty
pe
s 
an
d 
ro
ut
es
 o
f e
xp
os
ur
e
R
.1
4.
3.
 D
et
er
m
in
an
ts
 o
f o
cc
up
at
io
na
l e
xp
os
ur
e 
an
d 
R
M
M
s
R
.1
4.
4.
 E
xp
os
ur
e 
es
tim
at
io
n 
m
ea
sr
ue
m
en
ts
 / 
m
od
el
lin
g
R
.1
4.
5.
 H
ig
he
r t
ie
r e
xp
os
ur
e 
as
se
ss
m
en
t
R
.1
4.
6.
 R
ef
er
en
ce
s
A 
R
.1
4-
1.
 E
va
po
ra
tio
n 
ra
te
A 
R
.1
4-
2.
 D
er
iv
at
io
n 
of
 s
ho
rt 
te
rm
 in
ha
la
tio
n 
ex
po
su
re
A 
R
.1
4-
3.
 C
on
tro
l g
ui
da
nc
e 
sh
ee
t n
um
be
rin
g 
sy
st
em
Applicability of SUs
Applicability of PROCs
Applicability of ERCs
Complexity of measurement programmes and data
Discrimination from background particles
Maximum particle size x
Metrics
Use of instruments x
Data handling -Uncertainty of measurement
Use of exposure models x x
Applicability of REACH ES
Hierarchy of control
Existing methods (in general)
Modification and substitution
Enclosure
Ventilation, LEV, including fume hood, cabinets
Filtration
Administrative controls
Respiratory protective equipment - RPE
Other PPE, gloves suits etc
Control banding
Development of OELs
Medical surveillance
Safety Data Sheets
Consumer RMM
Environmental RMM
Operational Conditions
Discrimination from background nanoparticles x
Measurement of size distribution x
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Clause relevant to the issue but applies to NM as for other substances
Clause relevant to the issue and change required x
Clause not relevant to the issue
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7.11 R.15 Consumer exposure estimation 
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7.12 R.16 Environmental exposure Estimation 
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Clause relevant to the issue but applies to NM as for other substances
Clause relevant to the issue and change required x
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7.13 R.17 Exposure Assessment of Substances in Articles 
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8 APPENDIX 3 – CONSIDERATION IN RELATION TO 
MEASUREMENT OF INHALATION EXPOSURE TO 
NANOMATERIALS 
8.1 Preamble 
8.1.1 Measurement of exposure to nanomaterials provides particular challenges.  
These have been highlighted in several publications (e.g. Brouwer 2009, 
2010). They include discrimination from background particles, collection and 
analysis of size information, effective high spatial and temporal variability, 
choice of metrics and measurement instruments, and measurement of high 
aspect ratio nanomaterials. The state of knowledge on these issues is 
continuing to develop. Further information on current approaches is provided 
in BSI 6699/3 (2010), OECD (2009). 
8.2 Discrimination from background nanoparticles 
8.2.1 Typical urban air contains anywhere between 10,000 to 40,000 particles.cm-1 
which come from a variety of sources including, industrial pollution, traffic and 
domestic emissions.  
8.2.2 In industrial settings, evidence of measurement problems relating to 
background aerosols has been reported in several studies (e.g. Kuhlbusch et 
al., 2004, 2006; Demou et al., 2008; Park et al., 2009). Specifically identified 
sources include heating units, fork lift trucks and vacuum cleaners.  
8.2.3 These background number concentrations are dominated by particles smaller 
the 1000 nm and much of the distribution is typically in the range 10 to 300 
nm.  The presence of this ambient particulate creates problems when 
attempting to measure emissions of engineered nanoparticles from 
nanomaterials sources. 
8.2.4 Three strategies have been reported (including combinations) to address this 
issue of these with varying success. The first is to take time series, or time 
differentiated measurements with associated log of events, typically including 
activities such as pre-operation of reactor, to determine a plausible 
relationship between events and levels.  
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8.2.5 A second approach is to take parallel samples with the same instrumentation 
in an area where it is expected that there is only background aerosol present, 
i.e. there is no expected contribution from the source (e.g. Kuhlbusch et al. 
2004, 2006).  This is sometimes called the “far field” and can be outside, or at 
another point in the production building/laboratory.  For this type of approach, 
care is required that there is no contribution from the sources of interest, or 
from other background sources in the far field sample.  
8.2.6 A third approach is to collect physical samples of the aerosol for off-line 
analysis to confirm the that peak concentrations observed correspond to an 
identified NM, either by composition (elemental analysis of the primary 
material or impurity) or morphology or both, for example by Scanning Electron 
Microscopy (SEM)/ Transmission Electron Microscopy (TEM) and Energy-
dispersive X-ray Spectroscopy (EDAX) analysis (e.g. Methner et al., 2010; 
Brouwer et al., 2009). 
8.2.7 While all of these approaches have utility, all must be applied with care to 
ensure that no confounding effects, such as a change in the far field 
background with time, corrupt the data. Combination approaches have been 
described and are generally more successful. Brouwer et al. (2009) used a 
combination of these approaches as the basis of a semi-formal decision logic 
to determine whether nano-objects were present in the workplace air. This 
required an exceedance of a predetermined near-field/far field ratio (in the 
reference ratio 1.05 was used), that changes in concentration or size 
distribution corresponded to observed activities and that the chemical 
composition of the sample (in the near and far field) matched that expected. 
The obvious limitation of the method in the light of the dynamic response, 
detection limits and the measurement uncertainty of the applied 
measurements is in its ability to detect statistically significant deviations in the 
ratio. Currently available sampling and analytical methods might also have 
insufficient sensitivity to assess very low levels required when in due course 
in many cases  OELs/DNELs for nanomaterials may be substantially lower 
than current OELS/DNELS,(e.g. NIOSH (2005) for TiO2)). 
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8.3 Measurement of size distribution  
8.3.1 Measurement of size distribution is clearly an important parameter.  The size 
information may me obtained through a number of instrumental routes.  It is 
unlikely that the size distribution of aerosols measured in the workplace is the 
same as the size distribution of the primary material. Evidence is that 
distributions are not log normal (as might be expected for laboratory 
generated samples) but more complex, sometimes but not always bi-modal.  
8.3.2 Various reasons have been suggested for this. One is that the smaller mode 
represents primary particles and the larger mode either agglomerates or 
aggregates of these materials or agglomerates in combination with 
background particles, following scavenging by these particles. Given the 
irregular nature of the distribution in most cases, it is inappropriate to 
summarise the distribution by a single set of parameters such as median and 
diameter and geometric standard deviation. 
8.3.3 Devices which measure size distribution such as the SMPS and FMPS 
provide a particularly data rich output. These devices produce count data in 
several size bins either collected in parallel (in the case of the FMPS) or in a 
very close time sequence (in the case of the SMPS). There are several ways 
in which this data might be used. The simplest approach in to inspect the 
complete size distribution. This is particularly useful in assessing single 
events or single changes (e.g. the implementation of a control measure, or 
the comparison between an aerosol and a background). However, this type of 
analysis is difficult to quantify as multimodal distributions cannot be easily be 
described and compared by summary statistics such as the geometric mean 
and standard deviation.  
8.3.4 An alternative is to sum the total counts to provide a single number. However 
this approach looses the size information and so it is of limited value. In the 
reviewed studies, several authors (e.g. Fujitani et al., 2008; Bello 2008, 2009) 
have grouped (integrated) the size distribution into several discrete size 
ranges e.g. < 10 nanometres, < 100 nm , < 1000 nm etc. and examining the 
examiningcompared their respective time series to support the development 
of the background discrimination strategies or understanding of the particle 
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formation dynamics. for each. This can be highly effective in looking at how 
different parts of aerosol distribution change with time.  
8.4 Maximum relevant size  
8.4.1 Use of size dependent-health related criteria is common practice in 
measurement of occupational exposure (ISO, 1995). From the preceding 
section it is clear that the size distribution of aerosols which are present in 
workplaces where nanomaterials are synthesised or used typically have a 
broad distribution. An important issue to consider is whether it is appropriate 
to impose an upper size limit of the particles to be collected or measured in 
order to characterise exposure to NM. One option would be to exclude all 
particles with physical dimensions greater than 100 nm, providing methods 
were available. This would allow estimation of people’s exposure to 
“nanoparticles” as formally defined in ISO/TS 27687:2008 (BSI, 2008).  
8.4.2 Evidence from the studies reviewed suggests that emissions are rarely in the 
form of single nanoparticles (this is not to exclude this possibility entirely). In 
most cases the measurements indicated that where nanoparticles were 
present, they were in an aggregated or agglomerated form or were associated 
with other materials including background particles. In the main studies 
reviewed, the selected strategies were to maximise the information available 
by looking at a wide particle size range (and thus not operate with a 100nm 
cut-off). The implicit assumption in that is that agglomerates, aggregates and 
other combined particles are at least potentially relevant NM exposures. The 
relevance of these agglomerated forms, including potential for dissolution, or 
dissagregation, needs to be considered also from the toxicological 
perspective in the risk characterisation.  
8.4.3 Many devices used do already have a maximum measurable particle size. For 
example several of the CPCs have a cut-off (maximum size) of 1000 nm 
which is achieved by including an impactor in the inlet. This can be to protect 
the instruments’ detection system or because of decreasing detection 
efficiency beyond that size. There is a rationale to standardise that, 
particularly if emphasis is given to (total) number concentration as a 
parameter. Otherwise, two instruments, with different maximum sizes will give 
different results.  However, this is not a health based selection criterion.   
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8.4.4 One approach could be to use the respirable convention as an upper size limit 
(ISO, 1993). This would have the advantage of being biologically relevant and 
would provide coherence with current practice in occupational exposure 
assessment. Use of the respirable convention has been recommended by 
several authors (e.g. Schneider and Jensen, 2008). Respirable 
concentrations have been measured in several of the reviewed studies (e.g. 
Peters et al., 2009; Han et al., 2008). 
8.4.5 In general however, given the current state of knowledge, the practice 
adopted in the reviewed studies, assessing multiple parameters with multiple 
instruments, seems correct. Where the maximum (and indeed minimum) size 
limits of an instrument are known, and the instrument response function, this 
should be clearly stated.   
8.5 Effect of high spatial and temporal variability 
8.5.1  In occupational settings it is common that airborne concentrations are higher 
and closer to the source worker (near-field) than at some distance point (far-
field). High spatial variability has been reported in the studies reviewed. 
Demou et al. (2009) reported both high and low spatial variability in different 
settings. Plitzco (2009) reported “genuine nanoparticles” emitted from a 
reactor that agglomerated in a very short time and immediately led to a 
lowering of the number concentration. Seipenbusch et al. (2008), as part of 
the FP6 project NANOTRANSPORT, investigated the evolution in time of a 
nanoparticle (NP) aerosol released into a particle-free atmosphere and in 
presence of a pre-existing background aerosol and demonstrated rapid 
agglomeration and scavenging by the background aerosol. 
8.5.2 High spatial and temporal variability emphasis the need for measurements of  
exposure in workplaces are based on personal sampling, i.e. by using a 
sampling device located in the breathing zone of the worker being assessed.  
Studies have generally shown that personal exposure is higher compared to 
exposure as measured in the general environment of a workplace. This is 
partly because the worker is usually closer to the source than static 
environmental monitors are able to be placed but also from the activities 
undertaken by the worker himself, and the extent to which these modify the 
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exposure levels. This may be particularly relevant for NM due to high 
transport, agglomeration and scavenging rates.   
8.5.3 Measurements of workplace air concentrations will not adequately represent 
personal exposure. Therefore a preferred approach is the use of personal 
sampling devices. However given the current lack of such a device, 
measurements strategies which encourage (even limited) comparison 
between workplace air concentrations and personal exposure are 
recommended.   
8.6 Metrics 
8.6.1 There are three main metrics, all of which could have some utility in 
measuring exposure to nanoparticles. These are: i) mass concentration (units 
mg m-3); ii) number concentration (units m-3) and; iii) surface area 
concentration units (m2 m-3). A case may be made for the use of any of these 
metrics under certain circumstances. 
8.6.2 The metric used to assess exposure to nanomaterials should be that which 
most closely links to any potential health effect. Analysis that no single metric 
(or method) for monitoring nano-aerosol exposure will suit all nanomaterials. 
Rather, there will be occasions where particle number, surface area and mass 
concentration measurements or their combination will play an important role 
in evaluating potential impact.  
8.6.3 Instrumentation is available to measure each of these metrics but there are 
identified practical issues in the selection and use of metrics. For mass, a key 
issue is a lack of sensitivity towards the nanoparticles of interest. 
Measurement of number concentration is in contrast highly sensitive. 
However, measuring particle number concentration in isolation can be 
misleading. In all particle number concentration measurements, the 
integration limits over which a particular instrument operates are critical to the 
reported results. Real-time measurements of surface area concentration are 
technically feasible but there is very limited practical experience with these 
instruments. The results obtained need to be carefully interpreted and the 
limitations and boundaries carefully examined. Issues to consider include the 
effect of initial aerosol charge, the composition of the material, how 
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 214 -
aggregates are dealt with (in particular where both external and internal 
surfaces are available) and the effect of extreme particle shape.  
8.6.4 An ideal approach is to choose a metric which is correlated with the health 
effect of concern, can be relatively easily measured and be both measurable 
and sensitive enough to detect differences in the probable ranges 
encountered. Which then, is the best metric for nanoparticles and is this even 
a sensible question to ask? Useful preliminary questions might be “what types 
of nanoparticles are we interested in?” and “what is the health effect we are 
trying to correlate with?”  
8.7 Assessment of high aspect ratio nanomaterials   
8.7.1 Exposure to fibrous aerosols is assessed by measuring the number 
(concentration) of fibres in the air with a specific shape and composition 
(WHO, 1997). Critical to the method is definition of a fibre, specifically a 
respirable fibre. WHO defines a respirable fibre as an object with length 
greater than 5 x 10-6 m (5000 nm) a width less than 3 x 10-6 m (3000 nm), and 
a length to width ratio (aspect ratio) greater than 3:1. It relies on manual 
counting of fibres by optical microscopy according to a set of counting rules 
governing size (as above), number of areas (graticules) scanned, number of 
fibres scanned,  number density of fibres on the collection substrate, and how 
to deal with “bundled” or overlapping fibres. The scope of application of the 
WHO method is broad, as indicated in the following statement: “The method 
[..] is applicable to the assessment of concentrations of airborne fibres in 
workplace atmospheres most commonly personal exposures-for all natural 
and synthetic fibres, including the asbestos varieties, other naturally occurring 
mineral fibres and man-made mineral fibres” (WHO, 1997). 
8.7.2 Several high aspect ratio nanomaterials (HARN) could fall within this scope. It 
has been suggested that fibre counting could be an appropriate method to 
assess exposure to HARN (BSI 6699-2:2007; BSI, 2007). However concerns 
have been raised regarding the applicability of the WHO for HARN, 
specifically for CNT. Optical microscopy would not detect individual CNT 
although it could detect bundles of CNT.  The higher magnification required 
would require SEM/TEM which would increase the counting time 
substantially.  
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8.7.3 It is known that optical microscopy is less sensitive than SEM/TEM to very 
fine fibres and therefore underestimates the total number of fibres collected. 
SEM/TEM will measure these very fine fibres which would not be observed by 
optical microscopy leading to larger counts in what would be an equivalent 
sample. This would lead to difficulties in making comparison with limit values 
for fibres set using optical microscopy. 
8.7.4 Han et al. (2008), used an approach based on the WHO method and report 
fibre concentrations. It is not clear the extent to which WHO counting rules 
were applied. However it is noted that all the fibres reported were shorter than 
the WHO definition and so by strict application of the fibre counting rules the 
count would be zero. Bello et al. also collected on to a filter for EM analysis, 
but no fibres were identified. Han et al. made measurements of total carbon 
using a portable aethalometer. Other investigators used CPC, OPC and 
SMPS to try to detect although these devices prove no morphological 
information. A recent review on options for CNT detection and analysis (SWA, 
2010a) concluded that the ELPI spectrometer may have some utility in this 
respect. Various off line measurement approaches reviewed by Tantra et al. 
(2007) concluded that none were immediately appropriate for measurement of 
occupational exposure. Currently there is no consensus on the most 
appropriate approach.   
8.7.5 Assessment of fibre concentration is likely to be relevant to some high aspect 
ratio nanomaterials in terms of their exposure. The presence of fibres is only 
likely to be detected by electron microscopy. Application of the WHO 
approach has not yet been validated for any types of high aspect ratio 
nanomaterials. No specific guidance can be given at this time towards 
quantitative assessment of bundles or clumps of high aspect ratio 
nanomaterials. However, their presence should be noted in any assessment. 
8.8 Available instruments  
8.8.1 There are a number of instruments available which measure the metrics 
discussed. The instruments have been described in a number of publications. 
Table 8.1 overleaf is taken from ISO/TR 27628:2007 (ISO, 2007) and 
describes the main types of instruments which are currently available along 
with the metric which they are most often used to measure. This table is not 
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inclusive of all of the commercial instruments which are available but 
nonetheless provide good general description of the instrument types and 
purpose. Similar tables can be found in other publications (eg BSI 2007, ISO 
2008) where further descriptions of these instruments can be found.  
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8.8.2 Table 8.1 Main instruments available for exposure assessment and 
metric measured (reproduced from ISO, 2007). 
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8.9 Data analysis 
8.9.1 Guidance for exposure data requires the use of summary statistics such as 
the mean and the 90th percentile. Many of the instruments suggested for use 
are real time devices which can either provide an instantaneous spot 
measurement or can be used to average over a set period. In some cases, 
summary statistics can be derived directly from the device. If this is not 
feasible then multiple measurements should be taken over appropriate fixed 
sampling periods to enable these statistics to be calculated. In these cases, 
the duration of the averaging period should be recorded.  
8.10 Strategy   
8.10.1 In this context, measurement strategy includes selection of instruments, how 
they are used and what samples are taken (incl. where and when/timing). 
Currently, there is no single consensus view on the most appropriate method 
for assessing exposure to nanomaterials. As indicated earlier in this report, 
there’s is unlikely to be a universal strategy due the many differing purposes 
for which measurements may be made. In studies published thus far, the 
purpose seems to have been to have been primarily for identification of 
emission sources, quantification of same, or for the evaluation of the 
effectiveness of control approaches. 
8.10.2 Initial approaches, for example that described by Brouwer et al. (2004), 
suggest a multi-instrument approach in an attempt to capture all relevant 
metrics and characteristics. In this study, based on the assessment of ultra-
fine welding fumes, the authors suggest a multi-instrument approach in which 
CPCs are used to identify potential sources of emissions (and background 
sources), an SMPS or ELPI is used to characterise size distribution and how 
this varies as a function of time or space combined with SEM or TEM analysis 
of samples collected on filters to characterise the physical or chemical form of 
the aerosol.  
8.10.3 The authors recognise that each of the measurement methods has its 
drawbacks, but when used in combination they “may give full insight into the 
presence of ultrafine particle aerosols in the workplace”. They recommend 
however that the use of static samplers at fixed locations hampers the 
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interpretation of the results for personal exposure of ambulatory workers and, 
even for workers who are positioned at fixed workstations, the interpretation 
will be “very inaccurate”. 
8.10.4 BSI 6699-2 describes a three step process (BSI, 2007). The first step would 
involve identifying the source of nanoparticle emissions using a CPC provides 
acceptable capability for this purpose, taking due consideration of any 
background. In the second stage aerosol surface area measurements should 
be conducted with a portable diffusion charger and aerosol size distributions 
should be determined with an SMPS or ELPI using static (area) monitoring. 
Lastly, personal sampling using filters or grids suitable for analysis by electron 
microscopy or chemical identification should be employed, particularly if 
measuring exposures to specific nanoparticles is of interest. Electron 
microscopy can be used to identify the particles, and can provide an estimate 
of the size distribution of the particle of interest. 
8.10.5 In the US, the National Institute for Occupational Safety and Health (NIOSH) 
has developed a multi-stage strategy (NEAT) with an initial assessment by 
CPC and OPC, plus electron microscopy and elemental identification 
(Methner et al. 2010). The document was developed by the NIOSH team to 
provide specific advice on how to use the many available techniques in a 
coherent way. The approach described by these authors comprises three 
main steps. These are: 
8.10.6 1. Identify potential sources of emissions. The recommendations are that 
this initial assessment should involve reviewing processes, work flow etc. to 
gain an understanding of where engineered nanomaterials may be used and 
including physical chemical properties such as size, shape, composition etc. 
Once the potential sources of the emissions have been identified the teams 
should conduct a walkthrough survey, determine the frequency and duration 
of each operation, determine the presence and absence of local exhaust 
ventilation and determine the process points where the containment is 
deliberately breached e.g. opening the system for product retrieval or for 
cleaning.   
8.10.7 2. Conduct particle number concentration sampling. Critical to this is 
determining the influence of background particle concentration, e.g. by 
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making measurements with CPC or OPC before processing or handling of 
nanomaterial begins. Potential incidental nanoparticles sources identified 
included heat sources, vacuum pumps, gas heating units, fork lift trucks etc.  
The authors also carried out measurements of background particle number 
concentration after the active processing or manufacturing took place. The 
average of the background number concentration before and after the task is 
then subtracted from the measurements made during the task. The authors 
identified a number of problems with their approach which could include e.g. 
the background particle number concentrations could remain elevated after a 
particular task indicating that release had occurred. Once background particle 
number concentrations had been determined process or task specific 
measurements are made with the CPC and OPC simultaneously at locations 
near to the suspected emissions source. Airborne particle number 
concentrations are then determined and compared to background to 
determine if an emission of nanomaterials occurred. 
8.10.8 3. Collect filter based samples. A pair of filter based air samples (in this 
case 37mm open face cassettes) were collected at the process task locations 
and or from workers engaged in the process. (Note that these open faced 
cassettes would not be size selective in nature). The authors comment that 
analysis of these samples by electron microscopy allows the determination of 
particle size range and degree of agglomeration of the aerosol collected. The 
authors indicate that one of the samples is analysed for airborne mass 
concentration and the other sample analysed by electron microscopy. For 
particle characterisation (e.g. size, shape, morphology etc.) by TEM or SEM 
using measurements specified in NIOSH methods 4702, 4704 or other 
equivalent methods. The analysis of the air samples using TEM with energy 
dispersive x-ray spectrometry can provide information on elemental 
composition. 
8.10.9 If measurements obtained with CPC and OPC indicate that engineered 
nanomaterial is emitted and workers are present then personal (breathing 
zone) samples should be collected using the two filter strategy. One further 
option is to use size selection in the collection of filter based samples, e.g. the 
use of a cyclone to collect the respirable fraction.   
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8.10.10 The approach described is the basis of the programme of work which is 
reported in Methner et al. (2010).   
8.10.11 One noticeable difference between this approach and that suggested by other 
authors is the lack of any real time collection of size information, e. g. with an 
SMPS or similar device. Rather the approach is dependent on collection of 
samples for off line analysis to determine particle size.  
8.10.12 The approached described by Methner et al. (2010) is very similar and has 
clearly influenced the approach suggested in guidance by OECD in their 
document ENV/JM/MONO(2009)16 Emission Assessment for the 
Identification of Sources and Release of Airborne Manufactured 
Nanomaterials in the Workplace: Compilation of Existing Guidance (OECD 
2009). Currently available guidance is reviewed in this document.  Also it is 
clear that the apparent lack of use of sophisticated real time size information 
gathering equipment provides a “relatively simple” approach towards 
assessing exposure to engineered nanomaterials.  It  is maybe less 
challenging both in terms of timescales between collection of the sample and 
subsequent analysis and also the usability of this method by e.g. small to 
medium enterprises without access to sophisticated TEM equipment.   
8.10.13 Brouwer et al. (2009) describe a strategy which has been developed within 
the EU sponsored NANOSH (EU FP6 contract NMP4/CT/2006/032777) 
project. This is a harmonised approach for measurement strategy, data 
analysis and reporting. In addition to time activity concentration profiles this 
approach enables a first step to estimate the potential for exposure to 
manufactured nano objects more quantitatively.   
8.10.14 The sampling strategy developed for the NANOSH field studies was based on 
a mixture of scientific desirability and practical feasibility for all the partners. 
With respect to the instrumentation, size distributive particles concentration 
devices, e.g., SMPS model 3080 (TSI, USA) with a differential mobility 
analyzer (DMA) and a CPC model 3025 (TSI, USA) or ELPI (Dekati, Finland) 
formed the basis for workplace air measurements. In addition, near-real- time 
active surface area concentration was measured by either of the two different 
types of DCs i.e., LQ1 (Matter Engineering, Switzerland), or an Aerotrak 9000 
(TSI, USA). The former device measures the active surface area 
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concentration, whereas the latter one mimics the active surface area of the 
lung- deposited particles (Asbach et al., 2009B). In addition, particle number 
concentrations were measured by CPC (TSI, model 3025). The measurement 
devices were located next to the work station with instrument inlets (tubing) in 
the workers’ breathing zone. 
8.10.15 For characterization, samples on TEM grids were collected by (electrostatic) 
precipitators, e.g., the Nanometer Aerosol Sampler 3089 (TSI, USA).  
8.10.16 Key element of this study was the development of a “decision logic” to 
estimate the likelihood of exposure to manufactured nanomaterials. A 
preliminary ‘‘decision logic’’ was developed to take advantage of the array of 
measurement results and to assist the evaluation of the results with respect to 
exposure to manufactured nano objects. First, for a case-by-case 
comparison, the average concentration during a defined period of activity 
should be statistically different (p<0.05) from either a period of non-activity 
(‘‘near-field background’’), or from a concentration at a ‘‘far-field’’ background 
position during the activity. In addition, the difference should be equal to or 
larger than 5%, i.e., a ratio of activity–non-activity >=1.05. Second, the 
characterization of the samples during the activity should indicate the 
presence of primary particles<100 nm or agglomerates, and the EDX 
elemental analysis should confirm the (elemental) identity of the objects or 
agglomerates similar to the MNO. Ideally, there should be a confirmation, that 
the particle size distribution (or the mode) as determined by SMPS or ELPI, is 
different from the background. Finally, the observations during the 
measurements should be evaluated, especially with respect to other sources 
that might generate nano- sized aerosols. 
8.10.17 The issue of determination of background concentration was addressed in 
two ways, by comparison between near and far field and between periods of 
activity and non activity.  
8.10.18 The decision logic as presented in this article offers guidance as regards how 
to proceed with data analysis. The NANOSH approach formulates decision 
criteria explicitly e.g. statistical significance and substantiality of difference 
and gives a framework to combine the difference types of results. In the case 
that an application of decision logic shows evidence that the increment of 
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concentration during the activity is associated with manufactured nano objects 
is still unclear what the relevance of this observation might be in view of a risk 
assessment. The authors conclude that it can be stated that workplace air 
measurements still are not able to generate data for the quantitative 
assessment of exposure. However these studies can contribute to a better 
understanding of the potential for the exposure for different types of exposure 
situations. This contribution can be more effective and powerful if the design 
of measurement strategies, the data analysis and reporting are compatible.   
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9 APPENDIX 4 – POSSIBLE FUTURE APPROACH FOR 
PERFORMING ANIMAL TO HUMAN EXTRAPOLATION 
FOR NANOMATERIALS 
9.1 Preamble 
9.1.1 The following appendix describes an approach to the derivation of a human 
equivalent dose (HED) from animal experimental data. The approach takes 
into account interspecies differences and exposure duration to derive a 
corrected HED for further derivation to an acceptable human exposure limit.   
9.1.2 The information discussed herein has been developed after the standard RIP-
oN 3 consultation process in response to comments and as such has not been 
reviewed by the European Commission appointed Stakeholder Consultation 
Group (SCG). Therefore the information should not be seen as a reflection of 
the RIP-oN consultation process and is for information purposes only, but 
could be followed up as R&D and/or considered for future updates of the 
guidance. 
9.1.3 It should be noted that the approach outlined here refers to the mass metric. 
9.2 Alternative approach to deriving a human no effect level 
9.2.1 When considering the data obtained from an animal inhalation study, the value 
of greatest interest for deriving safe exposure limits is the no observable 
adverse effect level (NOAEL). This value provides the basis for deriving a 
level at which no adverse effects would be seen within humans exposed to 
the same substance. As there are numerous differences between humans 
and the experimental animal model as well as the exposure conditions, it is 
inappropriate to directly use the animal NOAEL for humans without making 
adjustments for these variables. There are several ways in which such an 
extrapolation from animal to humans can be made for inhalation exposure 
and these are discussed within the RNC/RIP-oN3/C1/2/FINAL and RNC/RIP-
oN3/C2/2/FINAL. The REACH default approach for making and extrapolation 
from animal to HED begins with an adjustment to the calculated experimental 
external exposure value to account for certain experimental parameters such 
as differences in exposure duration. Once these modifications to the starting 
NOAEL are made, an assessment factor is applied to account for interspecies 
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differences. This figure, corrected for differences in experimental attributes 
and interspecies differences, is then subject to additional assessment factors 
to account for other areas of variability and uncertainty such as intraspecies 
differences and the data quality.  
9.2.2 However, this approach is an extrapolation based upon on the external 
concentration resulting in no adverse effects. This external concentration is 
however not the concentration that drives the effect; it is the dose within the 
lung which drives the effect. In order to establish the internal dose, several 
pieces of information are required and these are summarised below and in 
figure 2: 
− Respiratory minute volume (RMV)  
− Exposure duration  
− Deposition fraction  
− Clearance rate 
9.2.3 The first piece of information required is the inhaled dose which is the 
proportion of the external aerosol concentration drawn into the body via the 
airways. To calculate this, one needs to know the respiratory minute volume 
(RMV) which is simply the volume of air moved in and out of the lung over a 
period of 1 minute and the time over which exposure occurred (in minutes). 
Whilst not commonly reported (although it is calculated in both the Pauluhn 
2010 and NEDO 2009 reports), the RMV can be calculated using the equation 
of Bide, Armour and Yee (2000) which is as follows: 
RMV=0.499 x Body weight 0.809 
9.2.4 Using this calculation, the RMV of a typical 70kg human is 15.5 l/min-1 and the 
RMV of a rat weighing 0.35 kg is 0.2 l/min-1. These values are in keeping with 
those within REACH guidance which reports default values of 14 l/min-1 for a 
standard human respiratory rate and 20.8 l/min-1 for a person undertaking light 
activity (worker). When calculating the RMV for an experimental animal, the 
body weight can be based upon a standard convention which normally reports 
a rat weight as between 250g and 350g or may be subject specific as a 
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record of the individual animal weight is required for compliance to OECD test 
guidelines. 
 
 
9.2.5 Figure 2: Route of extrapolation from experimental NOAEL derived from animal 
exposure to human equivalent aerosol concentration taking into account 
species specific factors. Adapted from Oller and Oberdörster (2010) 
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9.2.6 The next step is calculating the inhaled dose over an average time period 
which for a worker is considered 8 hrs/ day and for the general population this 
is considered to be 24 hrs (continuous exposure). A typical exposure duration 
for a rodent in a non-acute exposure scenario is 6hrs/day (e.g. OECD TG 
412). The inhaled dose is calculated by multiplying the RMV by the exposure 
duration (in minutes) to derive the total volume of air inhaled per exposure 
day.  
9.2.7 Taking firstly the animal, based on an exposure duration of 360 minutes 
(6hrs), the inhaled volume of a rat would be 0.072 m3/day. Within the study of 
Pauluhn (2010), the aerosol concentration resulting in a NOAEL was 0.1 
mg/m3 and as such, the rodents within the study inhaled a dose of 0.0072 mg 
of CNT during an average 6hr day.  
9.2.8 As figure 2 shows, the Dae of a particle influences what proportion or fraction 
of the inhaled dose deposits in the different zones of the respiratory tract. The 
graph shows that with larger particles (~10 µm) the majority of deposition 
occurs within the pharyngeal region of the respiratory system without 
penetrating the conducting airways. As particle size reduces into the 
respirable range (<3 µm), deposition in pulmonary region increases. The 
largest level of deposition is at the smaller sub-micron size range, with 
particles able to penetrate the trachea-bronchial and alveolar regions. When 
particle size decreases further (<0.2 µm), deposition by Brownian diffusion 
increases and a larger proportion of particles deposit in the upper respiratory 
tract. Deposition of particles in the range > 0.5 µm is related to aerodynamic 
diameter whilst smaller particles of less than 0.5 µm deposition is related to its 
diffusion equivalent diameter (Gehr, Brand, & Heyder 2000). This metric 
relates to the displacement sustained by a particle due to air molecules 
causing these smaller particles can behave more like a gas.  
9.2.9 Whilst figure 3 shows the fractional deposition by particle Dae in humans, data 
also exists showing fractional deposition in experimental animals, for example 
see Miller et al. 2000. Another approach is the use of modelling software such 
as the Multiple-Path Particle Dosimetry Model (MMPD; Applied Research 
Associates, Inc.). The Dae may be reported for the primary particle in the case 
of mono-dispersed non-agglomerated particles or the diameter and density of 
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an agglomerate/ aggregate. When calculating the deposition fraction, it is the 
aerosol form of the particle/ agglomerate which dictates the particle 
deposition. As such, if a primary particle size is reported yet the aerosol form 
is a large agglomerate, then this will invalidate the deposition fraction. When 
performing inhalation exposure, OECD test guidelines require experimenters 
to record and report a range of inhalation data such as particle distribution, 
mass median aerodynamic diameter (MMAD) and geometric standard 
deviation as well as primary particle size analysis.  
9.2.10 Within the NEDO sponsored studies (Hanai et al 2009; Kobayashi et al. 
2009), the deposition fraction in rats was established from Miller at al. 2000 at 
a value of 10% based on a particle mass mean aerodynamic diameter 
(MMAD) of 1.44 µm. The Pauluhn study in contrast used the MPPD model 
and estimated a deposition fraction for a particle with a 3 µm MMAD of 5.7% 
in rats and 11.8% in humans in the pulmonary region. With these values it is 
possible to calculate what proportion of the inhaled dose depositing within the 
lung. Using the Pauluhn value of 5.7 %, the deposited fraction of the 0.0072 
mg inhaled dose rate is 0.0004 mg.   
RNC/RIP-oN3/FPR/1/FINAL 
 
 
 - 229 -
9.2.11  
9.2.12 Figure 2: Deposition of particles in the human respiratory tract. The fractional 
particle deposition in the different regions of human respiratory tract based on particle 
size is shown. Reproduced from (Snipes 1994). 
9.2.13 Particles depositing within the lung are cleared and the rate of this clearance 
is dependent on the zone of deposition. Particles depositing in the upper 
airways are cleared far more rapidly (24-48 hrs; Geiser and Kreyling 2010) as 
the particles are trapped by mucus and rapidly moved up the respiratory tract 
by the beating action of cilia present on the cell surface of these larger, 
ciliated airways. Particle clearance in the proximal alveolar region is much 
slower (Donaldson et al. 2008) as it mediated by alveolar macrophages which 
engulf the deposited particles and move them up to the mucocilary escalator. 
As a result, particles depositing within this region are retained for a greater 
length of time and as such exposure of the lung to the particles is greater. As 
particles are cleared, there is obviously a reduction in dose and as such in 
order to establish the true driving dose behind an effect (or lack of), one must 
factor in particle clearance to give a retained dose. Experimentally derived 
clearance half-times (t½) are available and have been suggested as ~ 60 
days for rats within the Pauluhn study based on the observations of 
Donaldson et al. (2008), Stober and McClellan (1997) and Brown et al. 
(2005). The clearance half time for humans is suggested to be approximately 
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320 days in humans (Bailey, Fry and James 1982) and suggested as 1 year 
in the Pauluhn paper.  
9.2.14 In order to calculate the retained dose one has to take into account the 
clearance rate (k). For a rat, based on a clearance half time of 60 days the 
clearance rate is 0.0116 using the following equation:  
k = ln(2)/ t½ 
9.2.15 The deposited dose rate is divided by the clearance rate to give the retained 
dose of 0.035 mg in the rat lung (0.0072/0.0116 = 0.035). This steady state 
occurs as a result of equilibrium between the incoming deposited dose rate 
and the outgoing clearance rate. As such, at any point after this steady state 
has developed, the rat lung would contain a total retained dose of 0.035 mg. 
This equilibrium occurs as a result of continued deposited dose over a long 
period, e.g. chronic exposure. In the case of acute exposure, a steady state 
would not have time to occur and as such a different value would be required 
to calculate the specific retained dose.   
9.2.16 As the derived value is the retained dose within a rat based, this value needs 
to be normalised in such a way to enable accurate extrapolation to a retained 
human dose. The approach taken by many, including both Pauluhn and 
NEDO is to normalise based on body weight, often at the initial calculation of 
inhaled dose rate (to give a value per m3/kg/day). The approach discussed 
herein calculates an inhaled and deposited dose rate and retained dose per 
rat, not per kg. At this stage, once a retained dose has been calculated, the 
dose can be normalised using a range of parameters including body weight 
but as the whole body is not the target organ, this may be somewhat 
inaccurate. As the target tissue is the lung, it would perhaps be more prudent 
to normalise and scale based on the lung as this in the organ receiving the 
dose. 
9.2.17 Many lung parameters could be used to normalise such as lung weight, lung 
volume, lung surface area or perhaps a component of the lung such as lung 
alveolar macrophage volume. A further degree of accuracy could be obtained 
by normalising based on the specific region of deposition/ interest, such as 
the proximal alveolar region (PAR) which has been suggested to be a key site 
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for the retention of respirable particles, as it receives high deposition but has 
slow clearance compared to the larger airways (Donaldson et al. 2008). The 
choice of normalisation parameter could be open to expert judgement 
depending one the nature of the effect of interest and the driving component.  
9.2.18 Using the approach of Pauluhn and NEDO, we shall normalise our retained 
dose on surface area based on a rat weighing 0.35 kg (which would 
correspond to a RMV of 2 l/min-1). This results in a normalised retained dose 
of 0.1 mg of CNT per kg body weight resulting in no observable effects. If we 
extrapolate this to a human we can see that the human equivalent retained 
dose is 7 mg based on an average human weight of 70 kg.  
9.2.19 As an internal dose is not suitable for setting and monitoring exposure limits, 
the external dose which generates the calculated retained dose needs to be 
derived. This is again based upon physiological, experimental and exposure 
parameters. Therefore the first step, is calculating the deposited dose which 
would result in a retained dose of the derived value based on the clearance 
rate of a typical human. This is then followed by calculating the inhaled dose 
that would result in the calculated deposited dose. To do this the deposition 
rate must again be calculated using the same aerodynamic diameter as the 
experimental system but instead for a human species. Once the inhaled dose 
rate is calculated, the human equivalent external exposure level which would 
result in the calculated inhaled dose rate is then derived. As with the initial 
calculations for the experimental animal, this calculation is based upon the 
RMV and the exposure duration over a period of a day. The RMV is 
calculated using the same equation as previously reported (Bide et al. 2000) 
but instead for a typical 70kg human which corresponds to a greater RMV. In 
addition the typical exposure period for a human worker (8hrs/day) is longer 
than that of an animal exposure period (6hr/per day) and as such the final 
calculation is based upon 480 minutes rather than 360 minutes. This results in 
a HED causing no observable adverse effects.  
9.2.20 These calculations using the data presented within Pauluhn (2010) are 
summarised in the following: 
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9.2.21 Experimental/ Exposure information 
− Rodent body weight – 0.35 kg 
− Human Body weight – 70 kg 
− Rodent exposure  duration – 360 minutes (6hr/day) 
− Worker exposure duration – 480 minutes (8hr/day)  
− MMAD - ~3 µm 
− Rat lung elimination halftime (t ½) – 60 days 
− Human lung elimination halftime (t ½) – 365 days 
9.2.22 Calculated information  
9.2.23 Respiratory Minute Volume 
9.2.24 The RMV is calculated based upon the generic rat weight of 0.35 kg and 
generic human weight of 70kg using the following equation of Bide et al. 
2000. This results in the following species specific RMV’s: 
− RMVrat = 0.499 x 0.35 0.809 = 0.2 l/min 
− RMVhuman = 0.499 x 70 0.809 = 15.5 l/min 
9.2.25 As the unit of measurement for external exposure is m3 rather than litres; the 
RMV is converted from l/min to m3/min by the equation:  
RMV m3/min = RMV l/min / 1000  
9.2.26 This results in an RMV for a 0.35kg rat of 0.0002 m3/min and a 70kg human 
as 0.0155 m3/min.  
9.2.27 Within the REACH guidance, the respiratory rate for a worker undertaking 
light activity is greater than that for a person at rest and the RMV calculate 
above corresponds to that of a person at rest. The REACH default respiratory 
volume of a worker over a period of an 8hr working day is 10 m3 which 
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corresponds to an RMV of 0.0283 m3/min. This daily respiratory rate is also 
used by Pauluhn and is used within the following example.  
9.2.28 Lung Deposition  
9.2.29 The rat and human alveolar lung deposition fractions shown were calculated 
by Pauluhn using MMPD software: 
− Rat lung alveolar deposition fraction – 5.7 % 
− Human lung alveolar deposition fraction – 11.8 % 
9.2.30 Clearance rate (k) 
9.2.31 The elimination halftime reported in Pauluhn 2010a for a rat was 60 days and 
the elimination half time of a human was reported as ~ 365 days based on the 
data of Snipes et al. (1989) which is in agreement with the literature and is 
subsequently used here. Based on the above equation the clearance rates for 
rats and humans are:  
Krat = ln(2)/60 = 0.0116 
Khuman = ln(2)/365 = 0.0019 
9.2.32 Based on the above experimental and calculated parameters, the HED based 
on rat NOAEL of 0.1 mg/m3 is summarised in figure 3. 
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9.2.33 Figure 3: Diagram of the computational process for deriving a human 
equivalent exposure based on an experimentally derived rat NOAEL from 
Pauluhn 2010. *human RMV based upon a higher ventilation rate than a 
standard 70kg human resting.      
9.2.34 As a process, this would result in a more accurate calculation of the 
interspecies difference when extrapolating from a test animal to a human 
taking into account corrections for time and ventilation rates. However, other 
differences may also need to be addressed between species such as 
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toxicokinetic and toxicodynamic differences. The approach of both Pauluhn 
and NEDO was that the effects seen were localised and as a result of the 
deposited dose within the lung. As such no additional correction for 
differences in toxicokinetics would be required and this is a perfectly valid 
conclusion based on the evidence shown within the Pauluhn study 2009 
which detected no systemic effects. However such a conclusion would need 
to be based upon valid scientific justification, as presented with the Pauluhn 
study, and in situations where systemic effects are noted or translocation of 
particles is thought to be a driving force behind an adverse effect, an 
additional correction for toxicokinetics may be required. In relation to 
nanomaterials, it is hypothesised that increased translocation and systemic 
availability may occur due to their small size. However there is considerable 
uncertainty if this is truly the case and to what extent differences occurs 
based on particle size, shape, surface properties and material type.  
9.2.35 Toxicodynamics relates to differences in species sensitivities to an agent. In 
the case of rats an increased sensitivity has been well documented in relation 
to lung overload. The phenomenon of rat lung overload is discussed more 
fully in the RNC/RIP-oN2/FPR/1/FINAL report (section 4.1.211, page 229) 
and is a situation which can occur during repeated exposure to high 
concentrations of poorly soluble low toxicity particles. At the point of overload, 
the steady state of particle deposition and particle clearance shifts in favour of 
particle deposition as clearance slows and then fails leading to a rapid 
increase in retained dose, driving an adverse effect such as inflammation. 
Humans and indeed other rodent species are more resistant to this effect and 
as such a rat is indentified as a more sensitive species. The approach of 
NEDO was to assign a toxicodynamic value of 1 to their calculation which due 
to the increased sensitivity of rats to lung overload they suggested erred on 
the side of caution.  
9.2.36 Within the Pauluhn study the difference in sensitivity to lung overload were 
accounted for using a direct extrapolative calculation based on differences in 
alveolar macrophage volume and number. This approach was taken as within 
the alveolar region of the lung it is the alveolar macrophage which is tasked 
with clearing deposited particles and it is this clearance mechanism which 
becomes overloaded. Of the various driving mechanism of lung overload, as 
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discussed in RNC/RIP-oN2/FPR/1/FINAL (section 4.1.211), volumetric 
overload of the macrophage is considered to be a potential driver and is the 
driver attributed within the Pauluhn study. Volumetric overload is considered 
to begin once roughly 6% of the macrophage volume has been filled with 
particles resulting in a reduction of macrophage mobility. Once 60% of the 
macrophage is filled, macrophage clearance ceases (Morrow 1988). As 
pointed out in the Pauluhn study, there are differences within the macrophage 
populations in humans and rats which generate an interspecies difference. In 
humans macrophages are larger and more numerous than in rats and as 
such, due to the volumetric hypothesis used by Pauluhn, these differences 
were accounted for a greater resistance to overload in humans. By calculating 
the total macrophage volume (total macrophage number x average 
macrophage volume) Pauluhn noted that humans had a ~6-fold higher total 
macrophage volume than rats. This is an interesting approach and of 
debatable merit as this correction is applied within the Pauluhn study at a 
concentration that does not result in overload (the NOAEL) but rather at a 
normal steady state. It could be argued that such a difference is already 
accounted for because within this region of the lung, clearance is via 
macrophages and within Pauluhn’s calculations the difference in clearance 
rate is already accounted for. Indeed when looking at the difference in 
macrophage capacity (as a figure of macrophage number and volume) as 
outlined by Pauluhn, this actually corresponds very well to the difference in 
clearance kinetics. Specifically the difference between macrophage capacity 
and clearance rate is 5.75 and 5.27 respectively.  
9.2.37 Depending on the driving factor behind the observed affect, other 
toxicodynamic differences may need to be accounted for. In the case of a 
soluble component driving an adverse effect, a species difference in the 
ability or rate of metabolism of the soluble component would be an example of 
a toxicodynamics difference which would need to be accounted for.   
9.2.38 The final human equivalent aerosol concentration would also be subject to 
assessment factors accounting for further uncertainties which cannot be 
addressed by extrapolation. These would include intraspecies differences, 
differences in duration of exposure, issues relating to dose response and 
quality of the whole database; all of which would still be equally valid and 
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require careful consideration. In relation to these further uncertainties the 
REACH approach could be followed either through the use of substance 
specific information to deviate from the default factors or the use of default 
factors in the absence of such information. In the example outlined above, a 
HED was calculated experimental animal data using information presented in 
Pauluhn (2010). This derived value is now subject to the following REACH 
assessment factors based on the reasoning outlined in RNC/RIP-
oN3/C1/2/FINAL report to derive a hypothetical derived no effect level 
(DNEL): 
− Intraspecies differences    -5 
− Differences in duration of exposure   -2 
− Issues related to dose-response   -1  
− Quality of whole database    -1 
9.2.39 These additional assessment factors are calculated to generate an overall 
assessment factor using the following equation: 
− Overall assessment factor = AF intraspecies (worker) x AF duration (sub-chronic 
to chronic) x AF dose-response x AF database quality) = 5*2*1*1 =10 
9.2.40 This overall assessment factor is then applied to the calculated HED as 
follows:  
− 0.01/ 10 = 0.001 mg/m3 
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